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Summary
The enteric adenoviruses were first identified from stool samples of infants with acute 
gastroenteritis (Flewett et al., 1973). Although enteric adenovirus particles were shed in 
large numbers from the gut, they were unable to be cultivated on conventional cell lines 
used to propagate other adenoviruses (Flewett et al., 1973; Madeley et al., 1977; Retter et 
al., 1979). However, they would grow in 293 cells, a human embryo kidney (HEK) cell 
line which had been transformed with the Ad5 El region (Graham et al., 1977; Takiff et al., 
1981), albeit at reduced levels compared to other serotypes. This observation suggested 
that functions encoded in the El region were poorly expressed or of intrinsically lower 
activity in certain cell types, thereby implicating the E l region in the restrictive growth 
properties of the enteric adenoviruses. Previous work had demonstrated that the Ad40 E1B 
region played a significant role in this phenotype (Mautner et al., 1989; Steinthorsdottir, 
1991; Gomes et al., 1992). However, the Ad40 E l A region had also been implicated due to 
a delay in the onset of Ad40 El A mRNA expression when compared to Ad5 El A mRNA 
expression (Ullah, 1997), and the observation that the Ad40 El A proteins appeared to be 
weaker fra«.s-activators when compared to the Ad5 El A proteins (van Loon et al., 1987b; 
Ishino et al., 1988).
Therefore to investigate the involvement of the El A region in the restricted growth of 
Ad40, a preliminary characterisation of sequences which were important for basal and 
fraws-activated transcription was undertaken. Comparison of the intact Ad40 E l A 
promoter with the intact Ad5 El A promoter in transient transfection assays, revealed that 
basal transcription from the Ad40 El A promoter was lowered by approximately 6 fold 
when compared to basal transcription from the Ad5 El A promoter. To identify sequences 
important for basal transcription within the Ad40 El A promoter, a series of promoter 
deletions were constructed using Bal 31 nuclease digestion, revealing a region between 
-349 to -140, relative to the cap site at +1, to be important for basal transcription from the 
Ad40 E l A promoter. Comparison of the Ad40 El A promoter with the transcription factor 
database, held at EMBL (Ghosh, 1990), revealed that this region contained a number of 
possible transcription factor binding sites similarly arranged to the Ad5 El A promoter. To
map sequences within the region -349 to -140, a series of deletions were constructed which 
deleted transcription factor binding sites known to be important for basal transcription from 
the Ad5 El A promoter. The deletions were characterised in parallel with the intact and 
Bal 31 deletion mutants of the Ad40 El A promoter by transient transfection assays, which 
revealed that the Ad40 E l A transcriptional control region contains an enhancer element 
located between -328 to -235 relative to the Ad40 E1A cap site at +1 similar to that in the 
Ad5 El A promoter (Hearing and Shenk, 1983a, 1986; Bruder and Hearing, 1989,1991).
To investigate whether the Ad40 El A 249R (equivalent to the Ad5 El A 13S mRNA which 
encodes a 289R protein) and 221R (equivalent to the Ad5 El A 12S mRNA which encodes 
a 243R protein) proteins were involved in the aberrant expression of the Ad40 El A region, 
a cDNA equivalent to the Ad5 E1A 13S mRNA was generated by RT-PCR of Ad40 
infected cell extracts, then cloned into a CMV expression plasmid. An Ad40 equivalent to 
the Ad5 E1A 12S mRNA was not generated by RT-PCR of Ad40 infected cell extracts 
However,a library of Ad40 El A specific cDNAs were generated, and four novel Ad40 El A 
specific cDNAs were characterised. Comparison of fraws-activated transcription from the 
Ad40 El A promoter by the Ad40 El A 249R protein and the Ad5 E l A 289R protein, 
revealed that fraws-activated transcription from the Ad40 El A promoter was approximately 
6 fold lower in the presence of the Ad40 El A 249R protein. To map sequences which were 
important for fraws-activated transcription from the Ad40 El A promoter, cells were co­
transfected with either the intact or deleted Ad40 E1A promoter and the Ad5 E1A 289R 
protein or the Ad40 E1A 249R E1A protein, revealing a region between -328 to -235, 
relative to the Ad40 El A cap site at +1, to be important for Ad5 E l A 289R activated 
transcription from the Ad40 El A promoter. Ad40 E l A 249R activated expression for both 
the Ad5 and Ad40 El A promoters was not discussed, due to an equipment (incubator) 
problem which rendered the experimental data unreliable. Comparison of the ratios of Ad5 
El A 289R activated expression to basal expression within the Ad5 and Ad40 promoter 
constructs indicated that no single sequence element could be identified which was 
uniquely important for /raws-activated expression. Rather those elements which affected 
the level of basal expression seemed to have an effect on the level of fra«s-activated
expression observed in the presence of the Ad5 El A 289R protein. Thus the Ad5 El A 
289R protein probably activates gene expression through the basal transcription apparatus, 
as demonstrated by the Ad5 El A promoter.
To investigate the number and size of Ad40 El A proteins, and the interactions of the Ad40 
El A proteins with other cellular and viral proteins during an Ad40 infection in vitro and in 
vivo, antisera were generated to conserved region (CR) 3 and the C-terminus of the Ad40 
El A 249R protein. The antibodies to CR3 and the C-terminus of the Ad40 El A 249R 
protein reacted with peptide in ELISA but did not efficiently detect Ad40 El A products in 
western blots of infected cell extracts or cell extracts overexpressing the Ad40 El A 249R 
protein, or in immunoprecipitations of Ad40 infected cells.
In summary, the work in this thesis suggests that in addition to the previously observed 
defects in the function of the Ad40 E1B region, the failure of Ad40 to propagate in cell 
lines used to propagate other adenoviruses can in part be attributed to: (i) the intrinsically 
lower activity of the Ad40 E1A promoter; (ii) aberrant splicing of E1A mRNAs; (iii) 
intrinsically lower fraws-activator function of the Ad40 El A 249R protein. These 
observations indicate that the Ad40 El A region is of intrinsically lower activity in tissue 
culture than the Ad5 E l A region, which would considerably affect progression of Ad40 into 
the late phase of the infectious cycle.
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INTRODUCTION
1. INTRODUCTION
1.1 The Adenoviridae
1.1.1 Classification
The adenovirus family is divided into two genera, mastadenoviridae and 
aviadenoviridae. The mastadenoviridae genus includes human, simian, bovine, equine, 
porcine, ovine and canine viruses. Rowe et al (1953) first discovered human 
adenoviruses in explants of adenoid tissue. To date there have been 49 serotypes of 
human adenoviruses identified, which are classified into six subgroups (A-F) based 
upon their immunological properties, oncogenicity in rodents, DNA homologies and 
morphological properties (table 1.1.1) (Hierholzer et a l , 1991). Two further candidate 
serotypes 50 and 51 have been identified in immunocompromised patients (de Jong et 
al. 1999). The human adenoviruses are pathogens associated with a number of 
infectious diseases including respiratory, ocular, urinary and gastrointestinal. 
Adenoviruses are widely used as model systems in molecular biology; their use as 
important biological tools particularly as vectors in gene therapy has been extensively 
reported (reviewed in Haddada et a l , 1995; Strayer, 1998). In the following sections it 
will become apparent that much of our current understanding of the human adenoviruses 
comes from extensive studies with adenovirus (Ad) type 2 and the closely related 
serotype Ad5.
1.1.2 Morphology
The adenovirus particle is approximately 90 nanometers (nm) in diameter, and consists 
of a nonenveloped, icosahedral particle (Home et a l , 1959), within which is a linear 
double strand of deoxyribonucleic acid (DNA) (approximately 20-30x106 Dalton (Da)) 
and at least eleven viral encoded polypeptides, which have been localised (figure 1.1.2) 
(Burnett, 1997). The capsid consists of 252 capsomers (Home et a l, 1959), 240 of 
which are hexon capsomers (virion protein II) located on the facets, the other 12 are 
penton base capsomers (virion protein IE) located at the vertices, arranged in a ring-like 
configuration with a central cavity (Ginsberg et a l,  1966). Inserted into each cavity is a 
fibre protein, which is a trimer of virion protein IV.
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Figure 1.1.2 Structure of the adenovirus particle. A. A schematic view of the Adenovirus 
particle. A schematic view of the adenovirus particle based on current understanding of its 
polypeptide components and viral DNA. No real section of the icosohedral virion would contain 
all these components, (reproduced from Stewart and Burnett, 1995). B. A diagram of the 
Icosohedral Adenovirus Capsid. The 240 copies of the hexon trimer are organised so that 12 lie 
on each of the 20 facets. The penton complex formed from the penton base and fibre lies at 
each of the 12 vertices. The central 9 hexons in a facet are cemented together by 12 copies of 
polypeptide IX. Dissociation of the virion releases the pentons, peripentonal hexons and the 
planar groups-of-nine hexons. (reproduced from Burnett et al, 1985).
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Hexon is the major structural component of the virus capsid and consists of a trimer of 
three identical polypeptide chains of protein n, with a hexagonal base facing the inside 
and a pyramidal top to the outside of the capsid (Griitter and Franklin, 1974; Roberts, 
M.M. et al., 1986; Akusjarvi et al., 1984; Athappilly et al., 1994). Hexons are found as 
either groups of nine hexons (GONs) which make up the facets, or as peripentonal 
hexons which link the facets i.e. they link the GONs and the pentons. Adjacent facets 
are linked by protein IHa spanning the capsid. Polypeptide IX stabilises GONs, whilst 
protein VI anchors the ring of peripentonal hexons by bridging with the DNA core (van 
Oostrum and Burnett, 1985; Furcinitti et al., 1989; Stewart et al., 1993; Mathews and 
Russell, 1995).
The penton capsomer consists of a penton base made up of five subunits, which are 
arranged in a ring-like structure with a central cavity (van Oostrum and Burnett, 1985; 
Furcinitti et al., 1989; Stewart et al., 1993). Inserted into the cavity is the trimeric fibre, 
which consists of three 62 kiloDalton (kDa) subunits (Devaux et al., 1990; Ruigrok 
et al., 1990; Stouten et al., 1992). The fibre protein consists of an N-terminal region 
which interacts with the penton base, a shaft region and a C-terminal globular head 
responsible for binding to the cell surface receptor designated coxsackie and adenovirus 
receptor (CAR), which binds all adenovirus serotypes except those belonging to 
subgroup B (Ruigrok et al., 1990; Bergelson et al., 1997; Roelvink et al., 1998). Most 
human adenoviruses have one fibre gene, although Ad40 and Ad41 have two (Pieniazek 
et a l, 1990). The other minor proteins VIE, X, XI and XII have not been localised 
within the capsid, however it is likely that they are contained within the capsid.
The DNA core of the virion is condensed with proteins V, VII and \i (a minor 
component); it is also covalently linked to terminal protein (TP) at each 5' end of the 
genome (reviewed in Shenk, 1996). The organisation of the DNA within the capsid is 
not well understood however, two models have been suggested. The first model 
suggested the DNA is organised into 12 globular domains (Brown et al., 1975; 
Newcombe et al., 1984) which fit into the 12 vertices of the icosahedral capsid of the 
virus. The second model involves winding of the DNA around protein VII in the form 
of nucleosomes (Corden et a l, 1976; Nermut, 1980; Vayda et al., 1983; Chatteijee et
al., 1986). Also inside the adenovirus capsid are 10 to 50 copies of the cysteine protease 
(p23) (Anderson, 1990; Mathews and Russell, 1995; Mangel et al., 1997).
1.1.3 Genome structure
The complete nucleotide sequences for human adenoviruses type 2 (Roberts et al., 
1986), type 5 (Chroboczek et al., 1992), type 40 (Davison et al., 1993), type 12 
(Sprengel et al., 1994) and type 17 (Zabner et al., 1999) are now available. The 
organisation of the Ad2 genome is shown in figure 1.1.3. It consists of a linear double 
stranded DNA molecule (approximately 35 kilo-base pairs (kbp) in size) which is 
divided into 100 map units (m.u.), and the two strands are denoted r and 1 for rightward 
and leftward transcription.
The deoxycytidine at the 5' end of each strand of the genome is covalently linked via a 
serine phosphoryl bond to a 55kDa TP (Robinson et al., 1973; Rekosh et al., 1977; 
Desideiro and Kelly, 1981). The TP is generated late in infection from an 80kDa 
precursor terminal protein (pTP) (Webster et al., 1993). The ends of the genome 
contain inverted terminal repeats (ITR) which vary in length (102 to 165bp) depending 
upon the serotype (Wolfson and Dressier, 1972; Shinagawa and Padmanabhan, 1980; 
Ishino et al., 1987). The ITRs contain a number of cw-acting elements, which are 
involved in the initiation of viral DNA replication (Tamanoi and Stillman, 1983), as 
well as a number of trans-acting elements capable of acting as upstream enhancers 
(Yoshida et al., 1995). Several regions within the ITRs are conserved in all serotypes, 
for example the minimal origin of DNA replication, which is located in the terminal 
18bp and contains a lObp region which is highly conserved amongst all adenoviruses 
(Stillman et al., 1982; Tamanoi and Stillman, 1983; van Bergen et al., 1983; Challberg 
and Rawlins, 1984; Lally et al., 1984; Wides et al., 1987; Harris and Hay, 1988). The 
minimal origin binds a heterodimer of virion proteins, pTP and adenovirus DNA 
polymerase (Adpol) (Miralles et al., 1989; Chen et al., 1990; Temperley and Hay, 
1992). The minimal origin is separated from two host cell protein binding sites by a 
defined spacer region (Wides et al., 1987); transcription factors which bind to the 
aforementioned sites stimulate the initiation of replication by different mechanisms 
(reviewed by Hay et al., 1995; van der Vliet, 1995; de Jong and van der Vliet, 1999).
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1.1.4 The lytic cycle
1.1.4.1 Viral entry into cells
The adenoviruses enter their host cell via receptor mediated endocytosis (reviewed in 
Greber, 1998; Nemerow and Stewart, 1999). Initially the adenovirus attaches to the 
cellular receptor via the fibre protein (Philipson et al., 1968; Henry et al., 1994; Louis et 
al., 1994). A common receptor, CAR, was reported for coxsackie B viruses and 
adenoviruses (Bergelson et al., 1997; Tomko et al., 1997) and shown to be a cellular 
receptor for subgroups A, C, D, E and F (Roelvink et al., 1998). An alternative receptor 
has also been identified as MHC class I (Hong et al., 1997). Entry is facilitated by the 
RGD sequence (Stewart et al., 1997) within the penton base binding with a vp3/5 
integrins (Wickham et al., 1993; Bai et al., 1994), allowing viral endocytosis into 
clathrin coated pits (Svensson, 1985; Varga et al., 1991; Bai et al., 1993; for detailed 
review see Nemerow and Stewart, 1999), at which point the fibre protein dissociates 
(Greber et al., 1993).
The virus particles then penetrate into the cytoplasm via endosomes; the endosomes are 
eventually lysed releasing viruses into the cytosol (Dales, 1978; Pastan et al., 1986). 
Lysis of the endosomes is thought to be catalysed by a viral factor which is activated by 
low pH (Pastan et al., 1986; Wohlfart, 1988; Varga et al., 1990). Stepwise uncoating of 
the viral particle continues through the cytoplasm (Greber et al., 1993) until the virion 
reaches the nucleus. Release and dissociation of the viral DNA requires the cysteine 
protease p23, which is activated by a redox-dependent conformational change, enabling 
degradation of protein VI thus weakening the cytosolic capsid (Greber et al., 1996; 
Mangel et al., 1997). Entry of viral DNA and the associated proteins V, VII, TP and p 
into the nucleus, requires interaction between the weakened cytosolic capsid and the 
nuclear pore complexes (NPC) (Greber et al., 1997). The TP p55 is covalently attached 
to the viral DNA and contains a nuclear localisation signal (NLS), which may function 
in threading the viral DNA through the NPC (Zhao and Padmanabhan, 1988; Schaack et 
al., 1990). The viral DNA is then tethered via the TP to the nuclear subregion 
characterised by the nuclear domain (ND10) antigens (Ishov and Maul, 1996).
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1.1.4.2 Transcription
The adenovirus genes are expressed in two distinct phases termed early (E) (El A, E1B, 
E2A, E3, E4 and LI) and late (L) (E2B, LI, L2, L3, L4 and L5) separated by the onset 
of DNA replication. However, several other genes are expressed at intermediate times 
(ppIX, IVa2, VA1 and VA2 RNA). VA RNAs are transcribed by cellular RNA 
polymerase IE whilst the other adenovirus genes are transcribed by cellular RNA 
polymerase II (Price and Penman, 1972; Weinmann et al., 1976).
Early Transcription
Early region 1A
The early region 1A (El A) transcription unit is situated on the r strand between 1.5-4.5 
m.u. (figure 1.1.3) (Jones and Shenk, 1979). A common nuclear precursor RNA or 
primary transcript is differentially spliced to produce five messenger ribonucleic acids 
(mRNA) known as 13S, 12S, 1 IS, 10S and 9S mRNA; each mRNA differs in size as a 
result of the excised intron size, which is determined by different splice donor sites 
linking to a common splice acceptor site (figure 1.1.4.2). The 13S, 12S, 1 IS, 10S and 
9S mRNAs share common 5' and 3' ends (Berk and Sharp, 1978; Chow et al., 1979; 
Stephen and Harlow, 1989; Ulfendahl et al., 1987). The 13S and 12S mRNAs are 
predominant in infection producing two proteins of 289 residues (R) and 243R 
respectively. These proteins differ in an internal 46 amino acid (aa) region that is 
present only in the 289R protein (Perricaudet et al., 1979). The 289R protein is 
primarily responsible for toa/is-activation of the E l A region and the other early regions 
(Jones and Shenk, 1979; Ricciardi et al., 1981; Montell et al., 1982; reviewed by Berk, 
1986). The 1 IS and 10S mRNAs are present late in infection, but are only minor 
species of mRNA (Stephens and Harlow, 1987). The 9S mRNA is predominant late in 
infection (Spector et al., 1978; Chow et al, 1979). An in depth review of the E1A 
region is undertaken in section 1.2.
Early region IB (E1B)
The early region IB (E1B) transcription unit lies downstream of the El A region 
between 4.6-11 m.u.. Transcription from the E1B promoter is maximised by a 
czs-dominant property of the early viral template, which does not allow transcription to
CR1 CR2 CR3
13S
12S
US
10S
AR1 AR2
289R
243R
217R
171R
9S 55R
Figure 1.1.4.2 The Ad2 E1A mRNAs and protein products. The mRNA is denoted by black 
lines; introns are denoted by caret symbols; open reading frames are denoted with boxes; 
conserved regions 1, 2 and 3 denoted by CR1, CR2 and CR3; and auxiliary regions 1 and 2 
denoted by AR1 and AR2. The size of the mRNA is denoted on the left-hand side and protein 
size indicated on the right-hand side (modified from Jones, 1992).
terminate between the El A gene and the E1B gene, instead readthrough transcription 
occurs offering maximum early E1B gene expression (Maxfield and Spector, 1997). A 
common precursor mRNA is then differentially spliced to produce a 22S, 14.5S, 14S, 
13S and 9S mRNA which share common 5' and 3' termini (Berk and Sharp, 1978; 
Pettersson et al., 1983). The 22S mRNA is predominant early in infection and encodes 
a 19kDa protein using the first AUG and a 55kDa protein using the second AUG 
(Halbert et al., 1979; Bos et al., 1981; Glenn and Ricciardi, 1988). The 19kDa proteins 
function is to suppress p53-dependent and p53-independent induced apoptosis during 
adenovirus infection; correct localisation of the 19kDa protein is essential for this 
function, and the interaction of the 19kDa protein with lamin A/C may represent a 
means for nuclear envelope localisation (Rao et al., 1997). The 19kDa protein is also 
capable of inhibition of tumour necrosis factor (TNF) cytolysis (Gooding et al., 1991). 
The 55kDa protein is a multifunctional phosphoprotein, which is required for complete 
oncogenic transformation of rodent cells, viral DNA replication and late viral RNA 
translation (Harada and Berk, 1999). The 14.5S and 14S mRNAs are minor species 
which are similar to the 13S mRNA, but have an additional third exon and encode for 
the 55kDa and 19kDa proteins (Anderson et al., 1984; Virtanen and Pettersson, 1985). 
The 13S mRNA however, is predominant at intermediate times after infection and also 
encodes the 19kDa protein (Halbert et al., 1979; Bos et al., 1981). The 9S mRNA is 
transcribed from a separate promoter within the ElB  region at intermediate times after 
infection and encodes the structural ppIX which is associated with the hexon-hexon 
interfaces of GONs within the capsid (Furcinitti et al., 1989; Stewart et al., 1993).
Early region 2 (E2)
The early region 2 (E2) transcription unit is situated on the 1 strand and lies between 
75.4-11.3 m.u. (Chow et al., 1979). It differs from other adenovirus transcription units 
by having two alternative promoter sites, E2A and E2B, which are used at different 
times in infection (Chow et al., 1979). The E2A promoter is activated by the El A and 
E4 ORF6/7 gene products (reviewed in Swaminathan and Thimmapaya, 1995), whilst 
the E2B promoter is repressed by the El A gene products (Rossini, 1983). Early in 
infection E2A transcripts are expressed from a promoter at 75.4 m.u., then terminate 
using the polyadenylation (poly A) site at 62.4 m.u.; following the early to late phase 
transition E2B transcripts are expressed from a promoter at 72.2 m.u., then terminate
using the poly A site at 11.3 m.u. (Nevins et al., 1979; Stillman et al., 1981; Glenn and 
Ricciardi, 1988). The E2A primary transcript is differentially spliced to produce two 
mRNAs which vary in length by approximately 100 nucleotides (nt) (Berk and Sharp, 
1978); both mRNAs encode a 72kDa single stranded DNA binding protein (DBP) 
(Lewis et al., 1976). DBP is essential for viral DNA replication (section 1.1.4.3) 
(reviewed in de Jong and van der Vliet, 1999), and is involved in the regulation of viral 
gene expression (Klessig and Grodzicker, 1979; Babich and Nevins, 1981). DBP also 
regulates its own synthesis and enhances transcription from the El A promoter, the E2A 
promoter and the major late promoter (MLP) (Morin et al., 1989; Chang and Shenk, 
1990; Zijderveld et al., 1994; Swaminathan and Thimmapaya, 1995). The E2B primary 
transcript is differentially spliced to produce three mRNAs (Stillman et al., 1981; Shu et 
al., 1988), two of which encode an 80kDa pTP and a 140kDa adenovirus DNA 
polymerase (Adpol). pTP acts as a primer for DNA replication (Smart and Stillman, 
1982; Salas, 1991) and is cleaved by p23 late in infection to produce the 55kDa TP 
(reviewed Challberg and Kelly, 1989; Hay et al., 1995). Adpol functions in the 
initiation and elongation of viral DNA replication (Stillman et al., 1982; Hay et al., 
1995; van der Vliet, 1995).
Early region 3 (E3)
The early region 3 (E3) transcription unit is situated on the r-strand between 76.8-85.9 
m.u.. The E3 primary transcript is polyadenylated at one of two poly A sites (E3A or 
E3B), producing two families of transcripts which differ in their poly A site (Berk and 
Sharp, 1977, 1978; Chow et al., 1979; Cladaras and Wold, 1985; Cladaras et al., 1985; 
Wold et al., 1995). The subgroup C adenovirus E3 region is predicted to encode nine 
proteins (reviewed Wold et al., 1995; Mahr and Gooding, 1999; Wold et al., 1999) of 
which five have been assigned functions. The E3B proteins interfere with either the 
host cell functions or the immune response during an adenovirus infection by a number 
of different routes. The E3 19kDa glycoprotein (gpl9K) is an abundant transmembrane 
protein which binds to certain alleles of the class I major histocompatibility complex 
(MHC), retaining them within the endoplasmic reticulum (ER) through an ER retention 
signal (reviewed in Sparer and Gooding, 1998). This has been shown to reduce 
cytotoxic T-lymphocyte (CTL) recognition of adenovirus-infected cells in vitro, 
however it is unclear if this is the case in vivo (reviewed in Ploegh, 1998; Mahr and
Gooding, 1999). The A di2 genome does not encode gpl9K, however it is still able to 
repress transcription of the class I MHC genes through the El A gene products. Ad 12 
can also mediate transcriptional repression of genes involved in antigen presentation, 
namely the transporter associated with antigen presentation (TAP) genes and MHC- 
encoded proteasome components (reviewed in Blair and Hall, 1998).
The E3 RIDa/p (heteromeric complex of E3 10.4kDa and 14.5kDa proteins) and 
14.7kDa proteins protect adenovirus-infected cells from cytolysis by tumor necrosis 
factor (TNF). Adenovirus infected cells are sensitised to TNF cytolysis by the El A 
proteins through the TNF receptor 1 (TNFR1), Fas and the TNF-related 
apoptosis-inducing ligand- (TRAIL) R l, (reviewed in Mahr and Gooding, 1999; Wold 
et al., 1999). The 14.7kDa protein is a nonmembrane protein located in the cytosol and 
the nucleus of infected cells. TNF cytolysis is circumvented by the 14.7kDa protein 
binding with cellular proteins such as the 14.7kDa-interacting protein (FIP) -3, FIP-2 
and FIP-1 (reviewed in Wold et al., 1999). The RIDa/p proteins are type I integral 
membrane proteins, located in the plasma membrane, which act as a complex consisting 
of one RIDp protein and two RIDa proteins. The RIDa/p protein complex is able to 
protect cells against TNF-mediated cytolysis by preventing activation of cytosolic 
phospholipase A2 (cPLA2) by TNF; or Fas-mediated cytolysis by downregulation of Fas 
at the cell surface (reviewed in Mahr and Gooding, 1999; Wold et al., 1999). The 
RIDa/p complex also mediates TNF cytolysis by downregulation of El A gene 
expression at the level of El A mRNA translation (Zhang et al., 1994). Other E3 
proteins include the 11.6kDa protein, also known as the adenovirus death protein 
(ADP), a glycoprotein located primarily at the nuclear membrane, which functions to 
program efficient cell death, that is lysis of infected cells (Scaria et al., 1992; Tollefson 
et al., 1996). The functions of the 12.5kDa and 6.7kDa proteins are still unknown 
(reviewed in Wold et al., 1999).
Early region 4 (E4)
The early region 4 (E4) transcription unit lies on the 1-stand between 91.3-99.1 m.u. 
(figure 1.1.3). The E4 promoter is activated by El A at early times after infection, 
resulting in an early peak of E4 transcription, followed by a decrease in E4 transcription 
at intermediate times after infection as a result of E4 promoter inhibition by DBP
(Nevins and Winkler, 1980; Handa et al., 1983; Glenn and Ricciardi, 1988). The E4 
primary transcript can produce up to 24 mRNAs by alternative splicing, these are 
temporally regulated during infection and can produce at least ten proteins (Freyer et al., 
1984; Tigges and Raskas, 1984; Virtanen et al., 1984; Ross and Ziff, 1992; Dix and 
Leppard, 1993). Five of the aforementioned proteins are produced from open reading 
frames (ORF) colinear with the viral DNA, denoted ORF 1, 2, 3, 4 and 6; and two 
proteins are created by alternative splicing of the primary transcript, denoted ORF 3/4 
and 6/7 (Freyer et al., 1984; Virtanen et al., 1984). Expression of ORF1 has not been 
demonstrated in most adenovirus infected cells, however it is expressed in Ad9 infected 
cells, where it cooperates with El A and E1B to produce mammary tumours in rats 
(Javier, 1994; reviewed in Leppard, 1997). The ORF2 protein is a soluble cytoplasmic 
component, which has not been found in association with any other infected cell 
components (Dix and Leppard, 1995). It is also unclear whether the ORF3/4 protein is 
expressed, as it has not been detected in Ad5 infected cells (Dix and Leppard, 1993). 
ORF4 produces a 14kDa protein, which regulates transcription from the El A and the E4 
promoters, by protein dephosphorylation of El A and c-fos by protein phosphatase (PP) 
2A (Bondesson et al., 1996; Whalen et al., 1997; reviewed in Leppard, 1997). It may 
also induce p53-independent apoptosis in a PP2A-dependent manner (Shtrichman and 
Kleinberger, 1998). The proteins from ORF3 (llkD a) and ORF6 (34kDa) increase late 
protein production at the level of mRNA accumulation. Both ORF3 and ORF6 stabilise 
unprocessed late viral mRNA within the nucleus of the cell, thereby increasing the pool 
of RNA available for maturation. ORF6 can also cooperate with the E1B 55kDa protein 
to increase nuclear export of viral mRNA and prevent nuclear export of cellular mRNA. 
ORF6 contains a nuclear export signal (NES), which is responsible for 
nucleocytoplasmic shuttling by ORF6 and E1B 55kDa (Weigel and Dobbelstein, 2000). 
The association of ORF6 and E1B 55kDa results in viral inclusion bodies within the 
nucleus, which are essential for late viral transcription and RNA processing. On the 
other hand ORF3 affects distribution of structures essential for transcription and 
replication, known as ND10 or PODs (Leppard and Everett, 1999). Finally ORF6 has 
been shown to inactivate p53-dependent apoptosis and cooperate with El A to transform 
primary rodent cells (Nevels et al., 1999). ORF6/7 encodes a 19.5kDa protein, which is 
located in the nucleus of infected cells (Cutt et al., 1987). Two molecules of ORF6/7 
stabilise cooperative binding of E2F on the E2F dimeric binding site, within the E2A
promoter (reviewed in Swaminathan and Thimmapaya, 1995; all the E4 proteins are 
reviewed in detail in Leppard, 1997).
Intermediate Transcription
The transcription unit encoding polypeptide (pp) IX lies within the EIB region (Wilson 
et al., 1979), and is expressed at intermediate times during infection (Spector et al.,
1978). Maximum transcriptional activity from the ppIX transcription unit requires viral 
DNA replication (Vales and Darnell, 1989), producing an mRNA which is unspliced 
and 3' coterminal with the E1B transcripts (Alestrom et al., 1980).
The virus-associated (VA) transcription unit is situated on the r-strand at 30 m.u. and is 
transcribed by host RNA polymerase El (Weinman et al., 1976; reviewed in Mathews 
and Shenk, 1991; Mathews, 1995). Most human adenoviruses have two VA genes (VAI 
and VAH), however adenoviruses in subgroups A, F and some of B have only one gene 
(Ma and Mathews, 1993; Kidd and Tiemessen, 1993; Ma and Mathews, 1996). The 
efficiency of late adenoviral protein synthesis is mediated by VAI RNA, which is 
responsible for repression of the cellular kinase PKR (also known as DAI), allowing 
viral protein synthesis to proceed (Thimmappaya et al., 1982; Kitajewski et al., 1986; 
reviewed in Mathews, 1995). VAH RNA can bind to RNA helicase A and NF90 (a 
component of the heterodimeric nuclear factor of activated T cells (NFAT)), suggesting 
that VAII RNA may mediate their regulation (Liao et al., 1998).
The IVa2 transcription unit is located on the 1-strand between 11.3-16 m.u.. 
Transcription from the IVa2 transcription unit terminates at the E2B poly A site. The 
IVa2 protein is found in the nucleus of cells (Lutz and Kedinger; 1996; Lutz et al.,
1996), and is required for late phase activation of the MLP (Lutz and Kedinger, 1996), 
and in assembly intermediates (Winter and D ’Halluin, 1991; Hasson et al., 1992). The 
IVa2 protein also forms complexes with LI 52kDa/55kDa protein complex, which is 
required to mediate stable association between viral DNA and the empty capsid (Gustin 
et al., 1996; Gustin and frnperiale, 1998). IVa2 is also able to bind to the adenoviral 
DNA packaging signal which suggests a role for IVa2 in viral DNA encapsidation 
(Zhang and Imperiale, 2000).
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Late Transcription
The MLP is situated at 16.8 m.u. on the r strand, and is active throughout adenovirus 
infection. However, a fully functional MLP is required to demonstrate a decrease in 
early gene expression, and is mediated in trans but not cis (Fessler and Young, 1998). 
Transcription from the MLP is increased late in adenovirus infection by two proteins 
known as DBP and IVa2. DBP enhances binding of upstream stimulating factor (USF) 
through conformational changes to the binding site (Zijderveld et al., 1994), while IVa2 
stimulates late phase activation by co-operation of the downstream promoter element 
(DPE) with factors bound to upstream elements. IVa2 binds to the DPE either as a 
homodimeric complex of DEF-B; or as part of a heteromeric complex known as DEF-A, 
which binds to the DPE1 and the 3' end of DPE2 (Jansen-Durr et al., 1989; Mondesert 
et al., 1992; Tribouley et al., 1994; Lutz et al., 1996). At late times in infection five 
mRNA families (LI, L2, L3, L4 and L5) are transcribed from this promoter (Shaw and 
Ziff, 1980; Nevins and Wilson, 1981). Each mRNA species contains a common set of 
three short 5' leader sequences, known as the tripartite leader, which are joined to 
different splice acceptor sites (Berget et al., 1977; Chow et al., 1977). The poly A sites 
LI and L3 contain czs-acting elements that are necessaiy to elicit a temporal switch in 
poly A site usage (Gilmartin et al., 1996; Prescott et al., 1997; reviewed in 
Edwalds-Gilbert et al., 1997; Zhao et al., 1999).
The late region (LI) region is expressed at early and late times during infection (Shaw 
and Ziff, 1980; Nevins and Wilson, 1981), producing mRNAs during the early phase of 
viral infection which differ from the major late mRNAs by the presence of an additional 
leader sequence (i), which is spliced between the second and third exons of the tripartite 
leader (Akusjarvi and Persson, 1981). The inclusion of the i leader is facilitated by E4 
ORF3 (Nordqvist et al., 1994). Transcripts from the LI region encode three proteins; 
the 52kDa and the 55kDa proteins are expressed at early and late times in infection, 
whilst protein m a is expressed at late times in infection (Akusjarvi and Persson, 1981; 
Kreivi and Akusjarvi, 1994). The 52kDa and the 55kDa proteins are required for 
assembly of virions (Gustin and Imperiale, 1998; reviewed in Greber, 1998), in 
particular they act as a scaffold mediating stable association of the viral DNA and the 
empty capsid. The protein ffia functions as a structural polypeptide linking adjacent 
facets of hexons by spanning the capsid wall (reviewed in Burnett, 1997). The L2
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region encodes four virion proteins, known as precursor (p)m, pVE, pV and pX, which 
is the precursor for p (Anderson et al., 1989; Russell and Kemp, 1995). Proteins V, VII 
and the minor component p are condensed with the viral DNA (reviewed in Burnett,
1997). The L3 region encodes three virion proteins known as pVI, hexon and p23 (see 
sections 1.1.2; 1.1.4.4) (reviewed in Burnett, 1997; Mangel et al., 1997). The L4 region 
encodes three proteins, one of which is structural pVm, and two non-structural proteins 
of 33kDa and lOOkDa in size. The minor protein pVIH is localised with the capsid, and 
is most likely to occur inside the capsid. The 33kDa protein has no known function 
(Oosterom-Dragon and Anderson, 1983), however the lOOkDa protein functions to 
assemble hexon into trimers (Oosterom-Dragon and Ginsberg, 1981; Cepko and Sharp, 
1982, 1983), and is necessary for the efficient initiation of translation of late mRNA 
(Hayes et a l, 1990). The L5 region encodes the fibre protein. A substantial fraction 
(30%) of fibre mRNAs, in addition to the tripartite leader, have various combinations of 
three ancillary leader sequences x, y and z (Chroboczek et al., 1995).
1.1.4.3 DNA replication
DNA replication is initiated at either end of the adenovirus genome, then proceeds 
unidirectionally by a strand displacement mechanism made up of Type I and Type II 
replication (reviewed in van der Vliet, 1995; de Jong and van der Vliet, 1999). Type I 
replication consists of initiation at the end of the terminus using a protein-primer (3' OH 
group) and elongation using a single strand as a template and Adpol; the non-template 
(or displaced) strand is then replicated during Type II replication, for which the origin of 
replication is a panhandle structure formed as a result of the ITRs base pairing 
(reviewed in Challberg and Kelly, 1989; Hay and Russell, 1989; Stillman, 1989). Adpol 
and pTP form a heterodimer (pTP-pol) which recognises the core origin in the ITR, this 
complex catalyses the formation of pTP-dCMP from which the 3' OH group originates 
(Smart and Stillman, 1982).
Initiation of DNA replication is enhanced by two cellular transcription factors nuclear 
factor (NF) I or CAAT transcription factor, and NFDI or octamer binding protein (for a 
detailed review see de Jong and van der Vliet, 1999), which bind to two adjacent sites 
near the core origin in the ITR; this region is known as the auxiliary region. NFI binds 
as a dimer to its recognition site and interacts with the pTP-Adpol heterodimer (Dekker
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et al., 1996), acting to stabilise the initiation complex on the template at the correct 
positions (Chen et al., 1990; Mul and van der Vliet, 1992; Armentero et al., 1994). 
NFm binds to its recognition site stimulating initiation of DNA replication by direct 
interaction with the pTP-pol complex (Coenjaerts et al., 1994). Initiation of DNA 
replication is also enhanced by DBP, which increases the binding efficiency of NFI to its 
recognition site (Cleat and Hay, 1989; Stuvier and van der Vliet, 1990), and lowers the 
Km value for the formation of the initiation complex (Mul and van der Vliet, 1992). 
DBP has helix destabilising properties (Zijderveld and van der Vliet, 1994) which could 
assist in strand displacement during replication. DBP is also required for elongation, 
during which it increases the rate of synthesis and processivity of Adpol, and covers the 
displaced strands (Lindenbaum et al., 1986).
1.1.4.4 Virion assembly
Adenovirus particles are formed during a multistage process (figure 1.1.4.4), the first of 
which results in the formation of hexon, penton base and fibre capsomers. The hexon 
trimers are formed in the presence of the L4 lOOkDa protein, which is thought to avoid 
assembly errors. The hexon trimer, along with the penton base and fibre are then 
transported into the nucleus where they are assembled into an empty capsid, composed 
of hexon, penton base, fibre and the proteins pllla, pVI and pVIfi (reviewed in 
D’Halluin, 1995). The empty capsids also contain the LI 52kDa/55kDa heteromeric 
complex, which is thought to act as a scaffolding protein. The next intermediate is 
known as the heavy intermediate, as it contains the viral DNA covalently linked to TP. 
However, it lacks most of the scaffolding proteins and the core proteins V, VII and p. It 
is not clear how the DNA is packaged into the empty capsid, however a number of 
proteins including LI 52kDa/55kDa, Dla and IVa2 are involved. The young virion 
contains pIQa, pVI, pVQ, pVDI, pX and pTP, which are cleaved by p23 to form the 
mature virion (reviewed in D’Halluin, 1995; Mangel et al., 1997; Greber et al., 1998).
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Figure 1.1.4.4 The adenovirus assembly pathway. The four stages of virus assembly; light 
intermediates, heavy intermediates, young virions and mature virions are shown. The 
polypeptides only present in some structures are also shown, (modified from D’Halluin, 1995).
1 . 2  E a r l y  R e g i o n  1 A
The El A region has been studied extensively, and found to play an important role in the 
regulation of adenovirus transcription and transformation. This section describes the 
El A promoter, El A gene transcription, the El A protein products and their functions.
1.2.1 The E1A promoter
The El A promoter is able to initiate transcription in the absence of any viral factors, 
however transcription of the remaining early viral genes requires E l A gene expression 
(Berk et al., 1979; Jones and Shenk, 1979; Nevins, 1981).
Eukaryotic promoters contain a core promoter element and upstream enhancer elements 
(Roeder, 1991). The El A promoter, like other eukaryotic promoters, contains a core 
promoter element and upstream enhancer elements (figure 1.2.1). The El A promoter is 
able to initiate RNA polymerase II directed transcription immediately after adenovirus 
infection through the core promoter and upstream enhancer sequences (sections 1.2.1.1 
and 1.2.1.2; reviewed in Yoshida et al., 1995).
1.2.1.1 The E1A core promoter
The core promoter consists of a TATA element, an initiator sequence, and a DPE, which 
binds TFIID to initiate the assembly of the preinitiation complex (PIC) containing RNA 
polymerase II and its associated basal transcription factors (Hoey et al., 1990; Verrijzer 
et al., 1995; Zawel and Reinberg, 1995; Burke and Kadonaga, 1997). The upstream 
enhancer elements are bound to a variety of cellular transcription factors, which are 
bridged by coactivators to the basal transcription factors bound at the core promoter, 
supporting enhancer-dependent transcription (reviewed by Hampsey, 1998). The three 
dimensional structure of TFIID consists of a horseshoe-like structure, which suggests 
some conformational flexibility (Brand et al., 1999; Andel et al., 1999). The TFIID 
complex consists of the TATA-box binding protein (TBP), and several TBP-associated 
factors (TAFs). TBP is located near the midpoint of the complex, adjoining a 4nm 
central cavity that most likely accommodates the DNA at the TATA box. Recombinant 
TBP has been shown to stimulate the initiation of basal transcription in vitro as 
efficiently as the TFIID complex, but it is unable to direct enhancer-dependent
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transcription as efficiently as TFIID (Kambadur et al., 1990; Meisteremst et al., 1990; 
Pugh and Tijan, 1990; Dynlacht et al., 1991; Tanese et al., 1991). The functional 
difference between TFIID and TBP in enhancer-dependent transcription can be 
explained by an additional set of factors found in association with TBP (approximately 
8-12 ranging in size from 250 to 20 kDa), known as TAFs, which mediate signals 
between upstream enhancer elements and TBP, and between fraws-activators and TBP 
(section 1.2.4.2) (Pugh and Tijan, 1990). TAFs not only function as activators of 
enhancer-dependent transcription, but also act as promoter selectivity factors, and in the 
case of TAFn250, are also able to act enzymically, modifying neighbouring proteins or 
histones in the chromatin-assembled DNA template and thereby controlling their 
function (reviewed in Albright and Tijan, 2000). The activity of TFIID also appears to 
be regulated by inhibitory proteins such as D rl, which interact with TBP. This may 
serve as an important regulatory function by keeping genes, which have been removed 
from inactive chromatin, in a repressed but rapidly inducible state (Inostroza et al., 
1992).
Like many other eukaryotic promoters, the El A core promoter also contains an initiator 
sequence (which includes the sequence where transcription actually begins, known as 
the cap site) and a DPE. The Ad2 E l A cap site is located at nucleotide 499 relative to 
the ITR, and occurs within a hyphenated symmetry (Baker and Ziff, 1981). Sequences 
between positions -35 to +20 (relative to the cap site) are important for efficient Ad5 
E1A transcription in vitro and in vivo. The E1A TATA box is located within this 
region, between positions -31 to -24 (relative to the cap site); deletion of the TATA box 
in vitro results in a complete lack of ElA-specific transcripts, whereas in vivo the 
number of ElA-specific transcripts is reduced by 62% (Hearing and Shenk, 1983a). 
The TATA box deletion mutant in vivo, still encodes reduced amounts of ElA-specific 
mRNAs, which suggests that other sequences within the core promoter direct RNA 
polymerase II to the transcription initiation site. The DPE (cw-acting) is located at +399 
(relative to the cap site), and shares homology with the simian virus 40 (SV40) enhancer 
(Weiher et al., 1983). A single base change at position +399 results in a five-fold 
reduction in transcription, due to inactivation of the 289R and 243R E l A proteins. The 
same element also acts in cis to reduce E l A mRNA and nuclear RNA concentrations by 
a factor of ten (Osbourne et al., 1984). These mutations may cause their effect at the
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post-transcriptional level. The out of frame mutation of the El A protein-coding region 
may cause premature termination in translation and instability of mutant El A mRNA, 
resulting in a reduction of El A mRNA levels (Hearing and Shenk, 1985).
1.2.1.2 Upstream enhancer elements of the E1A promoter
Since the E l A gene should be expressed soon after entry of viral DNA into the nucleus 
of the cell, it is therefore logical that the El A gene is preceded by multiple upstream 
enhancer elements. Four enhancer elements have been identified at the following 
positions relative to the cap site: -498 to -396 (Hatfield and Hearing, 1991); -343 to -320 
(Hen et al., 1983); -305 to -141 (Hearing and Shenk, 1983b); and -188 to -45 
(Imperiale et al, 1983).
The ITR contains a number of potential transcription factor binding sites (figure 1.2.1.); 
indeed several laboratories have found intrinsic promoter and enhancer activities within 
the ITR, although it is not clear whether they are of great functional significance. For 
example, when the ITR is placed adjacent to the E1A TATA box in vitro, transcription 
from the El A region increases (Hatfield and Hearing, 1991). Also transcription from 
the E4 promoter is enhanced by the ITR (Ooyama et al., 1989).
The Ad2 El A promoter contains a 24bp enhancer element, located between positions 
-343 and -320 (relative to the cap site) (Hen et al., 1983). This element can stimulate 
transcription from the MLP when inserted in the direction of transcription, however it is 
dispensable for efficient transcription within virus-infected cells (Hearing and Shenk, 
1983b). The requirement for the 24bp enhancer element is diminished in the presence 
of the El A proteins, so it is unclear whether it plays a part in transcription from the El A 
promoter before the onset of E1A protein synthesis (Sassone-Corsi et al., 1983). In 
rodent CREF cells, the 24bp enhancer element also functions as a repressor of the El A 
enhancer (Herbst et al., 1990). Repressor function is mediated by a 100-110kDa 
AP3-like protein called (pAP3, which binds to the 24bp enhancer element (Fognani et 
al., 1993). A second 60 kDa protein isolated from HeLa cells, also binds to the same 
region within the 24bp enhancer (Barrett et al., 1987). Overlapping the cpAP3 binding 
site are two potential binding sites for the transcription factors ATF (at position -330 to -
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323, relative to the cap site), and EF-1A (at position -344 to -338, relative to the cap 
site) (Lin and Green, 1988; Bruder and Hearing, 1989; Yoshida et al., 1989).
The Ad5 El A promoter contains a second enhancer region between positions -305 to 
-141 (relative to the cap site), deletion of which results in a 15 to 20 fold decrease in 
El A enhancer-dependent transcription in vivo (Hearing and Shenk, 1983b). The 
conformation of a portion of the El A enhancer element (from position -301 to -218) has 
been shown to facilitate transcription from the El A region. The enhancer adopts a 
curved structure, which may facilitate El A gene expression by influencing promoter 
melting and/or by providing a framework for protein-DNA and/or protein-protein 
interactions (Ohyama, 1996). Two distinct elements are responsible for El A 
enhancer-dependent transcription (element I and II) within this region (Hearing and 
Shenk, 1986).
The El A promoter contains two copies of element I, at positions -301 to -289 and -203 
to -192 (relative to the cap site) however, this location varies in adenoviruses from 
subgroups A and B (van Ormondt and Galibert, 1984; Hearing and Shenk, 1986). 
Element I specifically regulates transcription from the El A region within virus infected 
cells. A degenerate copy of element I is located at positions -272 to -263 (relative to the 
cap site); and two further copies of element I-related sequence lie further upstream. The 
two copies of element I (sites 1 and 3 figure 1.2.1.), and the three copies of the element 
I-related sequence (sites 2, 4 and 5 figure 1.2.1.), contain the consensus binding site for 
EF-1A (Bruder and Hearing, 1989; Yoshida et al., 1989). EF-1A binding is determined 
by the core nucleotides of each binding site, whereas transcriptional activation is 
determined by both core and peripheral nucleotides (Bolwig et al., 1992). However, 
efficient binding of EF-1A at the dimeric binding site (sites 2 and 3) is essential, but not 
sufficient to activate transcription. EF-1A binds cooperatively at sites 1 and 2, 2 and 3, 
and 4 and 5; and cooperative binding of EF-1 A at site 2 to neighbouring sites 1 and 3 in 
the El A enhancer region results in synergistic activation of E l A transcription (Bruder 
and Hearing, 1991). EF-1 A belongs to the ets oncogene family, and is composed of two 
subunits a  and p. Binding of both the a  and p subunits of EF-1 A at the binding site is 
necessary but not sufficient for transcriptional activation (Bolwig et al., 1992). EF-1 A a 
contains the ETS domain, which is responsible for site-specific DNA binding, whereas
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EF-lAp contains four 32-33aa ankyrin repeats in the N-terminal region, and possesses 
no DNA binding activity. The ETS domain and the ankyrin repeats are required for 
multi-heterodimerisation of a  and p subunits on the dimeric EF-1 A binding site which 
is associated with enhancer activity in vivo (Thompson et al., 1991).
Four copies of element II are situated between the two copies of element I (sites 1 and 3, 
figure 1.2.1), and span approximately 30bp from positions -250 to -218 (relative to the 
cap site, figure 1.2.1). Element II regulates transcription in cis from all early regions, 
however the factors which interact with element 13 have not been described. Elements I 
and II function independently, and neither is required for efficient viral DNA replication 
(Hearing and Shenk, 1986).
A third enhancer element, an E2F binding site, is repeated at positions -288 to -281 and 
-225 to -218 (relative to the cap site; figure 1.2.1). The E2F site at -288 to -281 has 
been shown to stimulate transcription of a heterologous linked gene in an 
ElA-dependent fashion (Kovesdi et al., 1987). However, in virus-infected HeLa cells, 
transcription of the El A gene is not influenced by deletion of the two E2F sites from the 
enhancer region (Bruder and Hearing, 1989).
A fourth enhancer element has been identified within the El A promoter, situated at 
positions -188 to -45, which is able to enhance expression of the E2A 72kDa protein 
when linked to the E2A gene (Imperiale et al., 1983). However, this enhancer element 
is unable to enhance transcription from the E1A promoter (Sassone-Corsi et al., 1983), 
and is dispensable for efficient transcription from the El A gene in virus-infected cells 
(Hearing and Shenk, 1983a).
1.2.2 El A transcription
The El A primary transcript or pre-mRNA is alternatively spliced to produce a 13S, 12S, 
1 IS, 10S and 9S mRNA species (figure 1.1.4.2); with the exception of the 9S transcript, 
all transcripts share 5' and 3' ends. The E l A primary transcript gives rise to three major 
mRNAs, the 13S, 12S and 9S mRNAs, by use of three alternative 5' splice sites 
(figure 1.1.4.2) (Berk and Sharp, 1978; Chow et al., 1979; Perricaudet et al., 1979).
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Two minor mRNAs are also produced from the El A primary transcript, the 11S and 
10S, by the removal of an additional intron i.e. the 9S 5' splice site is joined to a novel 
3' splice site located upstream of the 12S 5' splice site (figure 1.1.4.2).
Efficient splicing of the primary transcript requires a 5' cap structure to enable efficient 
utilisation of the adjacent 5' splice site, definition of the first exon, and removal of the 
first intron (Izaurralde et al., 1994). The primary transcript is spliced in a two-stage 
reaction (figure 1.2.2.1). In the first stage the primary transcript is cleaved at the 5' 
splice site, generating a first exon ribonucleic acid (RNA) species and an intron-second 
exon RNA species in lariat formation. During the second stage of the splicing reaction 
the 3' splice site is cleaved, allowing ligation of the exons to produce a spliced mRNA 
(Padgett et al., 1984; Ruskin et al., 1984). The splicing reaction takes place in a large 
macromolecular structure known as the spliceosome (figure 1.2.2.2), which consists of 
small ribonucleoprotein particles (snRNPs) U l, U2, U4/U6 and U5, and non-snRNPs. 
The non-snRNPs include a family of proteins known as the SR proteins. The SR 
proteins are a family of essential splicing factors required for early recognition of splice 
sites during the spliceosome assembly (Screaton et al., 1995). One such protein has 
been described for the El A primary transcript (p54), which is able to recognise and 
promote the use of the 5' splice site in the E l A primary transcript in a tissue- and 
substrate-dependent manner (Zhang and Wu, 1995). The SR protein function can be 
modified by phosphorylation/dephosphorylation: for example, in late adenovirus 
infected cells the SR proteins are inactivated as splicing enhancer or repressor proteins 
by E40RF4 induced dephosphorylation by PP2A (Kanopka et al., 1998).
The spliceosome assembles on the primary transcript in a stepwise manner, forming four 
discrete complexes E-A-B-C (figure 1.2.2.2). Complex E is believed to irreversibly 
define the exon-intron boundaries in the primary transcript, and is formed when Ul 
snRNP binds to the 5' splice site; at the same time U2AF binds to the pyrimidine tract 
between the branch point and the 3' splice site. Efficient recognition of the 5' splice site 
by U l snRNP is facilitated by the nuclear cap binding complex (CBC) (Lewis et al.,
1996). The RS domains of U l snRNP and U2AF associate with the non-snRNP 
proteins, forming a bridge between the 5' and 3' splice sites allowing functional
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Figure 1.2.2.1 The splicing reaction. Splicing occurs in a two step reaction (section 1.2.2 In 
step one, the hydroxyl group of the A residue at the branch point site, and p is the phosphate of 
G. In step 2, OH is the hydroxyl group of the last residue of exon 1, and p  is the phosphate 
group of the first residue of exon 2. ). Boxes denote exons 1 and 2; the single line denotes 
intronic sequences to be removed (reproduced from Green, 1991).
99999
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Complex C
Figure 1.2.2.2 Proteins involved in the mammalian splicing pathway. Two snRNP/pre- 
mRNA interactions form the basis o f the spliceosome. Firstly, U l snRNP binds to the 51 splice 
site while at the same time the splicing associated factor U2AF binds to pyrimidine tract 
between the branch point site (BPS) and the 3' splice site, thus forming complex E. Secondly, 
U2 snRNP, recruited by U2AF (Gozani & Potashkin, 1998), binds to a region encompassing the 
BPS. This step irreversibly commits the pre-mRNA to the splicing pathway and forms complex 
A. Complexes A and E are also called pre-spliceosomes. Thirdly, a pre-existing (U4/U6/U5) 
particle enters to form complex B, and just prior to splicing a confrontational change occurs that 
significantly destabilises the association of U4 snRNP with the complex transforming it into 
complex C. Following splicing, the snRNPs remain associated with the intron, and are 
recycled. Excised introns are degraded by a phosphodiesterase specific to the lariat structure. 
GU and AG are the 5' and 3' conserved residues recognised by splicing factors, A is the residue 
at the branch point site, (reproduced from Green, 1991).
interaction (Wu and Maniatis, 1993; Fu, 1995; Reed, 1996, Manley and Tacke, 1996). 
The U2 snRNP is then recruited by U2AF, in an ATP-dependent manner, forming 
complex A, which is believed to irreversibly commit the primary transcript to the 
splicing pathway (Gozani et al., 1998). A third complex, complex B also known as the 
mature spliceosome, is formed upon recruitment of U4/U6 and U5 snRNPs. Complex B 
is transformed into complex C, when a conformational change occurs, which 
significantly destabilises the association of the U4 snRNP. After the splicing reaction is 
complete, the snRNPs remain associated with the intron and are recycled, whereas the 
intron is degraded by a phosphodiesterase specific to the lariat structure. The spliced 
message is then polyadenylated, a reaction coupled to the splicing reaction in vivo 
(Cooke et al., 1999).
A poly A tail is essential for the survival, transport, stability and translation of most 
mRNAs. Processing of the 3' end is a two step process involving endonucleolytic 
cleavage of the primary transcript, followed by addition of the poly A tail. The core 
poly A site is made up of a cleavage site, a highly conserved hexanuleotide AAUAAA 
located approximately 11 to 25 nucleotides upstream of the cleavage site, and a 
downstream element (DE), which consists of a 6-20 nucleotide guanine (G) + 
uridine(U) or U-rich sequence approximately 14 to 70 nucleotides downstream of the 
hexanucleotide AAUAAA. The DE increases the efficiency of 3' end processing and, as 
a number of AAUAAA sequences are found within the coding region of the protein, the 
DE serves to position the polyadenylation apparatus at the correct AAUAAA sequence. 
Elements upstream of the core poly A site, which improve the efficiency of 
polyadenylation have been characterised for a number of poly A signals. During 31 end 
processing a 160kDa cleavage and polyadenylation specificity factor (CPSF) binds to 
the poly A site by recognition of the hexanucleotide AAUAAA, and a second 64kDa 
cleavage stimulatory factor (CStF) binds to the DE. For the reaction to proceed the poly 
A polymerase and at least one other factor are required, at which point cleavage occurs 
and the poly A tail of approximately 200 residues is added (Imperiale et al., 1995).
The 13S and 12S mRNAs are the major transcripts of the El A region (Perricaudet et al.,
1979), and are first detected at 1.5-2h p.i. (Nevins et al., 1979) and steadily increase to 
5h p.i., after which time a steady decrease is observed to 12h p.i. (Glenn and Ricciardi,
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1988). The 9S mRNA is also a major transcript of the El A region although it is 
produced at late times after infection (Chow et al., 1979; Wilson and Darnell, 1981; 
Ulfendhal et al., 1987). The minor transcripts of the El A region are the 1 IS and 10S 
mRNAs, which are detected at late times after infection (Stephens and Harlow, 1987). 
Considerable efforts have been made to elucidate mechanisms causing a switch between 
early and late production of El A transcripts. Viral DNA replication has been shown to 
play an important part in the switch between early and late E l A transcripts, but in the 
absence of late protein synthesis the switch is not complete, suggesting that viral 
proteins possess a regulatory role. (Adam and Babiss, 1991; Larsson et al., 1991). 
Indeed, E4 ORF3 and E4 ORF6 have analogous biological activities to ASF/SF2 and 
heterogeneous ribonucleoprotein particles (hnRNP) A l (Nordqvist et al., 1994), and are 
therefore believed to regulate El A alternative splicing in vivo. hnRNP A l and ASF/SF2 
(Mayeda and Krainer, 1992) or DSF and ASF/SF2 (Harper and Manley, 1991), are able 
to modulate 9S splicing in vitro. 13S 5' splice site usage is favoured by a high 
concentration of ASF/SF2, whereas 9S 5' splice site usage is favoured by a high 
concentration of hnRNP A l or DSF. E4 ORF4 is also able to induce dephosphorylation 
of the SR proteins by PP2A, thereby exerting regulatory control on alternative splicing 
(Kanopka et al., 1998).
1.2.3 El A proteins
El A proteins are proline-rich phosphoproteins located predominantly in the nucleus of 
infected cells (Bayley and Mymrk, 1994). They can be phosphorylated by 
cyclin-dependent kinases (cdk) (Mai et al., 1996), and cyclic adenosine-5'- 
monophosphate (cAMP) reduces the levels of phosphorylation through the activation of 
PP2A by the E4 ORF4 protein (Muller et al., 1992; Whalen et al., 1997). The 
phosphorylation state of the El A proteins has an effect on its biological function 
e.g. phosphorylated E1A is more efficient in its association with RB and in disrupting 
E2F/DP-RB than unphosphorylated E l A (Mai et al., 1996).
The major E1A proteins are the products of the 13S and 12S mRNAs, that is the 289R 
and 243R proteins respectively (figure 1.2.3). Comparison of the 289R and the 243R 
proteins from various adenovirus serotypes has identified three highly conserved regions
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Figure 1.2.3 Map of the major E1A proteins and the regions required for selected E1A 
activities. A. The 289R and 243R El A proteins, conserved regions (CR1) 1, 2 and 3, and 
auxiliary regions (AR) 1 and 2. B. Consensus sites for binding to cellular proteins. The hatched 
regions are of secondary importance. C.-G. Regions required for: C. general activation of 
transcription; D. transformation with activated ras in BRK cells; E. suppression of 
transformation, tumorigenicity and metastasis. The hatched region is required for suppression 
of transformation of virus. The solid black region is required for suppression transformation, 
tumorigenicity and metastasis resulting from repression of c-erbB2/neu transcription. The 
stippled region in exon 2 is required for suppression of transformation, tumorigenicity and 
metastasis with activated ras. F. Repression of gene suppression. Generally the hatched regions 
are necessary, but for repression of some genes either of the other two regions are required as 
well. G. Suppression of differentiation. Depending on the cells, minimum requirements are the 
hatched regions; either the hatched or the solid black regions; or all three. H. Induction of DNA 
synthesis, apoptosis and sensitivity to TNF. Minimum requirements are either the two hatched 
regions or the solid black region. I. Susceptibility to the host CTL response. Depending on the 
haplotype any of the three regions may be different (modified from Mymryk, 1996).
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(CR) within the proteins, designated CRl, CR2 and CR3 (figure 1.2.3) (Kimelman et 
al., 1985; Moran and Mathews, 1987). CRl is present in both the 289R and 243R 
proteins, and is required for transcriptional repression, transformation and induction of 
DNA synthesis (Lillie et al., 1987; Schneider et al., 1987; Jelsma et al., 1989; reviewed 
in Jones, 1995). CR2 is present in both the 289R and 243R proteins, and is required for 
transformation, induction of DNA synthesis but, may be dispensable for transcriptional 
repression ((Lillie et al., 1986; Moran et al., 1986a; Howe et al., 1990; Stein et al., 
1990). CR3 encompasses a 49aa stretch and is present only in the 289R protein, it 
possesses a potent fraHs-activation function (Shenk and Flint, 1991; Jones, 1992; Bayley 
and Mymrk, 1994). Protein fusion experiments show that this domain has two separable 
activities (Lillie and Green, 1989; Martin et al., 1990). The amino terminal 
(N-terminal) of CR3 contains the transcriptional activation region and the carboxy 
terminal (C-terminal) contains the promoter-targeting region. Located within the N- 
terminal of CR3 is a C4 type zinc finger; point mutations of any of the cysteine residues 
that define this motif eliminate /raws-activation function (Culp et al., 1988; Martin et 
al., 1990; Webster and Ricciardi, 1991). The non-conserved C-terminal E1A exon 
contains two interchangeable elements, designated auxiliary region (AR) 1 and 2. AR1 
contains glutamic acid-proline (EP) repeats, the number of which (or the net negative 
charge) are critical to its function as an enhancer of CR3-mediated /ra/w-activation. As 
it is required for efficient CR3-mediated /raws-activation it has been suggested that the 
C-terminal boundary for CR3 should be extended to include AR1 (Bondesson et al., 
1992; Strom et al., 1998).
1.2.4 Role of the E1A proteins in the regulation of transcription
The E1A proteins have four main functions: autoregulation of the E1A promoter, 
fraws-activation of viral and cellular promoters, transcriptional repression of enhancer 
containing promoters, and transformation. These functions are described in sections 
1.2.4.1, 1.2.4.2, 1.2.4.3 and 1.2.4.4.
1.2.4.1 E l A autoregulation
The 289R and 243R E1A proteins are expressed from the E1A gene at early times after 
infection (Perricaudet et al., 1979; van Ormondt et al., 1980). In the absence of the E1A
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proteins, transcription from the El A promoter is reduced approximately five fold 
suggesting a role for the E1A proteins in their own regulation (Montell et al., 1984a; 
Osborne et al., 1984). Indeed, El A has been shown to be capable of its own regulation 
at the level of transcription (Hearing and Shenk, 1985; Tibbetts et al., 1986). The E1A 
proteins, in particular the 289R protein, are able to trans-activate the E l A promoter 
(Osborne et al., 1984; Hearing and Shenk, 1985), and both the E1A proteins have also 
been associated with negative regulation of their own promoter at the level of 
transcription (Tibbetts et al., 1986; Cogan et al., 1992).
1.2.4.2 E l A tran 5-activation
The El A proteins can /raws-activate not only their own promoter and enhancer 
sequences, but also those of other viral (E1B, E2A, E3, E4 and MLP) and cellular 
(hsp70, c-fos, c-jun and PCNA) genes (reviewed in Jones, 1992, 1995; Flint and Shenk,
1997). The El A proteins are not thought to bind directly to DNA (Ferguson et al., 
1985; Chatteijee et al., 1988), rather they interact with other proteins (through CR1, 
CR2 and CR3) located at the core promoter, and upstream and/or downstream enhancer 
elements enabling Jra/w-activation.
The El A proteins can fraws-activate any promoter containing a TATA motif in vitro 
(Green et al., 1983; Wu et al., 1987; Simon et al., 1988). This may be due in part to the 
ability of the 289R CR3 to bind to the TBP subunit of TFIID (Horikoshi et al., 1991; 
Lee et al., 1991); and interact with TAFn250 (Geisberg et al., 1995), TAFnllO 
(Mazzarelli et al., 1995) and TAFn55 (Chiang and Roeder, 1995). TAFn250 possesses a 
histone acetyl transferase (HAT) activity, which may play a role in allowing access of 
the basal transcription initiation complex to repressed chromatin (Mizzen et al., 1996). 
TFIID (of which TBP and TAFs are essential components) plays a central role in the 
assembly of the PIC, therefore interaction of El A with the PIC may serve to bridge 
signals from upstream and downstream enhancer elements with the transcription 
machinery, as well as to stabilise the PIC. The 35 N-terminal residues of 243R can also 
bind TBP resulting in fraws-activation (Sang et al., 1997).
Both the 289R and the 243R proteins have also been shown to relieve transcriptional 
repression of the TATA motif, albeit that the 243R protein fra/is-activates to a lesser
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extent than the 289R protein. The 289R protein relieves p53-mediated transcriptional 
repression by binding TBP (within which the El A and p53 binding sites overlap), and 
displaces p53 from the TBP complex (Liu et al., 1993; Horikoshi et al, 1995). The 
N-terminal segment of the 243R protein is able to relieve Dr 1-mediated transcriptional 
repression by binding D rl, resulting in the release of TBP from the inhibitory complex 
(Inostroza et al., 1992; Kraus et al., 1994). In addition to /raws-activation through the 
basal promoter, the E l A proteins are also able to trans-a.ctiva.te through a number of 
transcription factors, which bind to sequences within the promoter and upstream and/or 
downstream promoter elements.
bZIP  Family
The bZIP family of transcription factors contain a DNA-binding domain, which consists 
of a cluster of basic amino acids, and a leucine zipper, hence the name bZIP. The bZIP 
proteins can form homodimers or heterodimers through the leucine zipper and bind to 
the cAMP response element (CRE) (Hai and Curran, 1991). Contained within the bZIP 
family are the proteins ATF, API and E4F, all of which interact with El A to 
trans-activate transcription.
The El A proteins are able to trans-activate ATF-2 either by a direct mechanism 
involving CR3 disruption of the inhibitory intramolecular interaction between the 
activation domain and the bZIP DNA binding domain, or by an indirect mechanism 
involving the N-terminal and CR1 interaction with a cellular 300kDa coactivator 
(p300). The relative contributions of CR1- and CR3-dependent E1A fraws-activation 
are dependent upon cell type. CR1-mediated /raws-activation of the promoter is 
independent of a direct interaction with El A, and takes place in a p300-dependent 
manner (Lee et al., 1996; Mannervik and Akusjarvi, 1997). p300 has been shown to 
bind to ATF-2 and TBP, which suggests that p300 normally acts as a coactivator, 
transducing signals between upstream enhancer elements and the basal transcription 
machinery (Lee et al., 1996; Dallas et al., 1997). p300 also activates transcription 
through its inherent properties as a HAT (Bannister and Kouzarides, 1996; Ogrysko et 
al., 1996), and its ability to form complexes with HATs, resulting in relief from 
chromatin induced transcriptional repression (Yang et al., 1996; reviewed in Howe et 
al., 1999). El A binds to p300 (Egan et al., 1988) through sequences overlapping the
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HAT binding domain, inducing repressive complexes of chromatin, which prevent 
transcription from cellular genes, thereby subverting cellular transcription factors for 
viral trans-activation. CREB binding protein (CBP) has also been shown to act as a 
coactivator in the context of ATF-2 trans-activation by El A (Sano et al., 1998).
CR3-mediated Jraws-activation is a result of a direct interaction of CR3 with the DNA 
binding domain of ATF-2, relieving inhibitory intramolecular interactions between the 
activation domain and the bZIP DNA binding domain, and it may also result in a 
positive conformational change within the El A and ATF-2 activation domains (Liu and 
Green, 1990; Liu and Green, 1994; Chatton et al., 1994). The CR3 subdomain which 
interacts with ATF-2 differs from the subdomain which interacts with TBP, which 
suggests that CR3-dependent trans-activation may also involve E1A acting as a 
coactivator between ATF-2 and the basal transcription machinery (Lee et al., 1991). 
The N-terminal 96 aa of ATF-2 are also essential for CR3-dependent fraws-activation, in 
particular the two threonine residues at positions 69 and 71, although no direct 
interaction with El A is evident (Liu and Green, 1994). This region activates ATF-2 via 
direct phosphorylation of threonines 69 and 71 by an N-terminal bound stress-activated 
protein kinase (SAPK) which may function to alter the conformation of ATF-2, 
positively regulating its function (Yen and Hung, 1994; Livingstone et al., 1995). 
CR1-dependent trans-activation is not dependent upon phosphorylation of threonines 69 
and 71 (Duyndam et al., 1996).
Another group of proteins belonging to the bZIP family are the AP-1 family, which 
includes members of the Jun and Fos gene families. The AP-1 family becomes 
transcriptionally active when homodimers of Jun/Jun or Fos/Fos, and heterodimers of 
Jun/Fos are formed at the AP-1 binding site. AP-1, like ATF-2 can be induced by 
cAMP and fraws-activated by E1A (Muller et al., 1989). CRl-dependent trans- 
activation of AP-1 is independent of direct interaction with E l A, but takes place in a 
CBP-dependent manner (Sano et al., 1998). CBP is a protein of the same family as 
p300, which is highly related within its biological functions to p300. CBP has been 
shown to bind to AP-1 and TFIIB (Kwok et al., 1994), which suggests that CBP 
normally acts as a coactivator, transducing signals between upstream enhancer elements 
and the basal transcription machinery (Bannister and Kouzarides, 1996). CBP also
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activates transcription through its inherent properties as a HAT (Oryzko et al., 1996; 
Bannister and Kouzarides, 1996), and its ability to form complexes with HATs, 
including P/CAF, ACTR and SRC-1 (Yang et al., 1996; Chen et al., 1997; Spencer et 
al., 1997), resulting in relief from chromatin induced transcriptional repression. El A 
binds to CBP through sequences overlapping the HAT binding domain, inducing 
repressive complexes of chromatin, which prevent transcription from cellular genes, 
subverting cellular transcription factors for viral /raws-activation (Sano et al., 1998).
The E4F/ATF sequence element contains a binding site for E4F and ATF-2, which 
mediate ElA-dependent fraw,s-activation by different mechanisms depending upon the 
transcription factor bound. E4F is a 50kDa protein, generated from the N-terminal part 
of E4F-1, the human homologue of the murine nuclear fragment <|>AP3 (Femades and 
Rooney, 1997). The 289R protein regulates phosphorylation of E4F-1 and E4F, leading 
to an increase in DNA-binding affinity, thereby /ra/«-activating the promoter 
(Raychaudhuri et al., 1989; Bondesson et al., 1992; Femades and Rooney, 1997). The 
289R C-terminal AR1 and AR2 are essential for efficient /raws-activation of E4F 
(Bondesson et al., 1992).
E2F Family
The E2F family is composed of two sets of proteins, known as E2F and DP (reviewed in 
Lam and La Thangue, 1994). E2F-1 heterodimerises with DP-1 to form physiological 
E2F, which is found in association with the retinoblastoma gene product (Rb), to 
prevent degradation of E2F by the ubiquitin-proteasome pathway (Helin et al., 1993; 
Hateboer et al., 1996). E2F binding sites shift from a negative to a positive role in 
transcription at the commitment point of the cell cycle, a cmcial point in G1 that 
precedes the Gl/S transition. Before the commitment point members of the pocket 
protein family, including Rb, p i07 and p i30, are found in repressive complexes with 
E2F (Claudio et al., 1996). When E2F-Rb complexes bind to their target promoter they 
actively repress transcription; Rb is able to achieve this by recmiting the histone 
deacetylase (HDAC) 1 (Weintraub et al., 1992, 1995; Ferreira et al., 1998), and by 
interacting with the C-terminal interacting protein (CtIP)/C-terminal binding protein 
(CtBP) repressor complex (Meloni et al., 1999). Progression through the commitment 
point into S phase is triggered by phosphorylation of the pocket proteins by a family of
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serine-threonine protein kinases, known as cdks 2, 4 and 6; which hyperphosphorylate 
the pocket proteins relieving E2F repression by disruption of Rb-associated complexes 
(Weinberg, 1992; Wolowiec and Ffrench, 1996). CBP/p300 is also 
hyperphosphorylated by cyclin E-cdk2 at the commitment point, increasing its intrinsic 
HAT activity, and thereby its ability to activate transcription (Ait-Si-Ali et al., 1998). 
Therefore cyclin E-cdk2 has a dual role with Rb inactivation by phosphorylation, and 
CBP HAT activation by phosphorylation. El A is also able to push the cell cycle 
through the commitment point into S phase by forming complexes with Rb and 
CBP/p300 (Ait-Si-Ali et a l , 1998).
The E l A proteins are able to relieve transcriptional repression either by CR1 and CR2 
disruption of the inhibitory E2F-RB complex (Whyte et al., 1989; Zamanian and La 
Thangue, 1992), by providing the coactivator CBP (Trouche and Kouzarides, 1996), or 
by disruption of the CtlP/CtBP inhibitory complex (Meloni et al., 1999). 
CRl/CR2-dependent trans-activation is a two stage process in which CR2 binds to Rb, 
then CR1 competes for Rb binding to E2F (Raychaudhuri et al., 1990, 1991; Fattaey et 
al., 1993; Ikeda and Nevins, 1993). E1A has been shown to bind to Rb through CR2 
sequences, however it has also been shown to bind Rb and p300 simultaneously, 
through an LXCXE motif in CR2 which binds Rb, and through the N-terminal of CR1 
which binds p300 and CBP (Wang et al., 1995). El A may act as a carrier for p300 or 
CBP, providing it to E2F-1 and fraws-activating E2F-1/DP-1 by direct interaction with 
the C-terminal domain of E2F-1 (Trouche et al., 1996; Trouche and Kouzarides, 1996), 
whilst binding to Rb and releasing E2F from repressive Rb complexes. El A binding to 
CBP also activates its HAT function, though a conformational change, activating 
transcription (Ait-Si-Ali et al., 1998). It is possible that the N-terminal and CR1 
sequences within El A, which compete with the Rb proteins (Rb, p i 07 and pi 30) for 
HDAC1, are also linked with CRl/CR2-dependent trans-activation, making it a three 
stage process. The release of HD AC 1 from Rb-E2F complexes relieves transcriptional 
repression from HDAC1 (Trouche et al., 1996; Ferreira et al., 1998).
YY1
The transcription factor YY1 has been shown to mediate transcriptional repression. 
This is believed to occur by YY1 binding of a repressive cofactor, RPD3, which purifies
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with a histone deacetylase activity, which represses transcription. The RPD3 binding 
site overlaps the El A binding site (Lewis et al., 1995; Taunton et al., 1996; Yang et al., 
1996), suggesting that the E1A N-terminal 35aa displaces the activity of RPD3, thus 
fraws-activating the promoter. The 289R protein can trans-activate YY1 binding sites 
through CR3 interaction (Lewis et al., 1995).
1.2.4.3 Transcriptional repression
The El A proteins can repress the transcription from several viral and cellular genes 
(reviewed in Jones, 1992; Hagmeyer et al., 1997). A number of elements within the 
E l A proteins are believed to mediate transcriptional repression, including the 
N-terminal and CR1 domain (Schneider et al., 1987; Jelsma et al., 1989; Stein et al., 
1990), CR2 domain and some second exon sequences (Lillie et al., 1986, 1987; 
Schneider et al., 1987; Velcich and Ziff, 1988; Jelsma et al., 1989), although in some 
studies CR2 is shown to be dispensable (Stein et al., 1990). The reason for the 
difference in the elements used is unclear, but could depend upon the promoter or the 
cell type studied.
The cellular proteins p300 and CBP are known to function as coactivators interacting 
with TBP and upstream enhancer sequences (Abraham et al., 1993), translating signals 
from upstream enhancer sequences to the basal transcription machinery. They have also 
been shown to bind to the N-terminal and CR1 of E1A (Egan et a l,  1988; Whyte et al., 
1989; Jelsma et a l,  1989; Stein et al., 1990; Moran, 1993). Deletion mutants in the 
E l A binding site of p300 or CBP loose their ability to drive El A enhancer-mediated 
transcriptional repression (Eckner et a l,  1994). Therefore a model in which the 
N-terminal 80 aa of the El A proteins sequesters p300 or CBP from TFIID complexes 
and upstream enhancer elements has been proposed (Song et a l,  1995).
1.2.4.4 Transformation
Adenoviruses were first shown to be oncogenic when a subcutaneous injection of Adi 2 
into newborn hamsters led to the development of rapidly growing tumours at the 
inoculation site (Trentin et a l, 1962). The majority of human adenoviruses are 
non-tumourigenic in hamsters (table 1.1.1.), however it was later shown that all
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adenoviruses were able to mediate immortalisation of primary rodent cells (Freeman 
et al., 1967). The genes responsible for oncogenicity and cell proliferation were located 
at the left end of the genome and comprised of early region 1 (reviewed in Dyson and 
Harlow, 1992). The E1A gene products alone were found to immortalise primary cells 
in tissue culture (Houweling et al., 1980; Ruley, 1983; Cone et al., 1988). However, in 
cooperation with the adenovirus E1B gene, the activated ras gene or the polyoma 
middle T oncogene, E l A can stably transform cells in culture, which would induce 
tumours in animals (van den Elsen et al., 1983; Ruley, 1983).
The El A regions which are necessary for immortalisation and cell proliferation include 
the nonconserved N-terminal region, CR1 and CR2; whereas CR3 is dispensable (Lillie 
et al., 1986; Lee et al., 1991). These regions were found to strongly correlate with areas 
required for interactions with certain cellular proteins (Egan et al., 1988; Whyte et al., 
1989; Howe and Bayley, 1992). Indeed out of the three active sites found to be 
important for immortalisation and cell proliferation in El A, two were found to bind 
cellular proteins. The first active site consists of CR2 plus the N-terminal end of CR1, 
which binds the Rb gene family (Rb, p i07 and p i30) via the pocket region. The second 
active site consists of the N-terminal of El A and the C-terminal of CR1, which binds 
the phosphoprotein family p300/CBP (reviewed in Moran, 1993; Wang et al., 1995). 
The third active site consists of a five amino acid NLS at the extreme C-terminal of 
El A; efficient nuclear localisation of the 243R protein is essential for cellular 
transformation. Sequences directly upstream of the NLS, and the protein context of the 
NLS have also been shown to play a significant role in the efficient localisation of the 
243R protein (Douglas and Quinlan, 1996).
The cellular proteins important for immortalisation and cell transformation were 
identified by co-immunoprecipitation with El A. Approximately ten proteins were 
identified, ranging in size from 300kDa to 28kDa (Harlow et al., 1989). A major 
advance in the understanding of viral oncogenesis came with the realisation that one of 
the proteins previously identified as an ElA-binding protein was the product of the 
retinoblastoma tumour suppressor gene (Whyte et al., 1989). The physical interaction 
of the oncogenic El A proteins with a key tumour suppressor protein, involved in cell
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cycle control, provides a mechanistic view for the oncogenic capacity of the 
adenoviruses.
The retinoblastoma gene product, also known as Rb or p i05, is regulated by 
phosphorylation i.e. the phosphorylation state of Rb changes through the different 
phases within the cell cycle (Ludlow et al., 1990). The underphosphorylated form of Rb 
is thought to be the active form, and it is in this state that Rb can complex with E2F, 
whilst the hyperphosphorylated form is inactive (Kaelin et al., 1992). Phosphorylation 
of Rb is controlled by cdks (for example cyclin E/cdk2 kinase, cyclin D/cdk4 kinase and 
cdk6), whose activity is controlled by association with a protein known as cyclin, and by 
their own post-translational modifications i.e their phosphorylation and 
dephosphorylation (Wolowiec and Ffrench, 1996). The S-phase cdks are activated at 
the end of the G1 phase of the cell cycle, resulting in a switch from an active to an 
inactive form of Rb, which is no longer able to form repressive complexes with E2F, 
resulting in the release of free E2F for use in S phase gene transcription. El A is also 
capable of pushing the cell cycle through the commitment point into S phase by forming 
complexes with Rb to release E2F from repressive complexes (section 1.2.3), and by 
forming complexes with CBP/p300 (Ait-Si-Ali et al., 1998). The El A proteins bind to 
Rb and Rb-related proteins through the pocket region, which consists of two regions A 
and B, separated by a non-conserved spacer region, which is of different lengths in Rb 
and p i07 (Raychaudhuri et al., 1991; Corbeil and Branton, 1994). The phosphorylation 
of the El A proteins at Ser-132 also regulates Rb, by enhancing their binding affinity for 
Rb and Rb-related proteins (Whalen et al., 1996).
Cell protein p i 07 was first identified by association with El A and SV40 large T antigen 
(Dyson and Harlow, 1992), and shares many structural and biochemical similarities with 
Rb, including a pocket region which binds E2F and E1A (Zhou et al., 1993; 
Starostik et al., 1996). However, unlike Rb, p i07 can form complexes with cyclin A 
(p60), cyclin E and cdk2 (Faha et al., 1993). p i07 functions as a tumour suppressor, 
which is mediated by inactivation of E2F through pl07-repressive complexes. The 
pl07-E2F complex also acts as a general transcriptional repressor when tethered to the 
promoter via an E2F binding site.
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Cell protein p i30 is a phosphoprotein located within the nucleus of the cell, which has 
many similarities with Rb and p i07, including a pocket region, which binds E2F and 
El A. However, pl30 is more closely related to pl07 than Rb, as pl30 and pl07 have 
similar sized spacers between the pocket region domains A and B (Li et al., 1993). Also 
like p i07, p i30 interacts with cyclins A and E, including the pocket region, and is able 
to bind E2F and El A (Cobrinik et al., 1993). The El A viral oncoprotein-associated 
kinase targets p i 30, controlling phosphorylation of the pocket proteins and therefore the 
amount of free E2F during the cell cycle, reaching a peak of activity at the onset of 
S-phase (Baldi et al., 1995; Mayol et al., 1995).
Simultaneous E l A binding of Rb and p300/CBP is important in modulation of gene 
expression and oncogenic transformation by E l A (Dyson and Harlow, 1992; Peeper and 
Zantema, 1993; Bayley and Mymrk, 1994). E l A has been shown to bind to Rb through 
CR2 sequences, however it has also been shown to bind Rb and p300 simultaneously, 
through an LXCXE motif in CR2 which binds Rb, and through the N-terminal of CR1 
which binds p300 and CBP (Wang et al., 1995). El A may act as a carrier for p300 or 
CBP, providing it to E2F-1 and fra«.s-activating E2F-1/DP-1 by direct interaction with 
the C-terminal domain of E2F-1 (Trouche et al., 1996; Trouche and Kouzarides, 1996); 
whilst binding to Rb and releasing E2F from repressive Rb complexes. By binding to 
these and other cellular regulatory proteins, E l A is able to alter or inhibit their normal 
functions within the cell, reprogramming cell growth and differentiation.
Cell protein p300 is able to function both as a coactivator and a transcriptional 
repressor, as such it has been found in complexes with TBP (Abraham et al., 1993; 
Eckner et al., 1994; Arany et al., 1995). p300 also has similar functional properties to 
CBP, which is a coactivator for protein kinase A (PKA) (Lundblad et al., 1995). CBP 
functions as a coactivator by binding, via a Cys/His-rich region termed C/H2, to a group 
of bZIP proteins, including ATF-2, c-Jun and CREB (Sano et al., 1998). CBP also 
binds to an RNA helicase A, which is a component of the RNA polymerase II complex, 
suggesting that CBP functions as a coactivator, by bridging upstream enhancer elements 
with the basal transcription machinery (Nakajima et al., 1997). CBP/p300 also 
possesses an intrinsic HAT activity, which is essential for its function as a coactivator. 
CBP repression is controlled by El A binding to the C/H3 domain of CBP (a 12 residue
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transcriptional adapter motif (TRAM), which contains binding sites for El A and 
numerous cellular transcription factors e.g. E2F, TFHB and p53), thereby inhibiting the 
acetyltransferase activity. The HAT activities of CBP/p300 are differentially modulated 
by factors such as p300/CBP interacting protein (p/CIP) and p300/CBP associated 
factors (p/CAF), which bind to distinct regions within CBP/p300. These interactions 
are likely to result in differential effects on the coactivator functions of CBP/p300 for 
different classes of transcription factors (Perissi et al., 1999; O'Connor et al., 1999).
v
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1 . 3  E n t e r i c  A d e n o v i r u s e s
Viral gastroenteritis in children can be caused by several different pathogens including 
adenovirus, which is second only to rotavirus as a causal agent (Estes et al., 1983; 
Uhnoo et al., 1984; Brandt et al., 1985). Human adenoviruses had been suspected of 
causing gastroenteritis, but it had been difficult to prove, and was hampered by 
prolonged periods of asymptomatic faecal shedding after adenovirus respiratory tract 
infections (Fox et al., 1977). The subgroup F adenoviruses were established as casual 
agents of gastroenteritis by epidemiological and clinical studies (Uhnoo et al., 1984; 
Kidd et al., 1986; Kotloff et al., 1989; Tiemessen et al., 1989; Kim et al., 1990; Cruz 
et al., 1990; Lew et al., 1991). A close correlation has now been established between 
Ad40 and Ad41, and gastroenteritis (Brandt et al., 1979; de Jong et al., 1983; Yolken 
et al., 1982; Chiba et al., 1983; Uhnoo et al., 1983, 1984; Leite et al., 1985; Kidd et al., 
1986; Kotloff et al., 1989).
1.3.1 Identification and classification
The enteric adenoviruses were first identified from stool samples of infants with acute 
gastroenteritis (Flewett et al., 1973), and then observed by electron microscope (EM) 
analysis (Gary et al., 1979; Retter et al., 1979; Takiff and Straus, 1982). The viruses 
identified in the stool samples of infants with acute gastroenteritis, were unable to be 
cultivated on conventional cell lines used to propagate other adenoviruses (Flewett et 
al., 1973; Madeley et al., 1977; Retter et al., 1979). However, they would grow in 293 
cells, a human embryo kidney (HEK) cell line which has been transformed with the Ad5 
E l region (Graham et al., 1977; Takiff et al., 1981), albeit at reduced levels compared to 
other serotypes.
The enteric adenoviruses were shown to be distinct from the other established 
adenovirus subgroups, by serology and DNA restriction analysis (Jacobsson et al., 1979; 
Johansson et al., 1980; Kidd and Madeley, 1981). Studies with large numbers of 
clinical isolates revealed the presence of two enteric adenovirus serotypes, 40 and 41, 
(de Jong et al., 1983; Uhnoo et al., 1983) which possessed different DNA restriction 
patterns (Uhnoo et al., 1983; Takiff et al., 1984; Adrian et al., 1986). The two serotypes 
identified are now classified separately as subgroup F adenoviruses; based upon various
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criteria including immunological cross reactivity, DNA homology and size of internal 
structural polypeptides (van Loon et al., 1985a; Wadell et al., 1987; Hierholzer et al., 
1988). Within each serotype a number of variants were observed through restriction 
enzyme analysis, including eleven variants of Ad40 and twenty-eight variants of Ad41 
(Kidd, 1984; Kidd et al., 1984; van der Avoort et al., 1989), for which a classification 
scheme has been presented (van der Avoort et al., 1989; Kidd et al., 1993).
1.3.2 Epidemiology
Enteric adenoviruses have been detected in stool samples of infants and young children 
with acute gastroenteritis, in the developed and developing world (reviewed in Uhnoo 
et al., 1990; Wadell et al., 1994; Mautner et al., 1995). Enteric adenoviruses are 
reported to be associated with approximately 5 to 20 percent of cases of paediatric 
diarrhoea (Mautner et al., 1995); being prevalent throughout the year, with little 
seasonal variation, indicating that they may be endemic (de Jong et al., 1983, 1993; 
Uhnoo et al., 1984; Brandt et al., 1985; Johansson et al., 1985; Tiemessen et al., 1989; 
Kotloff et al., 1989).
1.3.3 Pathogenesis
The incubation period for enteric adenovirus infection is 7 to 8 days (Richmond et al., 
1979). Illness typically lasts 5 to 12 days (Uhnoo et al., 1984; Kotloff et al., 1989), but 
can occasionally last for more than two weeks. Enteric adenoviral gastroenteritis lasts 
longer than other types of viral gastroenteritis, however it produces a milder infection 
with reduced frequency of vomiting and moderate elevation of temperature. The most 
prominent feature of the disease is watery diarrhoea, which is followed by 1 to 2 days of 
vomiting (Uhnoo et al., 1984). The mean duration of diarrhoea in Ad41 (12.2 days) is 
longer than in Ad40 (8.6 days), however both viruses gave similar symptoms in patients. 
Other symptoms include low grade fever which lasts two to three days (rare), 
dehydration, and respiratory tract symptoms which occur in less than 20% of cases 
(Yolken et al., 1982; Uhnoo et al., 1984). Enteric adenoviruses have rarely been 
associated with fatal disease (Whitelaw et al., 1977; Johansson et al., 1985), but Ad41 
virus particles were isolated from cells in the small intestine of a fatal case of 
gastroenteritis. On propagation in tissue culture this strain did not appear to be
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unusually virulent (Johansson et al., 1985). Nosocomial outbreaks occur (Rodriguez 
et al., 1985; Kotloff et al., 1989), but spread to adults is not common (Chiba et al., 
1983).
1.3.4 The molecular biology of the enteric adenoviruses
The overall DNA homology between Ad40 and Ad41 is 62 to 69 percent (van Loon 
et al., 1985a), whereas enteric adenovirus identity compared to Ad5 is only 15 to 20 
percent. Phylogenetic analysis (the comparison of DNA sequence) reveals that Ad40 
and Ad 12 are more closely related than was previously shown by DNA hybridisation 
studies (Bailey and Mautner, 1994; Mautner et al., 1995). This is also observed in the 
homology within subgroup F, which is similar to that within subgroup A, but is lower 
than that seen within subgroups B to D (table 1.1.1). The complete nucleotide sequence 
of Ad40 strain Dugan has been reported (Davison et al., 1993) and is comprised of 
34 214 nucleotides, having similar genomic organisation to Ad2 and Ad5. The major 
differences between the Ad40, and the Ad2 and Ad5 genomes, are the presence of two 
fibre genes, one VA gene and variation within the E3 region of Ad40 (Davison et al., 
1993).
1.3.4.1 Early regions
The E l region of subgroup F adenoviruses has been extensively studied, because it has 
been implicated in the fastidious growth of the enteric adenoviruses. The El sequences 
of various strains of Ad40 and Ad41 have been determined including: Ad40 Dugan 
(van Loon et al., 1987a; Davison et al., 1993); Ad40 Sapporo (Ishino et al., 1988); 
Ad41 Tak (van Loon et al., 1987a); and Ad41 D389 (Allard and Wadell, 1988, 1992). 
The E l sequences of both Ad40 strain Dugan and Ad41 strain Tak are 85% identical to 
each other, and 52% homologous to the Ad5 El region (van Loon et al., 1987a). The 
overall organisation of the El region appears to be similar to that of the other 
adenoviruses. The ITR of adenovirus type 40, type 41 and type 12 are similar in length 
at 163bp, 163bp and 161bp respectively. However, the first 60-70bp of the adenovirus 
type 40 genome bears greater sequence homology with adenovirus type 5 than any other 
adenovirus serotype (Ishino et al., 1987; Shinagawa et al., 1987; Allard and Wadell, 
1988; Bailey and Mautner, 1994).
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Early region 1A
Ad40 El A mRNA is first detected approximately 36h p.i. in Ad40 infected cells (Ullah, 
1997) compared with approximately 3h p.i. in Ad5 infected cells (Glenn and Ricciardi,
1988). Both Ad40 and Ad41 have the potential to make E1A 13S, 12S and 9S 
transcripts (figure 1.3.4.1) (van Loon et al., 1987a; Ishino et al., 1988; Allard and 
Wadell, 1988). However, E1A transcription maps have only been obtained for El 
plasmid-transformed cells, and whilst all three mRNAs (corresponding to the Ad2 13S, 
12S and 9S mRNAs) were detected in Ad40 El plasmid-transformed cells, only the 13S 
transcript was detected in Ad41 El plasmid-transformed cells (van Loon et al., 1987a). 
CR1, CR2 and CR3 identified within other adenovirus El A proteins (Kimelman et al., 
1985) have also been identified in Ad40 and Ad41 (van Loon et al., 1987a; Allard and 
Wadell, 1988; Ishino et al., 1988). The conserved regions of Ad7, Adl2 and SAV-7 
share 60% homology to the equivalent Ad5 conserved regions, whilst Ad40 and Ad41 
have 51% and 45% homology respectively to the equivalent Ad5 conserved regions 
(van Loon et al., 1987a). Ad40 CR1 has the least homology, although Ad40 CR2 and 
CR3 also have low homology with Ad5 compared to other serotypes. CR3 is the 
trans-activating domain of the El A protein and differences in this sequence may 
account for the low trans-activating function of Ad40 and Ad41 El A, compared with 
Ad5 and Adl2 (van Loon et al., 1987a; Ishino et al., 1988).
Early region IB
The Ad40 and Ad41 E1B transcription maps have been determined in a lytic infection 
(figure 1.3.4.1; Steinthorsdottir and Mautner, 1991; Allard and Wadell, 1992). Both 
Ad40 and Ad41 produce transcripts equivalent to the Ad2 14S and 22S mRNA, but no 
13S mRNA equivalent was seen, which is the major species in the Ad2 E1B region. 
The Ad 12 E1B region also produces the E1B 14S mRNA as a major transcript, with no 
detectable 13S mRNA (Virtanen et al., 1982; Virtanen and Pettersson, 1985). In Ad41 
an additional small exon is detected in the 14S mRNA which is not observed in Ad40 
(Steinthorsdottir and Mautner, 1991; Allard and Wadell, 1992). In addition E1A-E1B 
co-transcript counterparts of the 14S and 22S mRNAs have been detected in Ad40, 
these contained the first 40 codons of the El A region spliced to a site 4-5 nt 
downstream of the E1B cap site (figure 1.3.4.1). The splice junction is unusual as it 
does not conform to splice consensus sequences (Steinthorsdottir and Mautner, 1991;
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Ishida et al., 1994). In a productive Ad5 infection, E1B 22S mRNA is produced at early 
times in infection, and E1B 13S mRNA is produced after the onset of DNA replication 
(Montell et al., 1984b; Glenn and Ricciardi, 1988). In HeLa cells infected with Ad40, 
no E1B mRNA is detected early in infection, and only low levels of the 22S and 14S 
mRNAs are observed after the onset of DNA replication (Mautner et a l,  1990; Bailey et 
al., 1994). However in 293 cells, KB 16 and INT407 cells, 22S mRNA is detected 
before the onset of DNA replication, and the 14S mRNA is first observed at the onset of 
DNA replication (Bailey et al., 1994). Ad40 El A and E1B mRNAs have also been 
detected before the onset of DNA replication in A549 cells (Hashimoto et al., 1991).
In comparisons of the E1B protein coding sequences, the Ad40 E1B ORFs are more 
similar to Ad 12 than to Ad2, and the E1B DNA homology is higher than for El A 
(Ishino et al., 1988). Unlike the E1A region there are no conserved regions in E1B, 
however an alanine rich region near the N-terminal of the 55kDa protein which is 
present in Ad2 and Ad 12, is not found in Ad40. A second central region within the 
55kDa protein responsible for p53 binding, transcriptional repression, and important for 
the transformation activity of Ad2, is moderately conserved in both Ad 12 and Ad40 
(Yew and Berk, 1992; Yew et al., 1990, 1994). The E1B 19kDa and 55kDa proteins 
can be detected in 293 and Kba+b cells (Bailey et al., 1993, 1994), whereas 55kDa 
cannot be detected in HeLa cells (Mautner et al., 1990), and 19kDa can only be detected 
in HeLa cells at late times during infection (White et al., 1991; Rao et al., 1992).
Early region 2
The E2A gene has been identified in Ad40 and Ad41 (Vos et al., 1988), and encodes for 
a single stranded DBP, which is smaller in Ad40 (473R) and Ad41 (474R), than in Ad5 
(529R). The Ad40 E2B gene encodes two proteins, pTP and Adpol, these share good 
DNA homology with the Ad2 equivalent proteins (Davison et al., 1993). Less DNA 
homology is shared between the Ad40 DBP and the Ad2 DBP (Davison et al., 1993). 
Another 52R exon has been identified upstream of the recognised E2 early and late 
promoters, between the E3 and fibre regions. Its sequence is highly conserved across all 
human adenoviruses and canine adenoviruses, which suggests that the region is 
functionally significant (Davison et al., 1993).
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Early region 3
The DNA sequence of the Ad40 E3 region reveals a pattern of ORF and transcriptional 
signals not unlike Ad2 (Cladras and Wold, 1985), however there are sufficient 
differences to suggest that a more detailed knowledge of the functions of the encoded 
genes may further our understanding of the tissue specificity of the enteric viruses. In 
fact, Ad40 E3 is more closely related to A di2 than to Ad2, which may not be surprising 
in view of their shared site of infection. Comparison of the E3 ORFs for Ad40, Ad 12, 
and Ad2 shows the E3B region to be well conserved, whereas there are major 
differences in the E3A region. The Ad40 E3A region has two large ORFs (276R and 
173R) with homologies in Adl2, but unrelated to the E3A 20.1kDa and 20.5kDa 
proteins found in Ad3 (Signas et al., 1986). The Ad40 276R sequence bears limited 
similarity to the mouse interleukin-1 receptor which may be of interest in the light of 
established relationship between various Ad5 E3 proteins and other components of the 
immune response. In particular, Ad40 lacks an equivalent of the Ad2 E3A 19kDa 
glycoprotein, which prevents cytolysis of infected cells by cytotoxic T lymphocytes 
(Wold and Gooding, 1991). A small ORF can be found out of frame in the 276R 
sequence which has limited similarity to the Ad5 19kDa glycoprotein, however it is 
unlikely that this is of functional significance, unless perhaps a 19kDa equivalent is 
generated by alternative splicing. The 12.5kDa ORF in Ad2 E3A has a homologue in 
Adl2, which is absent from Ad40. Ad41 possesses three unique E3 ORFs, which may 
explain why subgroup F adenoviruses differ substantially from other human 
adenoviruses in their host range (Yeh et al., 1996).
Early region 4
Ad40 complements the Ad2 E4 deletion mutant d/808 (which lacks all but ORF1 of the 
E4 region), indicating that Ad40 has a functional E4 region (Mautner and Mackay, 
1991). The Ad40 E4 region contains ORFs corresponding to those identified in Ad2 
and A di2, with the notable exception of ORF1. However, it is known that E4 ORF3 and 
ORF6 of Ad2 display redundancy in some functions (Bridge and Ketner, 1989; 
Ketner et al., 1989; Huang and Hearing, 1989a; Weiden and Gisberg, 1994), and this 
aspect of Ad40 E4 function has not been addressed.
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1.3.4.2 Intermediate regions
The human adenoviruses of subgroups A, F and some of B, and the simian adenovirus 
type 7 (SAV-7) have only one VA RNA gene (Kidd and Tiemessen, 1993; Kidd et al.,
1995). Ad40 and Ad41, unlike Ad2 are susceptible to lymphoblastoid interferon in 
Chang conjunctival cells (Tiemessen and Kidd, 1993); it is unclear if the expression or 
the function of the VA RNA gene correlates with this susceptibility. Susceptibility 
could occur through defective expression of the El A gene, which /raws-activates the 
VA RNA gene through the cellular transcription factor TFIIIC, leading to reduced levels 
of VA RNA, or by aberrant function of VA RNA itself. The El A proteins are also 
known to suppress transcription of interferon stimulated cell genes, so impaired El 
activity may act at this level.
1.3.4.3 Late regions
The subgroup F hexon proteins of Ad40 and Ad41 have 88% identity, which is in 
agreement with that detected between the subgroup C adenoviruses (Kinloch et al., 
1984; PringAkerblom and Adrian, 1993). Most differences occur in the loop regions, 
which are exposed on the surface of the virion (Toogood and Hay, 1988; Toogood et al.,
1989), and act as type specific antigenic determinants (Toogood et al., 1992; Crompton 
et al., 1994). The Ad40 penton base protein is 81% homologous to Ad 12 (Sprengel et 
al., 1994), but unlike other adenovirus penton bases (Ad2, 3, 5 and 12) which have an 
RGD motif, Ad40 has an RGA motif (Davison et al., 1993). The RGD motif lies within 
an alanine rich region that is common to Ad2 and Ad5, but is again absent from Ad40, 
avian adenovirus GAL-10 and Adl2; it is therefore possible that the enteric 
adenoviruses do not utilise this pathway for virus internalisation (Sheppard and Trist, 
1992; Davison et al., 1993). Furthermore there are no other recognised integrin-binding 
sites within the known penton base sequences (Hynes, 1992). The enteric adenoviruses 
have two fibre genes (IV-1 and IV-2), which encode proteins with distinct sequences, 
and different shaft lengths (Kidd and Erasmus, 1989; Pieniazek et al., 1989, 1990c; 
Kidd et al., 1990, 1993; Davison et al., 1993; Yeh et al., 1994). Phylogeny studies have 
revealed that the subgroup F fibre genes are more closely related to each other than to 
other adenovirus fibre genes (Bailey and Mautner, 1994). This could have arisen from 
gene duplication shortly after divergence of subgroups A and F, but before divergence 
of serotypes 40 and 41. EM analysis of Ad40 shows that only one type of fibre is
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incorporated at each vertex of the capsid (Kidd et al., 1993), in contrast to avian 
adenoviruses where two fibres of different shaft length are attached to each vertex 
(Laver et al., 1971). The lOOkDa L4 protein is the best conserved of the L4 proteins 
among the serotypes Ad40, A di2 and Ad2. The 33kDa protein is also well conserved, 
and a putative 22kDa polypeptide could be generated if the 33kDa splice is not used 
(Davison et al., 1993).
1.3.5 Growth properties of enteric adenoviruses in tissue culture
Although Ad40 virus particles are shed in large numbers from the gut they fail to 
propagate in cells normally used to propagate other human adenoviruses. They will 
however grow in Chang conjunctival cells (Kidd and Madeley, 1981), Hep-2 and tCMK 
cells (de Jong et al., 1983), 293 cells (Takiff et al., 1981; de Jong et al., 1983), HT-29 
cells (Uhnoo et al., 1983) and HRT-18 cells (Gomes et al., 1992), albeit at reduced 
levels compared to other serotypes. There has been dispute over these results, as some 
studies have shown that the enteric adenoviruses can be propagated in these cells (Takiff 
et al., 1981; de Jong et al., 1983), whilst others have not been able to propagate the 
virus in these cells (Chiba et al., 1983; Uhnoo et al., 1983). For example, Witt and 
Bousquet (1988) successfully grew Ad40 and Ad41 in Chang conjunctival, 293 and KB 
cells, but Ad41 would only grow in HeLa cells. Whereas, Pieniazek et al. (1990a, b) 
successfully propagated Ad41 in HeLa, Hep-2 and INT407 cells, but they could not 
propagate the virus in 293 cells. In addition, one group has reported that the Sapporo 
strain of Ad40 can produce plaques in A549 cells (Hashimoto et al., 1991). A study of 
approximately 200 enteric adenovirus isolates suggested that these contrasting 
observations may result from differences in virus growth due to the virus strain used, the 
host cell type used, differences in the growth characteristics of the cell line depending 
upon passage number, and differences in the growth of the same virus strain between 
laboratories (de Jong et al., 1983). Another factor, which may account for the apparent 
differences in the growth properties of Ad41 is serum concentration. As growth of 
Ad41 is restricted in a number of primary cell lines, but can be alleviated by a reduction 
in the serum concentration (0.2-1%) within the infecting medium. The apparent 
restriction of Ad41 growth in primary cell lines is thought to be mediated by a factor or 
factors present in the serum (Pieniazek et al., 1990b).
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Within an Ad40 infection in KB and HeLa cells, lower infectious titres of Ad40 
compared with Ad41 are found, and when high moi of virus was used no viral DNA 
replication could be detected. However, Ad40 will grow at a lower moi of input virus 
(Witt and Bousquet, 1988). This effect may be mediated by defective virus particles, 
which interfere with infectious non-defective virions. In 293 cells the production of 
Ad40 virions is 3 to 10 fold lower than in other adenoviruses, and the yield of infectious 
virus is 100 to 1000 fold lower (Brown, 1985). The majority of 293 cells in a culture 
can be productively infected, whilst only 10 to 20 percent of HeLa cells are infected, 
however the uninfected HeLa cells are capable of being infected. For 293 and HeLa 
cells the intracellular viral yield was comparable, however progeny virus are only 
released from 293 cells. The yield of viral particles is similar for the enteric 
adenoviruses compared with Ad5, however the particle to infectivity ratio and the block 
in release of virus from HeLa cells could be a major factor in the fastidious growth of 
enteric adenoviruses in tissue culture (Brown et al., 1992).
On the other hand the Ad41 growth restriction in tissue culture appears to be less severe 
than in Ad40, as a number of cell lines will support Ad41 growth but not Ad40 (de Jong 
et al., 1983; Uhnoo et al., 1983, 1984; van Loon et al., 1985b). The growth restriction 
of Ad41 can be complemented by Ad2 in semi-permissive Chang conjunctival cells and 
non-permissive HEF cells. However, in HEF cells Ad41 interferes with Ad2 
replication, the extent of interference depends upon the time for infection of each virus 
(Tiemessen and Kidd, 1988; 1990). This observation was made with other serotypes, 
and is mediated by the £ra«s-repression function of the El A proteins (Leite et al., 1986; 
Tibbetts et al., 1986; Larsen and Tibbetts, 1987). The Ad41 block in replication has 
been shown to occur within the early phase of the infectious cycle (Tiemessen et al.,
1996).
Ad40 can propagate in 293 cells (Takiff et al., 1981), a human embryo kidney (HEK) 
cell line which has been transformed with the Ad5 E l region (Graham et al., 1977; Kidd 
and Madeley, 1981), albeit at reduced levels compared to other serotypes. This 
observation suggests that the El function is poorly expressed, and is therefore 
implicated in the growth restriction of enteric adenoviruses. To date this has mainly 
been attributed to the E1B function (Mautner et al., 1995), however the Ad40 El A
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region may also be subject to aberrant expression, as Ad40 El A mRNA is first detected 
at approximately 36h p.i. in Ad40 infected cells (Ullah, 1997) compared with 
approximately 3h p.i. in Ad5 infected cells (Glenn and Ricciardi, 1988). The Ad40 El A 
promoter has been shown to have a weaker cis-acting potential than the Ad 12 El A 
promoter (Ishino et al., 1988). The Ad40 and Ad41 E1A proteins have also been shown 
to be weaker fraws-activators of viral promoters (Ad2 E4, Ad5 E2 and E3) when 
compared with the Ad5 or the Adl2 E1A proteins (van Loon et al., 1987b; Ishino et al. 
1988).
The poor expression of the E l function has mainly been attributed to E1B, through 
indirect evidence such as the ability of Ad40 and Ad41 to partially transform BRK cells 
(van Loon et al., 1985b), and through more direct evidence of propagation of Ad40 in 
stably transformed KB cell lines which constitutively expressed Ad2 E1A (KB8), E1B 
(KB 18), both El A and E1B (KB 16, from now on referred to as KBa+b) and neither 
El A or E1B (KB7) (Babiss et al., 1983); Ad40 was able to grow in cells expressing 
E1B, but unable to grow in cells expressing El A alone. The latter observation is 
supported by coinfection assays on HeLa cells, where there was reciprocal 
complementation between Ad40 and the Ad5 El A mutant d/312, but not with Ad5 or 
Adl2 mutants which lacked the E1B region or were defective for the E1B 55kDa 
protein (Mautner et al., 1989; Steinthorsdottir and Mautner, 1991; Gomes et al., 1992).
To characterise expression of the Ad40 E1B region Ad5/Ad40 recombinants were 
constructed, to contain the Ad40 E1B coding region in place of the Ad5 E1B coding 
region in dl309, under the control of either the Ad5 E1B promoter (sub5P) or the Ad40 
E1B promoter (sub40P). The yield and growth rate of sub5P and sub40P were reduced 
in HeLa cells compared with 293 cells, whereas both were able to plaque on 293 cells 
but not on HeLa cells. These observations suggested that even when the Ad40 E1B 
region was under the control of the Ad5 E1B promoter, Ad40 E1B gene expression 
and/or protein function was impaired. Analysis of E1B transcription from sub5P and 
sub40P revealed a cell-type specific pattern, where the activity of the Ad40 E1B 
promoter is lower than of the Ad5 E1B promoter in all cell types, and the pattern of E1B 
RNA splicing and temporal regulation is characteristic of cell type, but the same for 
each recombinant. These additional observations suggested that not only was the Ad40
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E1B promoter important in determining the growth characteristics of Ad40, but also 
host cell type is important (Bailey et al., 1994).
The Ad40 E1B promoter has been shown to have minimal basal activity, and to be 
poorly trans-activated by the Ad40 El A proteins, Ad5 El A proteins and the 
promiscuous varicella zoster virus (VZV) /raws-activator p i40 (Everett, 1987), when 
compared with the Ad5 E1B promoter (Steinthorsdottir, 1991). The Ad5 E1B core 
promoter consists of a TATA box and an Spl binding site (Wu et al., 1987), although 
that upstream sequences are known to modulate its efficient functioning (Parks et al., 
1988; Parks and Spector, 1990; Spector et al., 1993). The Ad40 E1B promoter like the 
Ad5 E1B promoter consists of TATA box and an Spl binding site. The Spl binding 
site differs from that found in Ad5, but is identical to the Ad 12 Spl binding site, it also 
has a reduced affinity for the Spl protein, relative to the Ad5 site, which along with 
differences in Spl binding site core sequence influences Spl recognition. Sequences 
upstream of the Spl binding site mediate downregulation of the Ad40 E1B promoter; 
these sequences contain two protein binding sites which have been implicated in this 
effect (Mautner et al., 1999).
1.3.6 Aims of the project
The enteric adenovirus type 40 fails to grow in conventional cell lines used to propagate 
other human adenoviruses, but can be propagated in cells which express the El proteins, 
albeit at reduced levels compared with other adenoviruses. This suggests that the El 
function is poorly expressed, which has mainly been attributed to defects in E1B 
(Mautner et al., 1995), however El A expression has also been implicated (Ullah, 1997; 
van Loon et al., 1987b; Ishino et al., 1988). The aim of the work presented in this thesis 
was to characterise the Ad40 E l A region, in particular basal and trans-a.ctiva.ted 
transcription from the El A promoter.
-43-
MATERIALS
2. Materials
2 . 1  P l a s m i d s
The following plasmids were provided by the acknowledged authors or companies:
pNM80:
pLElA:
pnull-luc:
pHSV2ffi5-luc
pGL3-basic:
pGL3-control:
(Mautner et al., 1989) contains Ad40 El A sequences from 1-1643 
nucleotides.
(Dery et al., 1987) contains Ad5 E l A sequences from 1-1704 
nucleotides.
previously known as pBSKLT-6 (Dr. W. Dietrich-Goetz) contains a 
firefly (Photinus pyralis) luciferase gene upstream of the herpes 
simplex virus (HSV)-2 immediate early (IE)-5 polyadenylation 
signal, cloned via Hind IE and Bam HI restriction sites into the 
multiple cloning site (MCS) of pBluescript (figure 2.1.1). 
previously known as pKLT-55 (Dr. W. Dietrich-Goetz) contains an 
HSV-2 IE-5 promoter, inserted via a Cla I restriction site into the 
MCS upstream of the firefly luciferase gene luc in pnull-luc 
(figure 2.1.2).
(Promega) contains a modified firefly luciferase gene (luc+) 
upstream of the SV40 late polyadenylation signal (figure 2.1.3). The 
modifications which distinguish the luc+ gene from the native 
luciferase gene are as follows:
1. The C terminal tri-peptide has been removed to eliminate 
peroxisome targeting of expressed protein.
2. Codon usage was improved for expression in plant and animal 
cells.
3. Two potential sites of N-glycosylation were removed.
4. Several DNA sequence changes were made to disrupt extended 
palindromes, remove internal restriction sites, and eliminate 
consensus sequences recognised by genetic regulatory binding 
proteins, thus helping to ensure that the reporter gene itself is 
unaffected by spurious host transcriptional signals.
(Promega) contains a SV40 promoter inserted between the MCS and
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pRL-null:
pRL-SV40:
pCMV19K:
pCMV13S:
pCRH:
the modified firefly luciferase gene, and a SV40 enhancer inserted 
after the SV40 late polyadenylation signal in pGL3-basic 
(figure 2.1.4).
(Promega) contains a sea pansy (Renilla reniformis) luciferase gene 
upstream of the SV40 late polyadenylation signal (figure 2.1.5). 
(Promega) contains the SV40 early enhancer and promoter upstream 
of the sea pansy luciferase gene in pRL-null (figure 2.1.6).
(White and Cipriani, 1990) encodes the Ad5 E1B 19kDa protein, 
which is transcribed from the cytomeglovirus (CMV) immediate 
early promoter, then processed under the control of the SV40 late 
polyadenylation signal.
(Morris and Mathews, 1991) encodes the Ad5 13S El A protein, 
which is transcribed from the CMV immediate early promoter, then 
processed under the control of the SV40 late polyadenylation signal. 
(Invitrogen TA Cloning Kit) contains a MCS inserted into the LacZ 
gene (figure 2.1.7).
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X h o  I
A c c  I, S a l  I
L a c Z
f1 ori
p n u ll- lu c  
4 7 6 4  b p
lu c
A m p
C o lE 1  ori
H S V -2  l e - 5  
p o ly (A )  s ig n a l
S p e  I 
X b a  I 
E a g l  
N o t  I 
S a c  II 
B s tX I  
S a c  I
Figure 2.1.1 pnull-luc. Additional description: luc denotes a cDNA encoding firefly luciferase; 
LacZ denotes a cDNA encoding the N-terminal peptide fragment of (3-galactosidase; Amp 
denotes gene conferring ampicillin resistance in E. coli; fl ori denotes origin of replication 
derived from filamentous phage; ColEl ori denotes origin of replication in E. coli. Arrows 
within the LacZ, luc and Amp genes indicate the direction of transcription; the arrow in fl ori 
indicates the direction of ssDNA strand synthesis; the arrow in ColEl ori indicates the direction 
of dsDNA synthesis.
K pn I 
A p a  I 
X h o l  
A c c  I, S a l
L a c Z
H S V -2  IE5  
p ro m o ter
f1 ori
A m p
p H S V 2 IE 5 -lu c
5 6 4 4  bp
lu c
C o lE l  ori
H S V -2  IE 5  
p o ly (A ) s ig n a l
S a c  I 
S a c  II 
B s tX I  
E a g l  
N o t  I 
X b a l  
S p e  I
Figure 2.1.2 pHSV2EE5-luc. Additional description: luc denotes a cDNA encoding firefly 
luciferase; LacZ denotes a cDNA encoding the N-terminal peptide fragment of p-galactosidase; 
Amp denotes gene conferring ampicillin resistance in E. coli; fl ori denotes origin of replication 
derived from filamentous phage; ColEl ori denotes origin of replication in E. coli. Arrows 
within the LacZ, luc and Amp genes indicate the direction of transcription; the arrow in fl ori 
indicates the direction of ssDNA strand synthesis; the arrow in ColEl ori indicates die direction 
of dsDNA synthesis.
1742 Xba I
Figure 2.1.3 pGL3-basic. Additional description: luc+ denotes a cDNA encoding a modified 
firefly luciferase; Amp denotes gene conferring ampicillin resistance in E. coli; fl ori denotes 
origin of replication derived from filamentous phage. Arrows within the luc+ and Amp genes 
indicate the direction of transcription; the arrow in fl ori indicates the direction of ssDNA 
strand synthesis. Relevant restriction sites are marked with respect to the MCS.
SV40 late 
poly(A) signal
2094 Hpa I 
1934 Xba I
ynthetic poly(A) signal/ 
transcriptional pause site
Kpn 15 
Sac 111 
Mlu 115 
Nhe I 21 
Sma I 28 
Xho I 32 
Bgl II 36pGL3-contro!
5265 bp SV40 promoter 
Hind III 245
Nco I 278 
Nar I 313
2448
Bam HI 2442
SV40 enhancer
Figure 2.1.4 pGL3-control. Additional description: luc+ denotes a cDNA encoding a modified 
firefly luciferase; Amp denotes gene conferring ampicillin resistance in E. coli; fl ori denotes 
origin of replication derived from filamentous phage. Arrows within the luc+ and Amp genes 
indicate the direction of transcription; the arrow in fl ori indicates the direction of ssDNA 
strand synthesis. Relevant restriction sites are marked with respect to the MCS.
1498 Bam HI
SV40 late 
poly(A) signal
1246 Xba I
pRL-null
3320 bp
Chaemeric 
intron
T7 promoter
Nhe I 299 
sp45 I 315
Bgl II 1 
Xho I 5 
Sac 112 
EcolCR 110 
Hind III 15 
Nde I 24 
Nsi I 30 
Sph I 32 
Spe I 34 
Nar I 41 
Sal I 47 
Mlu I 51 
Eco Rl 58 
Xma I 65 
Sma I 67 
Pst I 77
Figure 2.1.5 pRL-null. Additional description: Rluc denotes a cDNA encoding Renilla (sea 
pansy) luciferase; Amp denotes gene conferring ampicillin resistance in E.coli. Arrows within 
the Rluc and Amp genes indicate the direction of transcription. Relevant restriction sites are 
marked with respect to the MCS.
Amp
PRL-SV40
3705 bp
Kpn I 58
SV40 early 
enhancer/prom oter
1883 Bam HI
SV40 late 
poly(A) signal
Chaemeric 
intron A1631 Xba I Hind III 420
Rluc
^T7 promoter Pst I 462 
V Nhe I 684
Csp45 I 700
Figure 2.1.6 pRL-SV40. Additional description: Rluc+ denotes a cDNA encoding Renilla (sea 
pansy) luciferase; Amp denotes gene conferring ampicillin resistance in E. coli. Arrows within 
the Rluc+ and Amp genes indicate the direction of transcription. Relevant restriction sites are 
marked with respect to the MCS.
C o lE l  o n
f1 ori
p C R I
3 9 3 2  b p
N s l  I 2 7 4  
H in d  III 2 7 7  
K pn I 2 8 7  
S a c  I 2 9 3  
B a m  HI 2 9 5  
S p e  I 3 0 1  
B s t  XI 3 2 2  
E c o  R l 3 2 6  
T  o v e r h a n g s  
E c o  R l 3 3 4  
E c o  R V  3 3 8  
B s t  XI 3 4 8  
N o t  I 3 5 3  
A v a  I P a e  R 7I X h o  
N s i  I 3 7 0  
X b a  I 3 7 1  
A p a  I 3 8 1
3 5 9
Figure 2.1.7 pCRII. Additional description: LacZ denotes a cDNA encoding the N-terminal 
peptide fragment of P-galactosidase; Kan denotes gene conferring kanamycin resistance in 
E. coli; Amp denotes gene conferring ampicillin resistance in E. coli; fl ori denotes origin of 
replication derived from filamentous phage; ColEl ori denotes origin of replication in E. coli. 
Arrows within the LacZ, Kan and Amp genes indicate the direction of transcription; the arrow in 
fl ori indicates the direction of ssDNA strand synthesis.
2 . 2  B a c t e r i a
The Escherichia coli (E. coli) strain NM522 [recA+ (supE thi 8(lac-proAB) hsd5 
(F  proAB lacF lacZ8M15))] was used for maintenance and propagation of pNM80 and 
pLElA DNA. The E. coli strain DH5a [F'/endAl hsdR17 (rk’nik+) supE44 thil recAl 
gyrA (Nal1) relAl A(lacZYA-argF)U169 (O80dlacA(lacZ)M15] was used for 
maintenance and propagation of pHSV2IE5-luc and pnull-luc based plasmids. The 
E. coli strain JM109 [F  traD36 proA+ proB+ lacT1 lacZ8M15/recAl endAl gyrA96 (Nalr) 
hsdR17 supE44 relAl S(lac-proAB) mrcA] was used for maintenance and propagation of 
pGL3-control, pRL-SV40, pRL-null and pGL3-basic based plasmids. The E. coli strain 
INVaF [endAl recAl hsdR17(rkm+k) supE44 X  thi-1 gyrA rel al 
O801acZaAml 5A(lacZYA-argF) deoR+F'] was provided with the Invitrogen TA 
Cloning Kit for the maintenance and propagation of pCRII based plasmids.
2 . 3  B a c t e r i a l  c u l t u r e  m e d i a
The E. coli strains NM522, DH5a and JM109 were routinely grown in L-broth (lOgram 
(g) sodium chloride, 16g bactotryptone, lOg yeast extract in 1 litre (1) distilled water 
(DW). For the preparation of competent cells (section 3.1.8) 2YT broth (5g sodium 
chloride, 16g Bactotryptone, lOg yeast extract in 11 of DW) was used. Agar plates were 
made with 1.5% agar in L-broth. Media was supplemented with 50p,g/ml ampicillin to 
maintain bacteria containing actual and derived plasmids from section 2.1. Screening 
for recombinant plasmids using the Invitrogen TA Cloning Kit is provided by 25pi 
40mg/ml X-Gal in dimethylformamide, which was spread on top of a LB agar plate 
containing 50pg/ml ampicillin lhr before plating (recombinant plasmids produce white 
colonies whereas non-recombinant plasmids produce blue colonies). Colonies of 
INVaF' cells containing experimental plasmids were routinely grown in L-broth 
containing 50pg/ml ampicillin.
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2 . 4  S y n t h e t i c  o l i g o n u c l e o t i d e s
Oligonucleotides AB34, FS1-5 and the M l3 -20 sequencing primer were synthesised in 
house by Mr. J. McGeehan using a Cruachem Ltd PS250 automated DNA synthesiser. 
Oligonucleotides Alex 1-6 were custom synthesised by Cruachem Ltd.
Table 2.4 Synthetic oligonucleotide primers.
Oligo Nucleotide Ad5 or 
Ad40
Sequence (5'-»3')
AB34 533-512
452-429
Ad5 and 
Ad40
g g g g a g a T  a g e  11CCTCCTCTTTTGAGATGAGCGA 
Hind HI
FS1 1-20 Ad5 and 
Ad40
gSTSrSTflV tcgacCATCATCAATAATATACCTT
Sal I
FS2 485-504 Ad40 g g g g V  a a  11 c  qV  g a  t  c  cATGAGAATGCTGCCGGATTT 
Eco R l Bam HI
FS3 1310-1291 Ad40 gggaTagcttTCAGGAGCACTTGGGGCGCT
Hind HI
FS4 610-627 Ad40 TCTTTTTGATGTGGAGGT
FS5 1201-1184 Ad40 CTGCACGGGATGGTTCTC
Alexl 512-535 Ad40 GGGAACTGGGATGACATGTTCCAG
Alex2 809-832 Ad40 GAAACTGATGAGGCTACAGAGGCG
Alex3 832-809 Ad40 CGCCTCTGTAGCCTCATCAGTTTC
Alex4 929-952 Ad40 GATTTCCATCGGGGCACTAGTGGC
Alex5 1150-1127 Ad40 TGGGGAAAATCAGTGTCCTCAGGC
Alex6 22571-
22548
Ad40 CTGGCTGCAGCTTAAGATCCTCCT
Lower case lettering denotes sequences containing restriction sites, which do not correspond to 
adenovirus sequences. The symbol ▼ shows the position at which the restriction enzyme cuts. 
The nucleotide numbers refer to the genome coordinates of Ad5 or Ad40 sequences, which are 
denoted in upper case lettering.
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2 . 5  R a d i o c h e m i c a l s
[a-35S]dATP and [35S]L-methionine were purchased from NEN, whilst [a-32P]dCTP 
was purchased from Dupont, with the following specific activity:
[a-35S]dATP 
[35S]L-methionine 
[a-32P]dCTP
2 . 6  E n z y m e s
1250Ci/mmol (12.5pCurie (Ci)/pl) 
1175Ci/mmol (lOpCi/pl) 
3000Ci/mmol (lOpCi/pl)
All restriction enzymes were obtained from Boehringer Mannheim except for Aci I, 
Bsm FI, Bsl I and Hph I which were obtained from New England Biolabs. Other 
enzymes were obtained from the following manufacturers:
Amersham:
Boehringer Mannheim:
Gibco BRL Life Technologies: 
Promega:
Sigma:
Stratagene:
RNasin
Bal 31 nuclease, DNA polymerase I large 
(Klenow) fragment, proteinase K, T4 DNA ligase 
Taq DNA polymerase
Moloney murine leukaemia virus (M-MuLV) 
reverse transcriptase, RQ1 RNase free DNase 
Lysozyme, RNase A 
Pfu DNA polymerase
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2 . 7  A n t i s e r a  a n d  m o n o c l o n a l  a n t i b o d i e s
The anti-peptide E1B 19kDa antibody (Mautner et al., 1990) which recognises an 
epitope within the C-terminal region of the E1B 19kDa protein was obtained from 
Dr V. Mautner.
The anti-Ad5 hexon monoclonal antibody (mAB) (10/5.1) was obtained from Dr I. 
Sharpe, Central Public Health Laboratory, Colindale.
The anti-Ad5 El A monoclonal antibody M58 which recognises the Ad5 El A proteins 
(Harlow et al., 1985) through an epitope contained within the last 266 amino acids of 
the 13S El A protein C-terminal region, was obtained from Pharmingen, San Diego, CA.
Protein A horseradish peroxidase (HRP) conjugate and FITC conjugated to goat 
anti-mouse immunoglobulin were supplied by Sigma.
2 . 8  C e l l s  a n d  t i s s u e  c u l t u r e  m e d i a
293 cells (ATCC N°. CRL-1573, Graham et al., 1977) are an HEK cell line which has 
been transformed with the Ad5 El region. They were grown in Glasgow modified 
Eagle’s medium supplemented with 10% foetal calf serum (FCS).
KBa+b cells (otherwise known as KB 16 cells, obtained from the authors of Babiss et 
al., 1983), are a human, oral, epidermoid carcinoma cell line which has been 
transformed with the Ad2 El region. They were grown in Glasgow modified Eagle’s 
medium supplemented with 5% FCS.
WS HeLa cells (ATCC N°. CCL-2) are a cervical carcinoma cell line. They were grown 
in Dulbecco’s modified Eagle’s medium (Gibco BRL) supplemented with 2.5% FCS, 
2.5% newborn calf serum (NCS), 4mM L-glutamine, 100 units/ml penicillin and 
lOOpg/ml streptomycin.
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2 . 9  V i r u s e s
Ad5 strain 75 (obtained originally from Dr H. G. Pereira, NIMR) was propagated in 293 
cells.
Ad40 strain Dugan (obtained from the authors of de Jong et a l, 1983) was propagated 
in KBa+b cells to produce a passage 9 stock (p9) which was used throughout.
2 . 1 0  P e p t i d e s
Peptides corresponding to the Ad40 El A 13S sequences outlined in table 2.1.10 were 
synthesised in house by Mrs K. McAulay using a Shimadzu Europa PSSM - 8  peptide 
synthesiser.
Table 2.10 Peptide sequences.
Peptide Amino acids Sequence
1051C 1-15 (N-terminal) (MRMLPDFFTGNWDDMGGGG) 4 k 2k a
1051D 162-176 (CR3) (CALC YMRLTGHCIYSGGGG) 4 k 2k a
1051E 236-249 (C-terminal) (DEPLNLSLKRPKGGGG) 4 k 2k a
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2 . 1 1  S o l u t i o n s
ABTS substrate:
10X Agarose gel loading buffer: 
10X Bal 31 nuclease buffer:
3X Boiling mix:
Chase mix:
Citrate phosphate buffer:
50X Denhardt’s solution:
DNase I buffer:
dT-0:
dC-0:
dG-0:
dA-0:
Extraction buffer:
Formamide dye mix:
Gel soak I:
Gel soak II:
0.5mg/ml 2 , 2-Azino-di-[3-ethylbenzthiozoline 
sulphonate (6 )] (ABTS), 0.0003% H2O2 in citrate 
phosphate buffer
IX TBE, 1% sodium dodecyl sulphate (SDS), 50% 
glycerol, 1 mg/ml bromophenol blue 
0.5M Tris.HCl, lOOmM MgCl2, lOOmM CaCl2, 
6 M NaCl, 0.25mg/ml bovine serum albumin 
(BSA), pH 8
29% SGB, 6 % SDS, 2M P-mercaptoethanol, 29% 
glycerol, 1 mg/ml bromophenol blue 
0.25mM dTTP, dCTP, dGTP and dATP 
lOOmM citric acid, lOOmM Na2HP0 4 , pH 4.2 
1% polyvinylpyrrolidone, 1% BSA, 1% ficol 
40mM Tris.HCl, lOmM NaCl, 6 mM MgCk, 
lOmM CaCl2, pH 7.9
lp l 5mM dTTP, 20pl 5mM dCTP, 20pl 5mM
7-deaza dGTP, 50pl 10X TE, 370pl DW
20pl 5mM dTTP, lp l 5mM dCTP, 20pl 5mM
7-deaza dGTP, 50pl 10X TE, 370pl DW
20pl 5mM dTTP, 20pl 5mM dCTP, lp l 5mM
7-deaza dGTP, 50pl 10X TE, 370pl DW
20pl 5mM dTTP, 20pl 5mM dCTP, 20pl 5mM
7-deaza dGTP, 50pl 10X TE, 540pl DW
250mM NaCl, 50mM HEPES, 0.1% NP-40,
pH 7.0
lOmM EDTA, 1 mg/ml xylene cyanol FF, 1 mg/ml 
bromophenol blue in formamide 
1.5M NaCl, 0.5M NaOH
1.5M NaCl, 0.5M Tris.HCl, ImM sodium 
ethylenediamine tetra-acetic acid (EDTA), pH 7.2
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2X HBS:
Phosphate buffered saline (PBSa):
PBS-complete:
Pre-hybridisation solution:
RGB (resolving gel buffer):
RNA lysis buffer:
10X Sequencing buffer:
T sequencing mix:
C sequencing mix:
G sequencing mix:
A sequencing mix:
SGB (stacking gel buffer): 
Solution I:
Solution II:
Solution EH:
20X SSC:
STET:
Stripping buffer:
Tank buffer:
20X TBE:
TBS:
TE:
280mM NaCl, 50mM
N-2-hydroxyethylpiperazine-N'-2-ethane sulphonic 
acid (HEPES), 1.5mM Na2H P04, pH to 7.12 with 
NaOH
170mM NaCl, 3.4mM KC1, lOmM Na2H P04, 
1.8mM KH2P 0 4, pH 7.2
PBSa plus 0.001% CaCl2 .2H20 , 0.001%
MgCl2 .6H20
5X SSC, 5X Denhardt’s solution, 0.5% SDS,
20pg/ml salmon sperm (ss) DNA
1.5M Tris.HCl, 0.4% SDS, pH 8.9
150mM NaCl, 0.65% NP40, lOmM Tris.HCl
pH7.9
lOOmM Tris.HCl, lOOmM MgCl2, pH 8.5
500pl dT-0, 500pl 600pM ddTTP
500pl dC-0, 105 pi 140pM ddCTP
500pl dG-0, 155pl 200pM ddGTP
500pl dA-0, 250pl 140pM ddATP
0.5M Tris.HCl, 0.4% SDS, pH 6.7
50mM glucose, 25mM Tris.HCl, lOmM EDTA,
pH8
0.2M NaOH, 1% SDS
5M Potassium acetate, pH 4.8 with acetic acid 
3M NaCl, 0.3M tri-sodium citrate 
8 % sucrose, 5% Triton X-100, 50mM EDTA, 
50mM Tris.HCl, pH 8.0
lOOmM p-mercaptoethanol, 2% SDS, 62.5mM 
Tris.HCl, pH 6.7
0.05M Tris.HCl, 0.05M glycine, 0.1% SDS 
2.5M Tris.HCl, 800mM boric acid, 54mM EDTA 
0.02M Tris.HCl, 0.5M NaCl, pH 7.5. 
lOmM Tris.HCl, ImM EDTA, pH 8.0
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Towbin (blotting buffer):
TTBS:
Versene:
Wash buffer:
25mM Tris.HCl, 192mM glycine, 20% methanol, 
pH 8.3
TBS plus 0.05% Tween 20
0.6mM EDTA in PBS(A), 0.002% phenol red
PBS plus 0.3% Tween 20
-53-
2 . 1 2  C h e m i c a l s  a n d  r e a g e n t s
All chemicals and reagents were purchased from BDH Chemicals UK or Sigma 
Chemical Company, unless otherwise stated below.
Beecham Research:
Bio-Rad:
Boehringer Mannheim:
Difco:
Fisons:
Fluka:
Gibco BRL Life Technologies: 
JT Baker:
Melford Laboratories Ltd: 
National Diagnostics:
New England Biolabs: 
Pharmacia:
Prolabo:
Scotlab:
UKC Chemical Laboratories:
Ampicillin
Ammonium persulphate (APS), gelatin,
N, N, N', N' Tetra-methyl-ethylene-diamine
(TEMED), Bradford reagent.
Tris.HCl
Agar, bactotryptone, yeast extract
Acetone
Formamide
FCS, L-glutamine, NCS, penicillin, streptomycin 
Acetic acid, isopropanol, methanol 
Caesium chloride
30% Acrylamide (2.5% cross-linker)
Sal I linkers
dNTPs, ddNTPs
Boric acid, chloroform, glycerol
Acrylamide: N, N'-methylene-bis-acrylamide
19:1
Citifluor
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METHODS
3. Methods
Unless otherwise stated the method is fully referenced in “Current Protocols in 
Molecular Biology” (Ausubel et al., 1995).
3 . 1  M a n i p u l a t i o n  o f  D N A
3.1.1 Purification of synthetic oligonucleotides
Synthetic oligonucleotides were synthesised in house by Mr. J. McGeehan on a 
Cruachem Ltd PS250 automated DNA synthesiser, using 200pM synthesis columns. To 
remove the oligonucleotide from the column, 5ml disposable syringes were attached to 
both ends of the column with one containing 1.5ml ammonium hydroxide (0.88 specific 
gravity), and the solution was pushed through the column in 2 0 0 pl aliquots with 2 0 min 
incubation between each fresh addition. After incubation with the final aliquot, the 
1.5ml solution was pushed backwards and forwards through the column 4-5 times to 
mix the aliquots thoroughly. The eluted oligonucleotide solution was incubated in a 
tightly sealed tube for 5hr at 55°C to remove protecting groups. Following 
lyophilisation, the oligonucleotide was dissolved in 200pl DW. An equal volume of 
formamide plus lOpl formamide dyes were added before boiling for 5min prior to 
electrophoresis on a 12% denaturing polyacrylamide gel (section 3.1.4.2).
3.1.2 Polymerase chain reaction (PCR)
PCR was used to amplify specific fragments from either a DNA template using 
Pfu DNA polymerase, or from a cDNA template using Taq DNA polymerase. Pfu DNA 
polymerase shows high fidelity during amplification, therefore it was used to reduce the 
likelihood of aberrations during PCR amplification. Taq DNA polymerase, on the other 
hand, was used specifically for the construction of expression plasmids containing Ad40 
E1A cDNAs using the pCRII cloning kit (Invitrogen).
3.1.2.1 PCR using P fu  DNA polymerase
PCR reactions were set up in 50pl reaction volumes of IX Pfu DNA polymerase buffer 
(supplied with the enzyme) containing lOOng template DNA, 5pM each primer, 250pM 
each dNTP and 2.5 units (U) Pfu DNA polymerase; which was overlaid with 50pl light
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mineral oil to prevent evaporation during cycling. Following optimisation of the PCR 
reaction, cycling was carried out using a Cambio thermal cycler, where the cycles 
comprised 1 cycle at [94°Cx7min, 55°Cx3min, 72°Cx2min], 30 cycles at [94°Cx2min, 
55°Cxlmin, 72°Cx2min] and 1 cycle at [72°Cx5min].
3.1.2.2 PCR using Taq DNA polymerase
PCR reactions were set up in 50pl reaction volumes of IX Taq DNA polymerase buffer 
(supplied with the enzyme) containing template cDNA, lpM  each primer, 250pM each 
dNTP, 1.5mM MgCl2 and 2.5U Taq DNA polymerase; which was overlaid with 50pl 
light mineral oil. Template cDNA consisted of 5pi of a reverse transcription reaction 
containing an unquantified amount of cDNA, which was made from cytoplasmic RNA 
as in sections 3.2.1 and 3.2.2. Following optimisation of the PCR reaction, cycling was 
carried out using a Cambio thermal cycler, where the cycles comprised 1 cycle at 
[95°Cx5min, 70°Cxlmin, 72°Cx3min] then 50 cycles at [95°Cxlmin, 70°Cxlmin, 
72°Cx5min].
3.1.3 Digestion of DNA
3.1.3.1 B al 31 nuclease digestion o f DNA
Bal 31 nuclease digestion of restriction enzyme digested plasmid DNA (50pg) was 
carried out at 37°C for 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60min using 0.75U 
of pre-warmed enzyme in 200pl IX Bal 31 nuclease buffer. To terminate Bal 31 
nuclease digestion 0.5pl 0.5M EDTA was added to each 15pl aliquot of the reaction 
mix, which was immediately phenol: chloroform extracted. The DNA was then ethanol 
precipitated and resuspended in 20pl DW, before restriction enzyme analysis of a 2pi 
aliquot.
3.1.3.2 Restriction enzyme digestion o f DNA
Restriction enzyme digestion of DNA was carried out at 37°C (or the temperature 
specified by the supplier) in 20pl reaction volumes of IX buffer (supplied with the 
enzyme) containing 1U of enzyme per pg of DNA to be digested in an hour. The buffer 
system used most frequently was the Boehringer Mannheim A, B, H, L, M system. On 
all other occasions New England Biolabs NEBuffer 1, 2, 3, 4 system was used. Usually, 
0.5pg DNA was digested for diagnostic analysis, and 5-20pg for isolation of specific
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restriction fragments. Samples (2pl) of plasmid DNA prepared by the miniprep method 
(see section 3.1.9) were digested in the presence of 500pg/ml RNase A.
3.1.4 Electrophoretic separation and purification of DNA fragments
3.1.4.1 Non-denaturing agarose gels
DNA fragments produced by Bal 31 nuclease digestion, PCR or restriction enzyme 
digestion were resolved by non-denaturing agarose gel electrophoresis. Horizontal slab 
gels approximately 0.5cm thick were utilised and samples, including appropriate size 
markers, were loaded following the addition of 2 pi agarose gel loading buffer. 
Fragments greater than lOObp were separated on 0.5-2% agarose gels, run in IX TBE 
at 150 Volts (V) on a Gibco BRL 11-14 gel electrophoresis kit. Following 
electrophoresis the gel was stained with lpg/ml ethidium bromide, then the DNA was 
visualised under short wave ultraviolet (UV) light on an UV Products Inc. 
transilluminator (long wave UV light for preparative gels). Photography was carried out 
using the Appligene Imager.
3.1.4.2 Denaturing polyacrylamide gels
Vertical denaturing polyacrylamide (acrylamide:N, N'-methylene-bis-acrylamide 19:1) 
gels containing 7M urea and IX TBE, were used to resolve the products of DNA 
sequencing reactions and to purify synthetic oligonucleotides. Polymerisation was 
initiated by adding O.Olvol 10% APS and 0.00lvol TEMED. DNA sequencing gels 
containing 6 % or 8 % acrylamide were run at 60W in a Gibco BRL S2 sequencing kit for 
varying lengths of time depending upon the sequence to be visualised. Gels were then 
vacuum dried on a Bio-Rad S83 gel dryer and exposed to Kodak X-OMAT S film for 
1-3 days, before developing in a Kodak X-OMAT ME-3 processor. Gels for purifying 
oligonucleotides contained 12% acrylamide and were run at 250V, in a kit manufactured 
in house, until the bromophenol blue marker was approximately 3A way down the gel. 
Gels were then transferred to cling film on top of a thin layer chromatography (TLC) 
plate, and the oligonucleotides could be visualised at 254nm as dark shadows against a 
fluorescing TLC plate. Bands containing the oligonucleotides were cut out of the gel, 
crushed and covered with 200pl DW. The oligonucleotides were then eluted overnight 
at room temperature (RT), precipitated twice with ethanol, then washed once with 70% 
ethanol before resuspending in an appropriate volume of DW. The concentration of the
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oligonucleotide was determined by measuring the optical density (OD) at 260nm on a 
Beckman DU-62 spectrophotometer, this value was then used in the following 
calculation:
Concentration (pM) = (OD26o x dilution factor)/extinction coefficient 
[Extinction coefficient = (number (n)A x 15 200) + (nT x 8 400)+ (nC x 7 050)+ (nG x 12 010]
3.1.5 DNA purification from agarose gels
DNA fragments of the correct size were excised from gels under long wave UV light on 
a UV Products Inc. transilluminator, and the DNA recovered using the commercial 
GENECLEAN II kit (BIO101 Inc., La Jolla, CA). The kit contains a silica matrix, 
which binds DNA in the presence of high concentrations of sodium iodide. The gel 
slice was weighed to estimate its volume and cut into approximately 2 mm cubes to 
facilitate gel dissolution in 4.5 volumes (vol) sodium iodide solution plus 0.5vol TBE 
modifier, at 55°C for 5min. The silica matrix was then added to the solution (5pi for up 
to 5pg DNA then an additional lp l for every 0.5pg above 5pg), which was mixed by 
inversion before incubating on ice for 5min. Following a 5sec centrifugation at 13,000 
revolutions per minute (rpm) on a MSE microcentaur, the silica matrix pellet was 
washed three times in 10-50vol NEW wash. The DNA was eluted from the matrix into 
20pl DW by incubating at 55°C for 5min. The matrix was pelleted and the supernatant 
containing the DNA transferred to a fresh tube.
3.1.6 Production of blunt ended DNA fragments
Fragments generated by enzymes which produced 5' or 3' overhangs were blunt ended at 
37°C for 30min in a 20pl reaction volume of IX M buffer containing 50pM of each 
dNTP and 2U of DNA polymerase I large (Klenow) fragment.
3.1.7 DNA ligation
Suitably prepared insert and vector fragments in a 4:1 ratio (i.e. 200ng : 50ng), were 
ligated at RT overnight in a 20pl reaction volume of IX T4 ligase buffer (supplied with 
the enzyme) containing 2U of T4 DNA ligase. A lOpl aliquot of the reaction was then 
transformed into an appropriate strain of competent E. coli cells.
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3.1.8 Preparation and transformation of competent is. coli cells
The appropriate E. coli cells were streaked onto a LB agar plate and incubated at 37°C 
overnight. A single colony was picked and used to inoculate 10ml 2YT, which was 
incubated at 37°C in a shaking incubator for 2-3hr until the OD45o was approximately 
0.3. The cells were pelleted by centrifugation at 3,000rpm, 4°C for 5min in a Beckman 
GPR centrifuge, resuspended in 0.5ml ice cold 0.1M MgCl2 and repelleted at 3,000rpm, 
4°C for 2min. The pellet was resuspended in 0.5ml ice cold 0.1M CaCl2, then incubated 
on ice for 30min.
Approximately lOng of plasmid or Vi (lOpl) of a ligation reaction was added to a lOOpl 
aliquot of freshly prepared competent cells, then incubated on ice for 20min. The cells 
were heat shocked at 42°C for lmin, then added to 0.5ml L-broth prior to incubation at 
37°C for 30min. A 50pl aliquot of cells or the entire transformation mix was then 
plated onto a LB agar plate containing 50pg/ml ampicillin and incubated at 37°C 
overnight.
3.1.9 Small scale plasmid DNA preparation
Miniprep DNA for the analysis of bacterial colonies was prepared by alkaline lysis. A 
single bacterial colony was picked from a LB agar plate containing 50pg/ml ampicillin 
and used to inoculate 5ml L-broth, which was incubated in a shaking incubator at 37°C 
overnight. A 1.5ml aliquot of the culture was centrifuged (in a MSE microcentaur) at 
13,000 rpm, RT for 5 min, then the pellet was resuspended in 100pl solution I and 
incubated at RT for 5 min. A 150pl aliquot of freshly prepared solution II was then 
added and the reaction was incubated at RT for 5 min before the addition of 150pl 
solution in and incubation at RT for a further 5 min. Cell debris was pelleted by 
centrifugation at 13,000 rpm, RT for 5 min and the supernatant was transferred to a 
fresh tube where it was phenol xhloroform extracted and ethanol precipitated. The 
pellet was then resuspended in lp l lOmg/ml RNase A plus 19pl TE.
3.1.10 Large scale plasmid DNA preparation
E. coli containing the desired plasmid was streaked (from a glycerol stock or from a 
single colony picked from an agar plate) or spread (from an aliquot of newly 
transformed competent cells) onto a LB agar plate containing 50pg/ml ampicillin then
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incubated at 37°C overnight. A single colony was picked and used to inoculate 350ml 
L-broth containing 50pg/ml ampicillin, which was incubated in a shaking incubator at 
37°C overnight.
Plasmid DNA was prepared from bacteria according to the method of Holmes and 
Quigley (1991), and the bacterial lysate was purified further on a caesium 
chloride/ethidium bromide gradient to yield supercoiled plasmid DNA. Bacterial 
cultures were centrifuged at 5,000 rpm, RT for 8 min in a Sorvall GS3 rotor, and the 
pellets resuspended in 20ml STET plus 2ml freshly prepared lOmg/ml lysozyme in 
STET. The mixture was brought to the boil over a Bunsen flame and placed in a boiling 
water bath for 45sec, before pelleting cell debris by centrifugation in a Sorvall SS34 
rotor at 18,000 rpm, RT for 50min. Nucleic acids were precipitated from the supernatant 
by the addition of 0.9 volumes of isopropanol, and pelleted by centrifugation in a 
Beckman GPR centrifuge at 3,000 rpm, RT for 5min. The pellet was resuspended in lx 
TE to give a volume 5.5ml, then 6.2g caesium chloride and 0.2ml lOmg/ml ethidium 
bromide were added. The samples were incubated on ice for 20min prior to 
centrifugation at 3,000 rpm, 4°C for lOmin. The supernatant was transferred to a 
Dupont 03945 crimp-seal centrifuge tube using a syringe, then centrifuged at 45,000 
rpm, 15°C for 16-18hr in a Sorvall TV865 vertical rotor. The lower band (which 
contains supercoiled plasmid DNA) was removed using a syringe, taking care to avoid 
contamination with chromosomal DNA from the upper band. The ethidium bromide 
was removed from the plasmid solution by 2-3 extractions with TE saturated butan-l-ol, 
and the caesium chloride was removed by dialysing against IX TE at RT for 2hr. 
Following this the solution was treated with lOOpg/ml RNase A at 65°C for lhr, then 
lOOpg/ml proteinase K plus 0.1% SDS at 37°C for lhr. The plasmid DNA was cleaned 
by phenol:chloroform extraction, and concentrated by ethanol precipitation. The pellet 
was resuspended in 400pl 0.3M sodium acetate pH 5.5 then ethanol precipitated again. 
The final pellet was washed in 70% ethanol and resuspended in an appropriate volume 
of DW before storage at "20°C. The plasmid concentration was determined by 
measuring the absorbance at 260nm on a Beckman DU-62 spectrophotometer, assuming 
lA 26o=50pg/ml.
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3.1.11 Dideoxy sequencing of DNA
Plasmid DNA was sequenced by the dideoxy nucleotide chain termination method as 
described by Sanger et al. (1977). Miniprep DNA (lOpl i.e. half a miniprep sample) 
was denatured at RT for lOmin in a 20pl reaction volume containing 0.4M sodium 
hydroxide. The denatured DNA was then precipitated on ice for lOmin by the addition 
of 6 pl 3M sodium acetate pH 4.5, 14pl DW and 120pl ethanol, then pelleted by 
centrifugation in a MSE microcentaur at 13,000rpm, RT for lOmin. The pellet was then 
washed with 70% ethanol and resuspended in 8 pi DW.
The primer was annealed to the DNA template at 37°C for 20min in a lOpl reaction 
volume of IX sequencing buffer containing 5pmol of primer. Meanwhile four chain 
termination mixes were made up (for 6  samples: Labelling mix = 20pCi [a-35S] dATP + 
6 pi 11.8pM dATP. Chain termination mix = 12pl T, C, G or A sequencing mix + 2pl 
labelling mix), and 2 pl aliquots of each dispensed into one of four round bottomed wells 
on a 96 well microtitre plate. After the annealing reaction was completed, 2units of 
E. coli DNA polymerase I large (Klenow) fragment were added and 2pl aliquots 
dispensed into the 4 wells containing the chain termination mixes, the plate was then 
incubated at 37°C for 15min. Following this any newly synthesised strands which had 
not been terminated by incorporation of a dideoxy nucleotide were extended into high 
molecular weight products by adding 2pl chase mix which was incubated at 37°C for 
30min. The reactions were stopped by the addition of 2pl formamide dyes. The 
samples were boiled for lmin prior to electrophoresis on a denaturing polyacrylamide 
gel (section 3.1.4.2).
3.1.12 Southern blotting
Products from PCR reactions (section 3.1.2.2) were separated on agarose gels 
(section 3.1.4.1). The gels were incubated at RT, whilst shaking, in Gel Soak I for 
45min, then Gel Soak II for 45min. The gel was then placed face down onto a wick of 
Whatman 3mm paper (soaked in 10X SSC and descending into a 10X SSC reservoir), 
then a Hybond N+ filter (pre-soaked in 2X SSC), two pre-soaked sheets of Whatman 
3mm paper, a stack of absorbent paper towels and a light weight were placed on top of 
the gel. Care was taken to eliminate air bubbles between layers to prevent uneven
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transfer of DNA from the gel to the filter. After transfer at RT overnight, the filter was 
briefly rinsed in 2X SSC before denaturing the DNA by placing the filter (DNA side up) 
on Whatman 3mm paper which had been pre-soaked in 0.4N sodium hydroxide for 
20min, after which time the filter was rinsed in 2X SSC.
Hybond N+ filters were pre-hybridised for 3-4hr at 65°C in pre-hybridisation solution,
7  8then the probe DNA (10 -10 counts per minute (cpm), see below) was added to the 
mix, and incubation continued overnight at 65°C. The filter was washed twice in 
2X SSC plus 0.1% SDS for 30min at RT and then twice in 0.1X SSC plus 0.1% SDS for 
30min at RT. The filter was air dried and exposed to Kodak X-OMAT S film.
Plasmid DNA probes were prepared using the Megaprime system from Amersham. 
Approximately 25ng of DNA was mixed with 5pi Megaprime primer (Amersham) in a 
final volume of 20pl, then placed in a boiling water bath for 5min. The mixture was 
cooled and lOpl Megaprime buffer, 50pCi [a-32P]dCTP and 4-5U DNA polymerase I 
large (Klenow) fragment were added, bringing the reaction volume to 50pl, and the mix 
was incubated at 37°C for 20min. The reaction was stopped by the addition of 5pi 
0.2M EDTA. Bromophenol blue was added to colour the mix which was then loaded 
onto a Pharmacia G-50 Sephadex nick column which had been equilibrated with IX TE 
containing 0.1% SDS. Fractions (approximately 0.25ml) were collected from the 
column, then those containing the highest counts in the initial peak were pooled and 
used as probe. The probe was denatured at RT for lOmin with a l/20vol of 5N sodium 
hydroxide, then neutralised by adding a l/20vol of 5M hydrochloric acid.
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3 . 2  M a n i p u l a t i o n  o f  R N A
3.2.1 Preparation of cytoplasmic RNA
Cytoplasmic RNA was prepared from 60mm plates of Ad40 infected (5ffu/cell) 293 
cells as described by Ausubel et al. (1995). Reagents used in this protocol were made 
up in DEPC treated DW, and the entire protocol was performed at 4°C to minimise any 
RNase activity. The cell sheet was harvested into the medium at various time points 
post-infection (p.i.) (outlined in results figure legends), then transferred to a falcon tube 
where the cells were washed twice with ice cold PBS. The cell pellet was resuspended, 
by vortexing, in 200pl RNA lysis buffer and centrifuged in an Ole Dich Instrument 
Makers 157.MP microfuge at 20,000rpm, 4°C for 30sec. SDS was added to the 
cytoplasm to a final concentration of 0.2%, then the RNA was immediately 
phenolichloroform extracted twice and ethanol precipitated. To remove any DNA 
present in the sample the pellet was incubated in lOOpl IX DNase buffer containing 1U 
RNase free DNase at 37°C for 30min. The sample was then phenol xhloroform 
extracted, ethanol precipitated, and washed with 70% ethanol. The pellet was 
resuspended in a suitable volume of DEPC treated DW.
3.2.2 Reverse transcription of RNA
RNA was reverse transcribed to make a complementary DNA (cDNA) template for use 
in PCR. The primer was annealed to the RNA template (prepared as in section 3.2.1) at 
65°C for 15min in a 42pi reaction volume of IX M-MuLV reverse transcriptase buffer 
(supplied with the enzyme) containing lOOpmol of primer and 150pM each of dATP, 
dCTP, dGTP and dTTP. To half the annealing reaction, 1 OOpg/ml BSA, 20U of RNasin 
and 50U M-MuLV reverse transcriptase were added, and to the other half of the sample 
1 OOpg/ml BSA plus 20U of RNasin were added (the later reaction acted as a negative 
control determining whether or not DNase I treatment had been effective). The samples 
were incubated at 37°C for 2hr, then phenol:chloroform extracted, ethanol precipitated 
and the pellet resuspended in 50pl DW. Typically a 5pi aliquot was used in a 50pl PCR 
amplification using Taq DNA polymerase (section 3.1.2.2).
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3 . 3  M a n i p u l a t i o n  o f  p r o t e i n s
3.3.1 Preparation of protein extracts from transfected or infected 
cells
Protein extracts were prepared from 60mm plates of WS HeLa cells which had either 
been transfected with lOpg plasmid DNA or infected with Ad5 (5pfu/cell) or Ad40 
(5ffu/cell). Cells were harvested at the desired time point by removing the medium, 
washing the cell sheet twice with PBS, then incubating for 5min at RT with 
400pl IX boiling mix. The cell lysate was then transferred to an Eppendorf tube and 
stored at -20°C.
3.3.2 Preparation of protein extracts from [35S]L-methionine 
labelled cells
[35S]L-methionine labelled cells were prepared from 100mm plates of WS HeLa cells 
which had been infected with Ad5 (5pfii/cell) or Ad40 (5ffu/cell), then blocked with 
cytosine arabinoside (Ara C, 20pg/ml Ara C 12 hourly, section 3.5.3) to allow early 
viral proteins to accumulate. At 42hr post infection (p.i.) the cells were labelled at 37°C
i  r
for 2hr with lOOpCi [ S]L-methionine in methionine free medium. The cells were then 
scraped into the medium and transferred to a 15ml Falcon tube where they were washed 
twice with ice cold PBS, then resuspended in 200pl extraction buffer minus 0.1% NP- 
40. The cells were lysed by sonication in a Kerry sonibath at RT for 30-60sec, 0.1% 
NP-40 was added then the cell debris pelleted by centrifugation in an Ole Dich 
Instrument Makers 157.MP microfuge at 13,000rpm, 4°C for lOmin. An aliquot of the 
supernatant was stored at ”70°C for later analysis by electrophoresis on a SDS 
polyacrylamide gel (SDS-PAGE) section 3.3.4), the remainder was transferred to a fresh 
tube to be used in immunoprecipitation.
3.3.3 Immunoprecipitation
Proteins were immunoprecipitated by a modification of the method used by Stephens 
and Harlow (1987). The supernatant prepared in section 3.3.2 was pre-cleared (end over 
end mixing) at 4°C for lhr with 30pl 50% protein A sepharose (in extraction buffer), 
then pelleted by centrifugation in an Ole Dich Instrument Makers 157.MP microfuge at 
13,000rpm, 4°C for lmin. The supernatant was split into two equal amounts then
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incubated (end over end) at 4°C for 3hr with 20pl pre-immune or immune serum. Upon 
addition of 60pl of protein A sepharose the reactions were incubated for a further lhr at 
4°C. The protein A sepharose was washed 3X with 200pl extraction buffer to remove 
any non-specifically bound proteins. Specifically bound proteins were eluted into 2 0 pl 
IX boiling mix by boiling for 5min, before being separated by SDS polyacrylamide 
electrophoresis (SDS-PAGE section 3.3.4).
3.3.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) of 
proteins
Proteins were resolved on polyacrylamide gels using the Bio-Rad mini-protean II 
apparatus. A 10% resolving gel mix (3.33ml 30% acrylamide (2.5% cross-linker), 
2.5ml RGB, 4.17ml DW, 80pl 10% APS, 8 pi TEMED) was poured into the gel former 
apparatus, then overlaid with butanol and allowed to set. The butanol was washed away 
with water, and the resolving gel overlaid with the stacking gel mix (0.4ml 30% 
acrylamide (2.5% cross-linker), 0.6ml SGB, 1.4ml DW, 20pl 10% APS, 3pl TEMED) 
before inserting the comb and allowing the gel to set at RT. Protein samples in 
IX boiling mix were boiled for 2min prior to loading. Gels were run in IX tank buffer 
at 1 0 0 V until the dye front reached the bottom, then the gels were transferred to 
nitrocellulose membranes for western blot analysis (section 3.3.5).
3.3.5 Western blot analysis of proteins
Proteins resolved on SDS-PAGE mini-gels (section 3.3.4) were transferred to a 
nitrocellulose membrane in a Bio-Rad mini-transblot cell. A blotting sandwich was set 
up such that the gel was in contact with a sheet of nitrocellulose membrane (Schleicher 
and Schuell Inc.), which in turn were sandwiched between Whatman 3mm paper and 
sponges (contained within the kit), all of which had been pre-soaked in Towbin buffer. 
Transfer of proteins from the gel to the nitrocellulose was carried out in Towbin buffer 
at 0.25mA for 3h.
Nitrocellulose membranes were blocked by incubation at 37°C for 2X 30min in 100ml 
3% gelatin in IX TBS, whilst shaking. They were then washed 2X 5min at RT in TTBS 
before incubation overnight at RT (whilst shaking) with the first antibody diluted 
appropriately in 20ml 1% gelatin in TTBS. Following this the blots were washed at RT
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5X 5min in TTBS, then incubated at RT for 90min in 20ml 1/1000 dilution of protein A 
HRP conjugate (diluted in 1% gelatin in TTBS), before being washed again at RT 
3X 5min in TTBS. Proteins were detected using the Amersham enhanced 
chemiluminescence (ECL) system; the two reagents in the system were mixed in equal 
amounts then added to the filter, which was incubated at RT for lmin, then wrapped in 
cling film and exposed to Kodak X-OMAT S film. Blots were stripped at 55°C for lhr 
in stripping buffer before being blocked, and reprobed with a second antibody.
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3 . 4  T i s s u e  c u l t u r e
3.4.1 Growth of cells
Mammalian cells were passaged in sterile, 175cm plastic flasks in the appropriate 
medium (section 2. 8 ), and incubated at 37°C in a humidified incubator under 5% CO2 . 
Confluent monolayers were harvested by washing twice with versene for 293 and 
KBa+b cells, or twice with trypsin/versene (1:4) for WS HeLa cells, then resuspended in 
10ml of the appropriate medium. For continual passage 293 cells were split at a 1:4 
dilution, KBa+b cells were split at a 1:6 dilution, and WS HeLa cells were split at a 1:10 
dilution every 3-4 days. Plates (60mm) were seeded at 1.5xl06 cells/plate for 293 and 
KBa+b cells, and at lxlO6 cells/plate for WS HeLa cells to obtain approximately 70% 
confluency the next day.
3.4.2 Electroporation
*7
A 250pl aliquot of serum free medium containing 1x10 WS HeLa cells/ml was 
incubated on ice for lOmin with 20pg plasmid DNA. Meanwhile, the Invitrogen 
electroporator II was connected to a power supply set at 300V, 25mA, 25W, with the 
unit settings at lOOOpF, 00 Q. The unit was charged for 2min and the cells were pulsed 
according to the manufacturers instructions; the cells were then incubated at RT for 
lOmin. The sample was then inoculated into 5ml medium on a 60mm plate and 
incubated at 37°C, 5% CO2 for 48hr, at which point the cells were harvested according 
to section 3.3.1.
3.4.3 Calcium phosphate mediated transfection
WS HeLa cells were seeded at lx l0 6 cells/60mm plate in 5ml medium then incubated at 
37°C 5% CO2 overnight until cells were approximately 70% confluent; 2-4hr prior to 
the addition of the transfection mix the medium on the plates was replaced. Diluted 
plasmid DNA for transfection was standardised by spectrophotometric analysis at 
260nm and 280nm, and by agarose gel electrophoresis. The transfection mix contained 
the appropriate amount of plasmid DNA made up in 140pl with DW. A 20pl aliquot of 
2M calcium chloride followed by 160pl 2X HBS were then added dropwise to the DNA 
whilst vortexing and incubated at RT for 30min. The transfection mix was added to the 
medium on the plate while gently swirling, then the plate was incubated at 37°C, 5%
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CO2 for 6 hr. The medium containing the transfection mix was removed, the plate 
washed once with 5ml PBS, and then 5ml fresh medium was added. The plates were 
reincubated until 48hr had passed from the time when the transfection mix was initially 
added, at which point the cells were harvested. Cells were harvested using either the 
luciferase reporter assay system (Promega) for transfections of plasmids which 
contained the firefly luciferase gene (section 3.4.3.1), or the dual-luciferase reporter 
assay system (Promega) for dual plasmid transfections of plasmids containing the firefly 
and the sea pansy luciferase gene (section 3.4.3.2).
3.4.3.1 Harvest o f cells using the luciferase reporter assay system
Cells were harvested by passive lysis using the luciferase assay system from Promega. 
The growth medium was removed from the plate and the cells were washed twice with 
2ml PBS (making sure to remove as much of the final PBS wash as possible), then 
incubated with 400pl reporter lysis buffer at RT for 15min. To ensure the release of all 
the luciferase enzyme from the cells the samples were freeze thawed once, then 
vortexed for 10-15sec before pelleting the cellular debris in an MSE microcentaur at 
13,000rpm, RT for 15sec. The supernatant was transferred to a fresh tube, and 
immediately assayed for luciferase activity (section 3.4.4.1) and protein concentration 
(section 3.4.5).
3.4.3.2 Harvest o f cells using the dual-luciferase reporter assay system
Cells were harvested by active lysis using the dual-luciferase reporter assay system from 
Promega. The growth medium was removed from the plate and the cells washed once 
with 2ml PBS, making sure to remove as much of the PBS wash as possible. The cells 
were then harvested into 400pl IX passive lysis buffer using a rubber policeman. The 
accumulated lysate was pipetted up and down several times to obtain a homogenous 
suspension, from which an aliquot (2 0 pl) was taken and tested for luciferase activity 
(section 3.4.4.2).
3.4.4 Luciferase assay
3.4.4.1 Luciferase assay using the luciferase reporter assay system
Cells harvested by passive lysis (section 3.4.3.1) were assayed for firefly luciferase 
activity using the luciferase assay system (with reporter lysis buffer) from Promega. A
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20pl aliquot of cell extract was added to IOOjliI pre-dispensed luciferase assay reagent, 
and immediately read on a Biotrace Ltd M3 single sample luminometer, which had been 
programmed to have a two second pre-read delay, followed by a ten second 
measurement period for luciferase activity (transmitted light units (TLU)).
3.4.4.2 Luciferase assay using the dual-luciferase reporter assay system
Cells harvested by active lysis (section 3.4.3.2) were assayed for firefly and sea pansy 
luciferase activity using the dual-luciferase reporter assay system from Promega. A 
20pl aliquot of cell extract was added to lOOpl pre-dispensed luciferase assay reagent n, 
and firefly luciferase activity read using the Biotrace Ltd M3 single sample 
luminometer, which had been programmed to have a two second pre-read delay, 
followed by a ten second measurement period for luciferase activity (transmitted light 
units (TLU)). Sea pansy luciferase activity was then read using the same luminometer 
following the addition of lOOpl Stop & Glo reagent.
3.4.5 Protein assay
Protein concentration was assayed according to the method of Bradford (1976). A lOpl 
aliquot of passive lysis cell extract (section 3.4.3.1) was added to 1ml Bradford reagent, 
incubated at RT for 20min, then the OD595 was determined using a Beckman DU-62 
spectrophotometer. To determine the protein concentration of the samples a standard 
curve was created using BSA standards of 0, 0.2, 0.4, 0.6, 0.8 and lmg/ml.
- 6 9 -
3 . 5  M a i n t e n a n c e  a n d  g r o w t h  o f  v i r u s
3.5.1 Growth of virus seed stocks
Ad5 and Ad40 seed stocks were prepared by respectively infecting 10x60mm plates 
(approximately 80% confluent) of 293 or KBa+b cells with 0.1 plaque forming units 
(pfu)/cell or 5 fluorescence forming units (ffu)/cell. The virus was allowed to adsorb to 
the cells for lhr at 37°C, 5% CO2 before 5ml Eagles A+B plus 2% (Ad5) or 
0.5% (Ad40) FCS was added to each plate then incubated at 37°C, 5% CO2 for 3-5 days 
until a cytopathic effect (cpe) was visible. Cells were scraped into the medium with a 
rubber policeman, pelleted in a Beckman GPR centrifuge at 2,000rpm, 4°C for 15min 
and resuspended in 0.25ml Tris saline. Virus particles were released from the cells by 
three rounds of freeze/thawing. The cellular debris was pelleted at 2,000rpm, 4°C for 
lOmin. The supernatant containing the virus particles was stored at ”70°C.
3.5.2 Virus titration
3.5.2.1 Adenovirus type 5
Seed stocks were titrated on 293 cells to determine the pfu/ml (Williams, 1970). Two 
60mm plates of 293 cells (approximately 80% confluent) were infected with 10' 6 to 10' 9 
serial dilutions of Ad5. The virus was allowed to adsorb to the cells for lhr at 37°C, 
5% CO2, before 4ml titration medium (1 0 0 ml 1.3X Eagles, 35ml Eagles B without 
phenol red, 3.2ml FCS, 1.5ml 1.25M magnesium chloride, 40ml noble agar) was added 
to each plate and allowed to set. The plates were incubated at 37°C, 5% CO2 for 4 days, 
at which point a further 2 ml titration medium was added, and the plates re-incubated for 
2 days. The number of plaques/plate were counted then used to calculate the seed 
stocks pfu/ml.
3.5.2.2 Adenovirus type 40
Ad40 does not form plaques under any known conditions, therefore the titre of Ad40 
was estimated by the fluorescent focus assay. KBa+b cells were seeded on 13mm glass 
coverslips in a 24 well Linbro plate at 0.5x105 cells/well in 1ml medium, then incubated 
at 37°C, 5% CO2 overnight. Dilutions of the Ad40 seed stock (2 0 pl 1 / 1 0 , 1 / 2 0  and 1/40 
dilution) were allowed to adsorb to the cells for lhr at 37°C, 5% CO2 , before the 
addition of 1ml Eagles A+B plus 2% FCS, and re-incubation of cells for a further 47hr.
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The cells were then washed twice with ice cold PBS before being fixed at RT for lOmin 
with a 3:1 mix of ice cold methanol and acetone. The cells were washed twice with ice 
cold PBS, then incubated at RT for 30min with aliquots (20pl 1/20 dilution in PBS) of 
primary antibody (Ad5 anti-hexon monoclonal antibody (10/5.1), section 2.7). The cells 
were washed three times with ice cold PBS, then incubated at RT for 30min with 20pl 
1/40 dilution of goat anti mouse fluorescein isothiocyanate conjugate (FITC) (secondary 
antibody). After a further three washes with PBS the coverslips were mounted on glass 
slides with lOpl Citifluor, and single cells infected with Ad40 visualised as bright green 
spots as opposed to uninfected cells which were appear as dull red spots under a Nikon 
MICROPHOT-SA fluorescence microscope.
3.5.3 Virus infections
Ad5 and Ad40 infections were set up at 5pfu/cell for Ad5 or 5ffu/cell for Ad40 on 293 
or WS HeLa cells. The virus was allowed to adsorb to the cells for lhr at 37°C, 
5% CO2 . 5ml Eagles A+B plus 2% FCS was then added to each plate which was 
incubated at 37°C, 5% CO2 for various times before harvesting (sections 3.2.1, 3.3.1 or 
3.3.2). The addition of 20pg/ml Ara C to the medium every 12hr blocked DNA 
replication therefore allowing overexpression of adenovirus early proteins.
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3 . 6  A n t i b o d i e s
3.6.1 Production of antipeptide antibodies
Duplicate rabbits were injected by the intramuscular route with 50pg peptide in 0.5ml 
PBS plus 0.5ml Freund’s complete adjuvant; subsequent boosts were made with 50pg 
peptide in 0.5ml PBS plus 0.5ml Freund’s incomplete adjuvant. Test bleeds were taken 
two weeks after each boost, and the antiserum was tested for antibodies to its 
homologous peptide by enzyme linked immunosorbent assay (ELISA section 3.6.2).
3.6.2 Enzyme Linked Immunosorbent Assay (ELISA)
Rabbit test bleeds were allowed to clot at 4°C overnight, then the serum was transferred 
to a 15ml falcon tube and centrifuged in a Beckman GPR centrifuge at 2,000rpm, 4°C 
for 5min. The serum was transferred to a fresh tube and heat inactivated at 56°C for 
30min; 1ml aliquots were stored at -20°C.
The antiserum was tested against lOOng or lpg  (in 50pi PBS) of its homologous 
peptide, which had been adsorbed at 37°C overnight onto an Immulon I ELISA plate; 
excess peptide was removed by washing four times with wash buffer. To reduce 
non-specific background the plate was blocked for lhr at 37°C with lOOplAvell PBS 
plus 2% BSA, then washed four times with wash buffer. The antiserum was allowed to 
react with its homologous peptide by incubating 50pl/well of neat, 1/10 or 1/100 
dilution of the antiserum (diluted with PBS plus 2% FCS) at 37°C for lhr; unbound 
antibodies were then removed by washing four times with wash buffer. Any antibodies 
which had bound to the immobilised peptide were detected by incubating each well with 
50pi of a 1:500 dilution of Protein A HRP conjugate (diluted with PBS plus 2% FCS) 
for lhr at RT. The system was then washed free of any unbound Protein A HRP 
conjugate, and examined for bound enzyme by incubating each well with lOOpl ABTS 
substrate at RT for 15min. The products of enzyme cleavage were assayed at 405nm on 
a Titertek multiskan plus plate reader.
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RESULTS
4. Results
Introduction
The aim of this project was to characterise the adenovirus type 40 early region 1A. 
Previously it had been shown that Ad40 virus particles were shed in large numbers from 
the gut of infected individuals, but failed to propagate in cells such as HEK, KB, HeLa, 
HEP-2 and WI-38, which are normally used to propagate other human adenovirus 
serotypes in tissue culture. Ad40 will however grow in 293 cells (Takiff et al., 1981; 
Kidd and Madeley, 1981), a human embryo kidney (HEK) cell line which has been 
transformed with the Ad5 E l region (Graham et al., 1977), albeit at reduced levels 
compared to other serotypes. This observation suggests that the El functions are poorly 
expressed or of intrinsically lower activity in certain cell types. Previous work had 
demonstrated that the EIB region plays a significant role in this phenotype (Mautner et 
a l , 1989; Steinthorsdottir and Mautner, 1991; Gomes et al., 1992), however the Ad40 
El A region had also been implicated, due to a delay in the onset of Ad40 El A mRNA 
expression (Ullah, 1997) when compared with Ad5 E l A mRNA expression (Glenn and 
Ricciardi, 1988). The Ad40 E l A proteins were also shown to be weaker 
/rans-activators than the Ad5 El A equivalent proteins (van Loon et al., 1987b; Ishino et 
al., 1988). Taken together these data suggest that the Ad40 El A region may be subject 
to aberrant expression in tissue culture, which would considerably affect progression of 
Ad40 into the late phase of the infectious cycle.
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4 . 1  P r e l i m i n a r y  c h a r a c t e r i s a t i o n  o f  b a s a l  t r a n s c r i p t i o n  
f r o m  t h e  A d 4 0  E l  A  p r o m o t e r
Introduction
The aberrant expression of the Ad40 El region (Takiff et al., 1981; Kidd and Madeley, 
1981) had mainly been attributed to E1B (Mautner et al., 1989; Steinthorsdottir and 
Mautner, 1991; Gomes et al., 1992) however, El A was also implicated (Ullah, 1997; 
van Loon et al., 1987b; Ishino et al., 1988). Ad40 E l A mRNA was expressed 36h p.i. 
(Ullah, 1997) compared with Ad5 El A mRNA expression at 1.5-2h p.i.. The Ad40 El A 
proteins were demonstrated as weaker fraws-activators of the Ad2 E4 promoter 
(van Loon et al., 1987b) and the Ad5 E2 and E3 promoters (Ishino et al., 1988) 
compared with the Ad5 El A promoters in plasmid transformed cells. Taken together 
these data suggest the Ad40 El A region is either subject to aberrant expression or of 
intrinsically lower activity. Therefore, to investigate the involvement of the El A region 
in the restricted growth of Ad40, a preliminary characterisation of sequences which 
were important for basal transcription (section 4.1) was undertaken. This was achieved 
in a plasmid background rather than a viral background as Ad40 is unable to form 
plaques in tissue culture (de Jong et al., 1983), making it difficult to isolate and 
characterise promoter deletions within the virus.
The E l A promoter sequences of Ad5 (van Ormondt et al., 1978) and Ad40 (van Loon 
et al., 1987a) had previously been determined, allowing comparison of the Ad5 El A 
upstream enhancer and core promoter sequences (Yoshida et al., 1995), with the Ad40 
E l A promoter (figure 4.1). To identify possible transcription factor binding sites within 
the Ad40 El A promoter, sequences from the ITR (nucleotide 1) to the core promoter (as 
identified in Ad5 (Hearing and Shenk, 1983a); nucleotide 452) were compared with the 
transcription factor database held at EMBL (using a single mismatch algorithm; Ghosh, 
1990). This revealed a number of possible transcription factor binding sites within the 
Ad40 E l A promoter (figure 4.1). The known Ad5 El A core promoter and upstream 
enhancer sequences (Yoshida et al., 1995) were then compared with the proposed map 
of the Ad40 El A promoter (figure 4.1). This provided a basis for the design of a series
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of deletion mutants, which would be used to characterise sequences important for basal 
transcription from the Ad40 El A promoter.
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4.1.1 Construction of plasmids containing the Ad5 or the Ad40 
E1A promoters
To characterise basal transcription from the Ad40 El A promoter with the Ad5 El A 
promoter, sequences encompassing the Ad5 and Ad40 El A promoters were cloned into 
a luciferase reporter vector, pnull-luc (figure 2.1.1), then analysed in WS HeLa cells by 
transient transfection assays. The luciferase gene was chosen as the reporter, as 
previous transient transfection assays which had used the more traditional 
chloramphenicol acetyl transferase (CAT) reporter, under the control of the E1B 
promoter, resulted in CAT expression levels which were close to background, making 
analysis of the promoter difficult (Mautner et al., 1999).
The Ad5 (l-533bp) and Ad40 (l-452bp) El A promoters were generated by PCR of 
lOOng pLElA (section 2.1) or pNM80 (section 2.1) respectively, using Pfu DNA 
polymerase (section 3.1.2.1) and primers FS1 and AB34 (table 2.4). The primers FS1 
and AB34 contained Sal I and Hind m  restriction sites respectively, a design which 
allowed directional cloning of the promoters into pnull-luc (figure 2.1.1). Plasmids 
containing the cloned Ad5 (pAd5-luc) and Ad40 (pAd40-luc) El A promoters were 
identified by restriction analysis of miniprep DNA with Sal I and Hind ID, and then 
sequenced using the M l3 -20 sequencing primer to confirm the absence of mutations 
which may have arisen during the PCR. Large scale plasmid preparations of pAd5-luc 
and pAd40-luc, along with a positive (pHSV2IE5-luc; figure 2.1.2) and negative 
(pnull-luc; figure 2 .1 .1 ) control, were then prepared for use in transient transfection 
assays.
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4.1.2 Transient transfection of pnull plasmids containing the Ad5 
and the Ad40 E1A promoters
To characterise basal transcription from the Ad40 E1A promoter with the Ad5 E1A 
promoter, cells were transiently transfected with a calcium phosphate (CaP0 4 ) 
precipitate containing plasmids with the Ad5 and the Ad40 El A promoters, in parallel 
with a positive and a negative control. Before transient transfection of the 
aforementioned sequence elements, background levels of firefly luciferase luminescence 
were calibrated for the luciferase reporter assay system, and conditions for CaPC>4 
mediated transient transfection in WS HeLa cells were optimised.
Background levels of firefly luciferase luminescence result from instrumentation and 
sample tubes. The electronic design of the luminometer can greatly affect its 
measurable level of background signal, for example many luminometers do not read 
zero in the absence of a luminescent sample. Background signals can also be attributed 
to sample tubes, which may result from static electricity (particular when polystyrene 
tubes are used) or from phosphorescence, therefore handling and storage of tubes aimed 
to minimise static buildup. Samples were also handled away from sunlight and very 
bright lights before luminescence measurements were taken. To obtain the background 
signal contributed by the instrument and sample tube, 10x3 0mm plates of non­
transfected WS HeLa cells (seeded at 0.5x106 cells/plate) were harvested using the 
luciferase reporter assay system (section 3.4.3.1), then 5pi aliquots of cell extract were 
assayed for firefly luciferase luminescence (section 3.4.4.1) and protein content (section 
3.4.5). A series of protein concentration standards (Omg, 0.2mg, 0.4mg, 0.6mg, 0.8mg, 
l.Omg, 1.2mg and 1.4mg) were also assayed to calibrate the concentration of protein 
within each experimental sample. The firefly luciferase luminescence values 
(transmitted light units (TLU)) and the protein content (pg/pl) values for each sample 
were tabulated (see columns 2 and 3 in Table 4.1.2.1). The firefly luciferase 
luminescence values were then expressed as transmitted light units per pg of protein 
(TLU/pg) in order to compare the background values between samples (see column 4 in 
Table 4.1.2.1). The mean (p) transmitted light units per pg of protein was calculated 
across ten samples of non-transfected cells, and tabulated (see column 5 in Table
4.1.2.1). In subsequent experiments the mean firefly luciferase luminescence assay
- 7 7 -
Table 4.1.2.1 Firefly luciferase luminescence assay background due to sample tube and 
instrumentation, using the luciferase reporter assay.
Sample FLLfl(TLU/pl)
Protein
concentration
(HgW
TLU/pg (TLU/pg)
Non-transfected cells 6.4 0.91 7.0
1 0
Non-transfected cells 6 .2 0.78 7.9
Non-transfected cells 6 .2 0.70 8 .6
Non-transfected cells 6.4 0.84 7.6
Non-transfected cells 7.0 0.48 15
Non-transfected cells 8 .0 0.87 9.2
Non-transfected cells 8 .2 0.76 11
Non-transfected cells 7.8 0.76 1 0
Non-transfected cells 7.0 0.65 11
Non-transfected cells 6.5 0.58 11
FLL denotes firefly luciferase luminescence
b p. denotes mean
background (10 TLU/|iig) was subtracted from each firefly luciferase luminescence 
value per pg of protein (TLU/pg), in transient transfection assays with pnull-luc and 
derivatives.
The conditions for CaPCVmediated transient transfection were standardised with 
respect to: the total amount of DNA transfected lOpg (5pg pHSV2IE5-luc:5pg carrier 
(salmon sperm) DNA), 20pg (5pg pHSV2IE5-luc: 15pg carrier DNA) or 40pg (5pg 
pHS V2IE5-luc:35pg carrier DNA); the incubation period of the CaPCU precipitate with 
the cells (6 h or 16h); whether a glycerol shock was required to enhance transfection; and 
the ratio of plasmid to carrier DNA (lpg:9pg, 2pg:8pg, 3pg:7pg, 4pg:6pg, 5pg:5pg, 
6pg:4pg, 7pg:3pg, 8pg:2pg, 9pg:lpg or 10pg:0pg; pHSV2IE5-luc:carrier DNA). The 
plasmid used in each transfection, was the positive control pHSV2IE5-luc (figure 2.1.2), 
which contains the HSV-2 IE-5 promoter upstream of the luciferase gene in pnull-luc, 
and the carrier DNA was salmon sperm DNA. The experiment was set up with 
duplicate 30mm plates of WS HeLa cells (seeded at 0.5xl06 cells/plate), which were 
transiently transfected with independently derived CaPC>4 precipitates. Cells were 
harvested using the luciferase reporter assay system (section 3.4.3.1), then 5pl aliquots 
of cell extract were assayed for firefly luciferase luminescence (section 3.4.4.1) and 
protein content (section 3.4.5), to calculate the firefly luciferase luminescence (TLU) per 
pg protein. The standard conditions for CaPCVmediated transient transfection in WS 
HeLa cells were determined as: lOpg of total DNA, of which 5pg was plasmid DNA 
and 5pg was carrier DNA, a 6 h exposure to the CaP0 4  precipitate with no glycerol 
shock. These standard conditions were used for all CaPCVmediated transient 
transfections in WS HeLa cells using the pnull-luc plasmid and its derivatives.
To characterise basal transcription from the Ad40 El A promoter (pAd40-luc) compared 
with the Ad5 El A promoter (pAd5-luc), cells were transiently transfected with a 
calcium phosphate (CaPCV precipitate containing the aforementioned plasmids, in 
parallel with a positive (pHSV2IE5-luc; figure 2.1.2) and a negative (pnull-luc; figure
2.1.1) control. The negative control used in each experiment was pnull-luc, which 
contains a firefly luciferase gene upstream of the HSV-2 IE-5 polyadenylation signal 
(figure 2.1.1). Each experiment was set up with duplicate 30mm plates of WS HeLa 
cells (seeded at 0.5x106 cells/plate), which were transiently transfected with
-78-
independently derived CaPC>4 precipitates (section 3.4.3), in two independent 
experiments. Cells were harvested using the luciferase reporter assay system (section
3.4.3.1), then 5 pi aliquots of cell extract were assayed for firefly luciferase 
luminescence (section 3.4.4.1) and protein content (section 3.4.5). The tabulated values 
of firefly luciferase luminescence (TLU/pl) and protein content (pg/pl) (see columns 3 
and 4 in Table 4.1.2.2) were used to calibrate the firefly luciferase luminescence per pg 
of protein (TLU/pg), which was corrected for firefly luciferase luminescence assay 
background (TLU/pg) (see column 5 and 6  in Table 4.1.2.2). To determine the average 
number of transmitted light units per pg of protein within each duplicate, the mean was 
calculated (pi, P2) by summing the corrected transmitted light units per pg protein (see 
column 6  in Table 4.1.2.2) then dividing by the number of samples (n) within each 
independent experiment (see column 7 in Table 4.1.2.2). To determine the range of the 
observations made within each duplicate, the standard deviation was calculated by 
summing the squares of the differences between the corrected transmitted light units per 
pg protein (see column 6  in Table 4.1.2.2) and the duplicate mean (pi or p2, see column 
7 Table 4.1.2.2), dividing by (n-1), and then taking the square root (see column 8  Table
4.1.2.2). The mean (p, see column 9 Table 4.1.2.2) across the two independent 
experiments was calculated in the same manner as each of the duplicate means (pi, p2 ) 
however, the standard deviation across the two independent experiments was calculated 
using the following formula:
8=standard deviation for duplicates one and two 
Si=standard deviation duplicate one 
52=standard deviation duplicate two
The methods used to calculate the mean and standard deviations, for the replicates 
within each independent experiment, assumed a normal distribution for a large number 
of replicates. However, it should be noted that only a small number of replicates were 
actually made and therefore the mean (p) and standard deviation (5) obtained are 
estimated values. In addition, although comparisons within a single experiment are
- 7 9 -
valid, there may be problems in comparing between experiments. For example, 
measurement of ratios of Renilla to firefly luciferase between experiments might show 
an inherent variability due to differences in the activity or stability of the different 
substrates. For this reason, interpretation and discussion of the data focuses on the major 
qualitative trends seen within single experiments. In almost all instances (and unless 
discussed otherwise) the same general trends were consistently observed between 
experiments.
Figure 4.1.2 shows the mean (p) and standard deviation (8 ) values for firefly luciferase 
luminescence per pg of protein, for the Ad5 and the Ad40 El A promoters, in parallel 
with the positive control which contains the HSV2 IE5 promoter and the negative 
control which is promoterless. It is immediately apparent that the negative control 
which does not contain a promoter, expresses greater levels of firefly luciferase than the 
Ad40 El A promoter. The high levels of transcription from the negative control were 
thought to be mediated by cryptic promoter sequences lying upstream of the luciferase 
gene (Levitt et al., 1989; Enriquez-Harris et al., 1991). Cloning of the Ad40 El A 
promoter upstream of the firefly luciferase may have disrupted the cryptic promoter 
sequences. These results demonstrate that the negative control is no longer appropriate 
for studies of basal transcription from the Ad40 El A promoter. An alternative 
luciferase reporter system was therefore sought, in which a polyadenylation signal was 
situated directly upstream of the firefly luciferase gene, preventing readthrough 
transcription from cryptic promoter elements.
- 8 0 -
Table 4.1.2.2 Transient transfection of pAd5-luc and pAd40-luc
Duplicate Sample FLLfl(TLU/pl)
Protein
concentration
(M-g/fxl)
TLU/pg
protein
Corrected*
TLU/pg
cHi
^ 2
5 /
8 2
e 8f
1
Ad5 E1A 
promoter 11 0 . 2 2 50 40 45 6.4
32 15
Ad5 E1A 
promoter 2 0 0.34 59 49
2
Ad5 E1A 
promoter 1 1 0.79 14 3.9 18 2 0Ad5 E1A 
promoter 2 0 0.48 42 32
1
Ad40 E1A 
promoter 5.9 0.49 1 2 2 . 0 1.7 0.42
0.85 0.30
Ad40 E1A 
promoter 4.2 0.37 11 1.4
2
Ad40 E1A 
promoter 7.0 0.81 8 . 6 0
0 0Ad40 E1A 
promoter 7.2 0.91 7.9 0
1
Positive
control 84 0.50 168 158 157 2 .1
1 2 1 43
Positive
control 8 6 0.52 165 155
2
Positive
control 93 0 . 6 8 137 127 84 61Positive
control 43 0.85 51 41
1
Negative
control 1 0 0.43 23 13 9.5 5.0
6 .2 3.6
Negative
control 9.6 0.60 16 6 . 0
2
Negative
control 8.4 0.63 13 3.3
2 . 8 0.71Negative
control 8 .0 0.65 1 2 2.3
a FLL denotes firefly luciferase luminescence (TLU)
The assay background value was 10 TLU/pg 
pi denotes mean of duplicate one
d §! denotes standard deviation of duplicate one
e p denotes mean of duplicate one (pi) and two (P2)
/
6  denotes standard deviation of duplicate one (8 i) and two (8 2), which was calculated using 
the formula described in section 4.1.2
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Figure 4.1.2 Transient transfection of pnull plasmids containing the Ad5 or the Ad40 El A 
promoters. Two independent experiments were set up with duplicate 30mm plates of WS 
HeLa cells (seeded at 0.5xl06 cells/plate), which were transfected with independently derived 
calcium phosphate precipitates (section 3.4.3) containing 5pg of experimental DNA in parallel 
with a positive and negative control. The positive control contained the HSV2IE5 promoter 
(pHSV2IE5-luc; figure 2.1.2), whilst the negative control (pnull-luc; figure 2.1.1) was 
promoterless. The cells were harvested using the luciferase reporter assay system (section
3.4.3.1), then 5pl aliquots were assayed for firefly luciferase luminescence (section 3.4.4.1) and 
protein content (section 3.4.5) to determine the TLU/pg protein. The p and 5 (capped lines) 
values for the TLU/pg protein are shown for the Ad5 and the Ad40 El A promoter, along with 
the positive and negative control.
4.1.3 Subcloning of the Ad5 and the Ad40 El A promoters into 
pGL3-basic
An alternative luciferase reporter system was sought to prevent readthrough 
transcription from upstream cryptic promoter sequences (Levitt et al., 1989; 
Enriquez-Harris et al., 1991). The reporter system identified was known as the pGL3 
system (Promega), which contained two plasmids, one of which facilitated cloning of 
experimental promoters into a luciferase reporter system, and acted as a negative control 
in transient transfections (pGL3-basic; figure 2.1.3); whilst the second (pGL3-control; 
figure 2.1.4) was used as a positive control in transient transfections. pGL3-basic 
contains a synthetic polyadenylation signal and transcriptional pause site directly 
upstream of the multiple cloning site (MCS), downstream of the MCS is a modified 
firefly luciferase gene (luc+), which is processed under the control of the SV40 late 
polyadenylation signal (figure 2.1.3). pGL3-control contains the SV40 promoter 
inserted between the MCS and the modified luciferase gene (luc+), and a SV40 
enhancer inserted downstream of the late polyadenylation signal (figure 2.1.4). The 
intact Ad5 and Ad40 E1A promoters were subsequently cloned into pGL3-basic, then 
analysed by transient transfection to establish differences in basal transcription from the 
Ad40 El A promoter compared with the Ad5 El A promoter.
The Ad5 and Ad40 El A promoter fragments were generated by restriction digest of 
pAd5-luc and pAd40-luc, respectively with Sal I and Hind m , the promoter fragments 
were then ligated into pGL3-basic via Xho I and Hind IE restriction sites in the MCS 
(figure 2.1.3). Candidate clones were then identified by restriction digest of miniprep 
DNA with Sac I and Hind m , prior to large-scale preparation of pGL3-Ad5, 
pGL3-Ad40, along with a positive (pGL3-promoter) and a negative (pGL3-basic) 
control for use in transient transfection assays.
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4.1.4 Analysis of basal transcription from the Ad5 and the Ad40 
El A promoters
To characterise basal transcription from the Ad40 El A promoter compared with the 
Ad5 El A promoter, the promoter fragments had been cloned from the redundant pnull 
system into the pGL3 system. These plasmids were then assayed in transiently 
transfected WS HeLa cells, in parallel with a positive and negative control. Before 
transient transfection of the aforementioned plasmids could take place, a number of 
controls (described in the text below) were calibrated and the conditions for transient 
transfection were optimised using the pGL3 system.
Background levels of firefly luciferase luminescence in the dual luciferase reporter assay 
are also mediated by instrumentation and sample tubes (section 4.1.2). To obtain the 
background signal contributed by the instrument and sample tube within the dual 
luciferase reporter system, 10x60mm plates of non-transfected WS HeLa cells (seeded 
at lxlO6 cells/plate) were harvested (section 3.4.3.2), then 20pl aliquots of cell extract 
were assayed for firefly luciferase luminescence (section 3.4.4.2) measured in 
transmitted light units (TLU)). The firefly luciferase luminescence values (TLU) were 
tabulated (see column 2 samples 1-10 in Table 4.1.4.1). The mean (p) firefly luciferase 
luminescence assay background due to instrumentation and sample tube, was calculated 
across ten samples of non-transfected cells (see column 3 in Table 4.1.4.1) to obtain a 
statistically significant value. In subsequent experiments the mean firefly luciferase 
luminescence assay background (FLLAB) was subtracted from each firefly luciferase 
luminescence value (TLU). Subsequent transient transfection experiments included a 
single plate of non-transfected WS HeLa cells, which were assayed for firefly luciferase 
activity to establish that they approximated the control sample value (see column 3 in 
Table 4.1.4.1).
Conditions for CaPCVmediated transient transfection in WS HeLa cells were optimised, 
with respect to the total amount of DNA transfected (optimum = lOpg), the incubation 
period of the CaPC>4 precipitate with the cells (optimum = 6 h) and whether a glycerol 
shock was required to enhance transfection (optimum = not required) in section 4.1.2. 
The ratio of plasmid DNAxarrier DNA (0.5pg:9.5g, lpg:9pg, 2pg:8pg, 5pg:5pg, or
- 8 2 -
Table 4.1.4.1 Firefly luciferase luminescence assay background due to sample tube and 
instrumentation, using the dual-luciferase reporter assay
Sample
FLLa
(TLU) FLLAB*(TLU)
1 2 3 4 5 6 7 8 9 1 0
Non-transfected cells 26 25 24 26 23 25 23 27 25 25 25
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence assay background, which was calculated by 
taking the mean of samples 1 - 1 0
Table 4.1.4.2 Renilla luciferase luminescence assay background due to instrumentation, 
sample tube and auto-luminescence of coelenterazine
Sample
RLLfl
(TLU) RLLAB*(TLU)
1 2 3 4 5 6 7 8 9 1 0
Non-transfected cells 26 24 23 26 2 2 26 23 27 25 25 25
RLL denotes Renilla luciferase luminescence
RLLAB denotes Renilla luciferase luminescence assay background, which was calculated by 
taking the mean of samples 1 - 1 0
10pg:0pg; pGL3-Ad5:salmon sperm DNA, pGL3-Ad40:salmon:sperm DNA and 
pGL3-control:salmon sperm DNA) was then optimised for WS HeLa cells. Each 
experiment was set up with duplicate 60mm plates of WS HeLa cells (seeded at 
lxlO6 cells/plate), which were transiently transfected with independently derived CaPCU 
precipitates. Cells were harvested using the luciferase dual reporter assay system 
(section 3.4.3.2), then 20pl aliquots of cell extract were assayed for firefly luciferase 
luminescence (section 3.4.4.2) and protein concentration section 3.4.5). The optimum 
ratio of plasmid:carrier DNA was determined as lOpg plasmid DNA:0pg carrier DNA, 
for pGL3-Ad5, pGL3-Ad40 and pGL3-control.
The addition of an internal control, pRL-SV40 (figure 2.1.6), into the transfection 
protocol provided a single tube dual luciferase reporter system, which allowed 
normalisation of results within a single experiment. The co-reporter plasmid, 
pRL-SV40, contains a SV40 early enhancer/promoter region inserted upstream of the 
Renilla (sea pansy) luciferase gene, which is processed under the control of the SV40 
late polyadenylation signal (figure 2 .1 .6 ); the negative control for the co-reporter 
pRL-SV40, is pRL-null which contains a sea pansy luciferase gene upstream of the 
SV40 polyadenylation signal (figure 2.1.5). Renilla luciferase luminescence (like firefly 
luciferase luminescence) is subject to background signals, which can arise from three 
possible sources, including instrument and sample tube, auto-luminescence of 
coelenterazine caused by non-enzymatic oxidation of the coelenterazine in solution, and 
residual luminescence from the firefly luciferase reaction. To obtain the value of the 
Renilla luciferase luminescence background signal, contributed by the instrument and 
sample tube, and auto-luminescence of coelenterazine, 10x60mm plates of 
non-transfected WS HeLa cells (seeded at lxlO6 cells/plate) were harvested using the 
dual-luciferase reporter assay system (section 3.4.3.2), then 20pl aliquots were assayed 
for Renilla luciferase luminescence (section 3.4.4.2). The mean (p) was determined 
across ten samples to obtain a statistically significant value for Renilla luciferase 
luminescence assay background (RLLAB), contributed by instrument and sample tube, 
and auto-luminescence of coelenterazine; this value was subtracted from each Renilla 
luciferase luminescence value henceforth (see column 3 in Table 4.1.4.2). Subsequent 
transient transfection experiments included a single plate of non-transfected WS HeLa
- 8 3 -
cells, which were assayed for Renilla luciferase activity to establish that they 
approximated the control sample value (see column 3 in Table 4.1.4.2).
Renilla luciferase luminescence is subject to background signals from residual firefly 
luciferase luminescence, which are variable depending upon the levels of firefly 
luciferase gene expression. Therefore, it was important to verify that the maximum 
expected level of firefly luciferase luminescence did not yield significant residual 
luminescence, which may have impacted upon the accurate measurement of Renilla 
luciferase luminescence. To verify that the maximum expected level of firefly 
luciferase luminescence from the positive control (pGL3-control) did not yield 
significant residual luminescence, 10x60mm plates of WS HeLa cells (seeded at lxlO6 
cells/plate) were transiently transfected with independently derived CaPC>4 precipitates 
containing lOpg pGL3-control (section 3.4.3). Cells were harvested using the dual- 
luciferase reporter assay system (section 3.4.3.2), then 20pl aliquots of cell extract were 
assayed for firefly luciferase luminescence then Renilla luciferase luminescence (section
3.4.4.2). The sample values were tabulated, then the mean firefly (FLLAB) and Renilla 
luciferase luminescence assay background (RLLAB) values were subtracted from the 
respective sample values (see Table 4.1.4.3). The background contributed by residual 
firefly luciferase luminescence was either negligible or zero in relation to Renilla 
luciferase luminescence assay background (RLLAB), therefore residual firefly luciferase 
luminescence did not need to be taken into account within future experiments.
Before commencing transient transfection analyses with the internal control, pRL-SV40, 
it is important to realise that trans effects between promoters in co-transfected plasmids 
can potentially affect reporter gene expression (Farr and Roman, 1991). The occurrence 
and magnitude of trans effects depends upon several factors, including the combination 
and activities of regulatory enhancer and promoter elements within the co-transfected 
vectors, the ratio of experimental to co-reporter DNA, and the cell type. To ensure 
independent expression from the experimental (pGL3-Ad5, pGL3-Ad40 and 
pGL3-control) and the co-reporter (pRL-SV40) plasmids, the optimum ratio of 
experimental to co-reporter DNA (10:1, 20:1 or 50:1) was determined. Duplicate 60mm 
plates of WS HeLa cells (seeded at lxlO6 cells/plate) were transfected with 
independently derived CaPC>4 precipitates containing lOpg pGL3-Ad5, pGL3-Ad40 or
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pGL3-control to lpg, 0.5jLtg or 200ng pRL-SV40 (section 3.4.3). The optimum ratio of 
experimental to co-reporter DNA for pGL3-Ad5, pGL3-Ad40 and pGL3-control was 
determined as lOpg experimental to 200ng co-reporter DNA i.e. a ratio of 50:1.
Basal transcription from the Ad40 El A promoter (pGL3-Ad40) compared with the Ad5 
El A promoter (pGL3-Ad5) was established by transiently co-transfecting WS Hela cells 
with a CaPC>4 precipitate containing the aforementioned plasmids, in parallel with a 
positive (pGL3-control; figure 2.1.4) and negative (pGL3-basic; figure 2.1.3) control. 
The negative control used in each experiment was pGL3-basic, which contains a 
modified firefly luciferase gene (luc+) upstream of the late SV40 polyadenylation signal 
(figure 2.1.3). Each experiment was set up with triplicate 60mm plates of WS HeLa 
cells (seeded at lxlO6 cells/plate), which were transiently transfected with independently 
derived CaPC>4 precipitates, in two independent experiments (section 3.4.3). Cells were 
harvested using the dual-luciferase reporter assay system (section 3.4.3.2), then 20pl 
aliquots of cell extract were assayed for firefly luciferase luminescence and Renilla 
luciferase luminescence (section 3.4.4.2). The tabulated values of firefly luciferase 
luminescence (TLU) and Renilla luciferase luminescence (TLU) (see columns 3 and 5 in 
Table 4.1.4.4) were corrected for firefly luciferase luminescence assay background 
(FLLAB) and the Renilla luciferase luminescence assay background (RLLAB) 
respectively (see columns 4 and 6  in Table 4.1.4.4). Samples within a single experiment 
were then normalised with respect to each other by calculating the ratio of firefly 
luciferase luminescence to Renilla luciferase luminescence (see column 7 in Table
4.1.4.4), by dividing the corrected firefly luciferase luminescence value by the corrected 
Renilla luciferase luminescence value (see columns 4 and 6  in Table 4.1.4.4). The mean 
(Bi> B2) ratio of firefly luciferase luminescence (FLL) to Renilla luciferase luminescence 
(RLL) and standard deviation (8 1 , 8 2 ) for each triplicate were calculated (see columns 8  
and 9 in Table 4.1.4.4). The 8  (see column 11 in Table 4.1.4.4) value was calculated 
using the formula expressed in section 4.1.2. Table 4.1.4.4 shows the standard deviation 
(8 ) between the two independent experiments is acceptable. However if  the FLL:RLL 
ratio for the first triplicate containing the Ad5 El A promoter (pi is 21, taken from 
column 7 in Table 4.1.4.4) is divided by the FLLrRLL ratio for the first triplicate 
containing the Ad40 El A promoter (p2 is 3.2, taken from column 7 in Table 4.1.4.4),
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giving a value of 6 .6 , then compared with the equivalent figure for triplicate two whose 
value is 6.5, we can see that the co-reporter system provides a controlled system 
between independent experiments.
Figure 4.1.4 shows the mean (p) and standard deviation (5) values for the ratio of firefly 
luciferase luminescence (FLL) to Renilla luciferase luminescence (RLL) across two 
independent experiments, for the Ad5 and the Ad40 E l A promoters, in parallel with the 
positive control which contains the SV40 promoter and the negative control which is 
promoterless. Expression from the Ad40 El A promoter is significantly lower when 
compared with expression from the Ad5 El A promoter. The numerical value for the 
difference in basal transcription from the Ad40 El A promoter compared with the Ad5 
El A promoter, was calculated by dividing the mean (p) value for the Ad5 El A 
promoter by the mean (p) value for the Ad40 El A promoter (see column 10 in Table
4.1.4.4). Basal transcription from the Ad40 El A promoter in WS HeLa cells was 
lowered by a factor of approximately 6.5 when compared with basal transcription from 
the Ad5 El A promoter.
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Table 4.1.4.4 Transient transfection of pGL3-Ad5 and pGL3-Ad40
Triplicate Sample FLL"
(TLU)
FLL - 
FLLAB* 
(TLU)
RLLC
(TLU)
RLL - 
RLLAB'* 
(TLU)
FLL/
RLL
e
Hi
H2
5 /
$2
Hg 5*
Ad5 E1A 
promoter 23893 23958 1473 1448 17
1 Ad5 E1A promoter 21329 21304 993 968 22 21 3
Ad5 E1A 
promoter 22563 22538 1013 988 23
17 2.1
Ad5 E1A 
promoter 11563 11538 891 866 13
2 Ad5 E1A promoter 10988 10963 852 827 13 13 0
Ad5 E1A 
promoter 11256 11231 869 844 13
Ad40 E1A 
promoter 8421 8396 2650 2625 3.2
1 Ad40 E1A promoter 8285 8260 2581 2556 3.2 3.2 0
Ad40 E1A 
promoter 8293 8268 2610 2585 3.2
2.6 0.14
Ad40 E1A 
promoter 3589 3564 1994 1969 1.8
2 Ad40 E1A promoter 3911 3886 1956 1931 2.0 2.0 0.2
Ad40 E1A 
promoter 4112 4087 1869 1844 2.2
Positive
control 15121 15096 1164 1139 13
1 Positivecontrol 4116 4091 404 379 11 12 1.0
Positive
control 15523 15498 1264 1239 13
8.1 0.72
Positive
control 6593 6568 1648 1623 4.1
2 Positivecontrol 4566 4541 1062 1037 4.4 4.2 0.2
Positive
control 5463 5438 1366 1341 4.1
Triplicate Sample FLL"
(TLU)
FLL - 
FLLAB* 
(TLU)
RLLC
(TLU)
RLL - 
RLLABrf 
(TLU)
FLL/
RLL
Vi
V*.
5 /
62
\x8 8 *
1
Negative
control 73 48 4403 4378 0.01
0.01 0
0.01 0
Negative
control 31 6 2646 2621 0.01
Negative
control 51 26 3454 3429 0.01
2
Negative
control 45 20 2563 2538 0.01
0.01 0Negativecontrol 61 36 3765 3740 0.01
Negative
control 51 26 3112 3087 0.01
a
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence assay background
c
RLL denotes Renilla luciferase luminescence
d
RLLAB denotes Renilla luciferase luminescence assay background 
|ii denotes mean of triplicate 1
/
81 denotes standard deviation of triplicate 1
g
p denotes the mean of triplicate 1 ( j l i i ) and two (1H2)
8 denotes the standard deviation o f triplicate one (81) and two (82), which was calculated 
using the formula described in section 4.1.2
FLL:RLL
10
t
15
I
20
Ad5
Ad40 II
Positive
control
Negative
control
Figure 4.1.4. Analysis of the Ad5 and the Ad40 E1A promoters. Two independent 
experiments were set up with triplicate 60mm plates of WS HeLa cells (seeded at lxlO6 
cells/plate), which were transfected with independently derived calcium phosphate precipitates 
containing lOpg of experimental DNA plus 200ng pRL-SV40, in parallel with a positive and 
negative control (section 3.4.3). The positive control pGL3-control (figure 2.1.4) contained the 
SV40 promoter, whilst the negative control pGL3-basic (figure 2.1.3) was promoterless. 
pRL-SV40 (figure 2.1.6) contains the Renilla luciferase gene under the control of the SV40 
promoter, which acts as a co-reporter for the assay system. The cells were harvested using the 
dual luciferase reporter assay system (section 3.4.3.2), then 20pl aliquots were assayed for 
firefly luciferase luminescence and Renilla luciferase luminescence (section 3.4.3.2). The p and 
5 (capped lines) values for the ratio of firefly luciferase luminescence (FLL) to Renilla 
luciferase luminescence (RLL) are shown for the Ad5 and Ad40 El A promoters, along with a 
positive and negative control.
4.1.5 Construction of Bal 31 deletions of the Ad5 and Ad40 E1A 
promoters
Transient transfection analyses had revealed that basal transcription from the Ad40 El A 
promoter was significantly reduced (6.5 ± 0.04 fold) when compared with the Ad5 El A 
promoter. In order to delineate the sequences important in basal transcription from the 
Ad40 El A promoter, a series of Bal 31 deletion mutants were constructed for use in 
transient transfection assays. A second series of Bal 31 deletion mutants were also 
constructed for the Ad5 El A promoter, allowing comparison of sequences known to be 
important for basal transcription in the Ad5 El A promoter, with sequences in the Ad40 
El A promoter.
Deletions of the Ad5 and the Ad40 El A promoters were generated by Bal 31 nuclease 
digestion of 50pg Sal I digested pAd5-luc and pAd40-luc for 0, 5, 10, 15, 20, 25, 30, 35, 
40, 45, 50, 55 and 60 min. To confirm that a range of fragments between l-533bp for 
the Ad5 El A promoter, and l-452bp for the Ad40 El A promoter had been generated, a 
sixth of each aliquot was digested with Hind El, and visualised on an ethidium bromide 
stained agarose gel. The aliquots were pooled, and then cloned via Sal I (using Sal I 
linkers) and Hind m  restriction sites into pnull-luc (figure 2.1.1). Plasmids containing 
Bal 31 deletions of the Ad5 and the Ad40 El A promoters were identified by restriction 
analysis of miniprep DNA with Sal I and Hind IE, then sequenced using the 
M l3 -20 sequencing primer to confirm the length of each deletion mutant (figure 4.1.5). 
Bal 31 deletion mutants were chosen to approximately divide the Ad40 El A promoter 
into four (pAd40-luc.349, pAd40-luc.268, pAd40-luc.l40), however the smallest 
deletion (pAd40-luc.37) containing the predicted TATA box was not generated, 
therefore it was constructed by restriction digest ' of the Ad40 El A promoter 
(section 4.1.7). Bal 31 deletions of the Ad5 El A promoter (pAd5-luc.428, 
pAd5-luc.321, pAd5-luc.l71, pAd5-luc.42) were selected to correspond with the 
predicted transcription factor binding sites contained within the Bal 31 deletions of the 
Ad40 El A promoter.
The Bal 31 deletion mutants of the Ad5 and the Ad40 E l A promoter had been cloned 
into pnull-luc before the system was found to be inappropriate (section 4.1.2), therefore
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Figure 4.1.5 The intact and Bal 31 deleted Ad5 and Ad40 E l A promoters. Transcription 
factor binding sites within the intact and deleted Ad5 El A promoter are indicated by :#  denotes 
ORP-A; O denotes NF I; #  denotes NF III; 0 denotes SP1; I  denotes ATF; □ denotes 
EF-1A; 0 denotes E2F; ► denotes Element I> » * * denotes Element II; I—► denotes 24bp
enhancer; E denotes CAAT; □ denotes TATA; r *  denotes cap s i t e ;  denotes hyphenated
symmetry around cap site.
deletions were subcloned into pGL3-basic. The Ad5 and the Ad40 El A promoter 
fragments were generated by restriction digest of pAd5-luc.428, pAd5-luc.321, 
pAd5-luc.l71, pAd5-luc.42, pAd40-luc.349, pAd40-luc.268 and pAd40-luc.l40 with 
Sal I and Hind IE, the promoter fragments were then ligated into pGL3-basic via Xho I 
and Hind IE restriction sites in the MCS (figure 2.1.3). Candidate clones were 
identified by restriction digest of miniprep DNA with Sac I and Hind IE, prior to 
large-scale preparation of pAd5-luc.428, pAd5-luc.321, pAd5-luc.l71, pAd5-luc.42, 
pAd40-luc.349, pAd40-luc.268, pAd40-luc.l40 and pGL3-Ad40.37 for use in transient 
co-transfection assays.
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4.1.6 Analysis of basal transcription from the intact and Bal31 
deleted Ad5 and Ad40 E1A promoters
To characterise sequences important for basal transcription from the Ad40 El A 
promoter compared with the Ad5 El A promoter, cells were transiently transfected with 
a CaPC>4 precipitate containing either the intact Ad5 (pGL3-Ad5) or Ad40 (pGL3-Ad40) 
El A promoters, or the Bal 31 deleted Ad5 or Ad40 El A promoters (pGL3-Ad5.428, 
pGL3-Ad5.321, pGL3-Ad5.171, pGL3-Ad5.42, pGL3-Ad40.349, pGL3-Ad40.268, 
pGL3-Ad40.140, pGL3-Ad40.37), in parallel with a positive (pGL3-control; 
figure 2.1.4) and a negative (pGL3-basic; figure 2.1.3) control. The experiment was set 
up with triplicate 60mm plates of WS HeLa cells (seeded at lxlO6 cells/plate), which 
were transiently transfected with independently derived CaP0 4  precipitates 
(section 3.4.3). Cells were harvested using the dual-luciferase reporter assay system 
(section 3.4.3.2), then 20pl aliquots of cell extract were assayed for firefly luciferase 
luminescence then Renilla luciferase luminescence (section 3.4.4.2). These values were 
tabulated (see columns 3 and 4 in Table 4.1.6) then used to calculate the mean (p) and 
standard deviation (8 ) for each sample, across two independent experiments (see 
columns 10 and 11 in Table 4.1.6).
Figure 4.1.6 A shows a diagrammatic representation of the intact and Bal 31 deleted 
Ad5 and Ad40 El A promoters, whilst B shows the mean (p) and standard deviation (8 ) 
values for the ratio of firefly luciferase luminescence (FLL) to Renilla luciferase 
luminescence (RLL) across two independent experiments, for the corresponding 
promoter construct in A. Basal transcription from the intact Ad40 E l A promoter 
compared with the intact Ad5 El A promoter is lowered by a factor of six, as in figure 
4.1.4. Subsequent deletion of sequences from the ITR to the TATA box in both the Ad5 
and the Ad40 El A promoters resulted in an almost identical pattern of expression 
(figure 4.1.6). Expression from the intact Ad5 El A promoter increased by an 
approximated 1.7 fold with the deletion of sequences from -498 to -428 (relative to the 
cap site), upon deletion of sequences from -428 to -321 an approximated 5.5 fold 
decrease in expression was observed. Basal transcription from the Ad5 El A promoter 
then steadily decreased with the subsequent deletion of sequences from -321 to -171
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Table 4.1.6 Transient transfection of the intact and Bal 31 deleted Ad5 and Ad40 El A 
promoters
Triplicate Sample FLLfl
(TLU)
FLL - 
FLLAB* 
(TLU)
RLL c 
(TLU)
RLL - 
RLLAB d 
(TLU)
FLL/
RLL
e
M”1
M2
5 /  1 s 
52 ^
5*
1
Ad5 E1A 
promoter 1738 1713 822 797 2.2
2.1 0.13
1.1
Ad5 E1A 
promoter 2696 2671 1290 1265 2.1
Ad5 E1A 
promoter 1132 1107 610 585 1.9
7.2
2
Ad5 E1A 
promoter 2705 2680 211 186 14
12Ad5 E1A promoter 3191 3166 319 294 11 1.6
Ad5 E1A 
promoter 3521 3496 329 304 12
1
Ad5 del.428 12001 11976 1806 1781 6.7
6.1 0.49
2.4
Ad5 del.428 3475 3450 652 627 5.5
Ad5 del.428 18516 18491 3051 3026 6.1
12
2
Ad5 del.428 10110 10085 607 582 17
18 3.3Ad5 del.428 4883 4858 353 328 14
Ad5 del.428 9187 9162 431 406 22
1
Ad5 del.321 4681 4656 2185 2160 2.2
2.1 0.25
2.2 0.32
Ad5 del.321 5151 5126 2192 2167 2.4
Ad5 del.321 2405 2380 1370 1345 1.8
2
Ad5 del.321 410 385 200 175 2.2
2.3 0.37Ad5 del.321 639 614 247 222 2.8
Ad5 del.321 396 371 222 197 1.9
1
Ad5 del. 171 882 857 1054 1029 0.83
0.66 0.12
0.71 0.10
Ad5 del. 171 493 468 895 870 0.54
Ad5 del. 171 1147 1122 1871 1846 0.61
2
Ad5 del.171 76 51 91 66 0.77
0.76 0.08Ad5 del.171 80 55 90 65 0.85
Ad5 del.171 104 79 147 122 0.65
1
Ad5 del .42 97 72 1614 1589 0.05
0.05 0.01
0.06 0.01
Ad5 del .42 119 94 1726 1701 0.06
Ad5 del.42 191 166 3336 3311 0.05
2
Ad5 del.42 30 5 98 73 0.07
0.07 0.01Ad5 del.42 30 5 111 86 0.06
Ad5 del.42 30 5 81 56 0.09
Triplicate Sample FLL"
(TLU)
FLL - 
FLLAB* 
(TLU)
RLLC
(TLU)
RLL - 
RLLAB d 
(TLU)
FLL/
RLL
e
Vl
R2
5 /
52
5*
Ad40 E1A 
promoter 1638 1613 1387
1362 1.2
1 Ad40E1A  promoter 10956 10931 8638 8613 1.3 1.2 0.06
Ad40E1A  
promoter 4005 3980 3313 3288 1.2
1.2 0.15
Ad40E1A  
promoter 87 62 91 66 0.94
2 Ad40E1A  promoter 147 122 114 89 1.4 1.2 0.20
Ad40E1A  
promoter 319 294 261 236 1.3
Ad40 del.349 5670 5645 3806 3781 1.5
1 Ad40 del.349 977 952 654 629 1.5 1.4 0.1
Ad40 del.349 1317 1292 1014 989 1.3
1.9 0.12
Ad40 del.349 675 650 300 275 2.4
2 Ad40 del.349 778 753 336 311 2.4 2.3 0.14
Ad40 del.349 946 921 466 441 2.1
Ad40 del.268 2280 2255 3827 3802 0.59
1 Ad40 del.268 3912 3887 5705 5680 0.68 0.63 0.04
Ad40 del.268 5820 5795 9189 9164 0.63
0.58 0.04
Ad40 del.268 168 143 284 259 0.55
2 Ad40 del.268 96 71 171 146 0.49 0.53 0.03
Ad40 del.268 133 108 223 198 0.55
Ad40 del. 140 76 51 887 862 0.06
1 Ad40 del. 140 145 120 1774 1749 0.07 0.09 0.04
Ad40 del. 140 81 56 414 389 0.14
0.10 0.03
Ad40 del. 140 44 19 180 155 0.12
2 Ad40 del. 140 36 11 169 144 0.08 0.10 0.02
Ad40 del. 140 42 17 178 153 0.11
Ad40 del.37 57 32 2661 2636 0.01
1 Ad40 del.37 54 29 2335 2310 0.01 0.01 0
Ad40 del.37 39 14 1331 1306 0.01
0.05 0.01
Ad40 del.37 39 14 233 208 0.07
2 Ad40 del.37 40 15 221 196 0.08 0.08 0.01
Ad40 del.37 41 16 201 176 0.09
Triplicate Sample FLLfl
(TLU)
FLL - 
FLLAB b 
(TLU)
RLL c 
(TLU)
RLL - 
RLLAB d 
(TLU)
FLL/
RLL
Hi*
P2
5 /
82
p* 5 A
Positive
Control 11512 11487 923 898 12
1 PositiveControl 55602 55577 4205 4180 13 13 0.6
Positive
control 22921 22896 1756 1731 13
14 0.6
Positive
control 1733 1708 141 116 14
2 Positivecontrol 547 522 63 38 13 14 0.6
Positive
control 893 868 85 60 14
Negative
control 34 9 910 885 0.01
1 Negativecontrol 30 5 833 808 0.01 0.01 0
Negative
control 34 9 1777 1752 0.01
0.03 0.01
Negative
control 30 5 220 195 0.03
2 Negativecontrol 28 3 109 184 0.04 0.04 0.01
Negative
control 31 6 154 129 0.05
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence assay background
RLL denotes Renilla luciferase luminescence
RLLAB denotes Renilla luciferase luminescence assay background
Pi denotes mean of duplicate one
5i denotes standard deviation o f duplicate one
j l i  denotes mean of duplicate one (pi) and two (P2)
5 denotes standard deviation o f duplicate one (5i) and two (82), which was calculated 
using the formula described in section 4.1.2
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Figure 4.1.6 Analysis of the intact and Bal 31 deleted Ad5 or Ad40 E1A promoters. Two
independent experiments were set up with triplicate 60mm plates o f WS HeLa cells (seeded at lxlO 6 
cells/plate), which were transfected with independently derived calcium phosphate precipitates containing 
lOpg experimental DNA plus 200ng pRL-SV40, in parallel with a positive and negative control. The 
positive control contained the SV40 promoter, whilst the negative control was promoterless. The cells 
were harvested using the dual luciferase reporter assay system, then were assayed for firefly luciferase 
luminescence (TLU) and Renilla luciferase luminescence (TLU). A. The Ad5 and the Ad40 El A full
B FLLrRLL 
10 15
A d5 prom oter
A d5.428
Ad5.321
Ad5.171
Ad5.42
) I
i
20
j — ►
A d40 prom oter
A d40.349 H
A d40.268
A d40.140
A d40.37
length and Bal 31 deleted promoters. Transcription factor binding sites are indicated by: §  denotes 
ORP-A; O denotes NF I; 0  denotes NF III; 0 denotes SP1; 1  denotes ATF; D denotes 
EF-1A; 0 denotes E2F; ► denotes Element I; denotes Element II; I— ► denotes 24bp
enhancer; 0  denotes CAAT; D denotes TATA; denotes cap site; -  -  denotes hyphenated 
symmetry around cap site. B. The p and 5 (capped lines) values for the ratio of firefly luciferase 
luminescence (FLL) to Renilla luciferase luminescence (RLL) are shown for the intact and Bal 31 deleted 
Ad5 and Ad40 E l A promoters.
(which mediated an approximated 3.1 fold decrease) and -171 to -42 (which mediated 
an approximated 12 fold decrease).
The Ad40 E l A promoter followed the same pattern of expression as the Ad5 E l A 
promoter, where deletion of sequences in the ITR resulted in an increase in basal 
transcription, followed by a decrease in basal transcription mediated by subsequent 
deletion of sequences to the TATA box (figure 4.1.6). Deletion of sequences from -416 
to -349 (relative to the cap site) mediated an approximated 1.6 fold increase in basal 
transcription from the Ad40 El A promoter, followed by an approximated 3.3 fold 
decrease in expression with the deletion of sequences from -349 to -268. The 
subsequent deletion of sequences from -268 to -140 resulted in basal transcription from 
the Ad40 E1A promoter close to background. The TATA box alone was unable to 
support basal transcription from the Ad40 El A promoter.
Summary
Basal transcription from the intact Ad40 E l A promoter was decreased by a factor of 6 
when compared to the Ad5 El A promoter. Deletion of sequences from -498 to -428 in 
Ad5 and from -416 to -349 in Ad40 resulted in increased expression from both 
promoters. Subsequent deletion of sequences from -428 to -171 in Ad5 and from -349 
to -140 in Ad40 resulted in levels of basal transcription from both promoters being 
reduced close to background, showing that sequences from -349 to -140 within the 
Ad40 El A promoter are important for basal transcription. Finally, both the Ad5 and the 
Ad40 TATA boxes alone were unable to support basal transcription.
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4.1.7 Construction of specific deletions within the Ad40 E1A 
promoter
Transient transfection analyses had revealed that a region between -349 to -140 (relative 
to the cap site) was important for basal transcription from the Ad40 El A promoter. 
Comparison of the Ad40 E l A promoter with the transcription factor database, held at 
EMBL (Ghosh, 1990), revealed that this region contained a number of possible 
transcription factor binding sites (figure 4.1), which would impose a similar structure to 
the Ad5 El A promoter. To map sequences within the region -349 to -140, a series of 
deletions were constructed which deleted transcription factor binding sites known to be 
important in basal transcription from the Ad5 El A promoter (figure 4.1.7). The 
deletions were characterised in parallel with the intact and Bal 31 deletion mutants of 
the Ad40 El A promoter, by transient transfection assays.
Deletions of the Ad40 El A promoter were generated by restriction digest of 50pg 
pGL3-Ad40with Hph I, Aci I, Bgl I, Bsm FI or Bsl I, digests were then separated on an 
ethidium bromide stained agarose gel, and DNA fragments containing the specific 
deletions of the Ad40 El A promoter identified. The excised bands containing the Ad40 
E1A promoter deletions were cleaned using a Geneclean II kit (BiolOl Inc., La Jolla, 
CA), before being digested with Hind IE, and cloned into the MCS of pGL3-basic via 
Sma I and Hind IQ restriction sites (figure 2.1.3). Plasmids containing specific deletions 
of the Ad40 El A promoter were identified by restriction analysis of miniprep DNA with 
Sac I and Hind IQ, prior to large-scale preparation of pGL3-Ad40.328, pGL3-Ad40.235, 
pGL3-Ad40.209, pGL3-Ad40.166 for use in transient co-transfection assays.
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Figure 4.1.7 Specific deletion mutants of the Ad40 E l A promoter. Sequence data for the 
deleted Ad40 El A promoter is available in appendix 1. Transcription factor binding sites are 
indicated by: §  denotes ORP-A; O denotes NF I; #  denotes NF III; 0 denotes SP1; I  denotes 
ATF; □ denotes EF-1A;0 denotes E2F; denotes Element II-like sequence; 0  denotes
CAAT; □ denotes TATA; I-*  denotes cap site; —  denotes hyphenated symmetry around 
cap site.
4.1.8 Analysis of basal transcription from the intact and deleted 
Ad40 E1A promoter
To map sequences between -349 to -140 (relative to the cap site) which were important 
for basal transcription from the Ad40 El A promoter, WS HeLa cells were transiently 
co-transfected with a CaPC>4 precipitate containing either the intact Ad40 (pGL3-Ad40) 
El A promoter construct, or the deleted Ad40 El A promoter constructs 
(pGL3-Ad40.349, pGL3-Ad40.328, pGL3-Ad40.268, pGL3-Ad40.235,
pGL3-Ad40.209, pGL3-Ad40.166, pGL3-Ad40.140 or pGL3-Ad40.37), in parallel with 
a positive (pGL3-control) and a negative (pGL3-basic) control. The experiment was set 
up with triplicate 60mm plates of WS HeLa cells (seeded at lxlO6 cells/plate), which 
were transiently transfected with independently derived CaPC>4 precipitates (section
3.4.3). Cells were harvested using the dual-luciferase reporter assay system (section 
3.4.3.2), then 20pl aliquots of cell extract were assayed for firefly luciferase 
luminescence then Renilla luciferase luminescence (section 3.4.4.2). Sample firefly 
luciferase luminescence (FLL) and Renilla luciferase luminescence values were 
tabulated (see columns 2 and 4 in Table 4.1.8) then used to calculate the mean (p) and 
standard deviation (6) for each sample (see columns 7 and 8 in Table 4.1.8; see section
4.1.4).
Figure 4.1.8 A shows a diagrammatic representation of the intact and deleted Ad40 El A 
promoter, whilst B shows the mean (p) and standard deviation (8) values for the ratio of 
firefly luciferase luminescence (FLL) to Renilla luciferase luminescence (RLL) for the 
intact and deleted Ad40 El A promoter. Expression from the intact Ad40 El A promoter 
increased by a factor of 1.9 upon deletion of sequences from -416 to -349, then deletion 
of sequences from -349 to -328 mediated a further increase in expression by a factor of 
1.3. Deletion of sequences from -328 to -268 mediated the largest decrease in 
expression, giving an approximated 5 fold decrease in expression from the Ad40 El A 
promoter. Deletion of sequences from -268 to -235 resulted in an approximate 2 fold 
decrease in expression, to a level which remained unchanged upon the deletion of 
further sequences from -235 to -37.
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Table 4.1.8 Transient transfection of the intact and deleted Ad40 El A promoter
Sample FLLa(TLU)
FLL - 
FLLAB* 
(TLU)
RLLC
(TLU)
RLL - 
RLLAB* 
(TLU)
FLL/
RLL
Ad40 El A promoter 87 62 91 66 0.94
1.2 0.2Ad40 El A promoter 147 122 114 89 1.4
Ad40 El A promoter 319 294 261 236 1.3
Ad40 del.349 675 650 300 275 2.4
2.3 0.14Ad40 del.349 778 752 336 311 2.4
Ad40 del.349 946 921 466 441 2.1
Ad40 del.328 1630 1605 581 556 2.9
3.0 0.49Ad40 del.328 1002 977 294 269 3.6
Ad40 del.328 658 633 287 262 2.4
Ad40 del.268 168 143 284 259 0.6
0.6 0.06Ad40 del.268 96 71 171 146 0.5
Ad40 del.268 133 108 223 198 0.6
Ad40 del .23 5 51 26 183 158 0.16
0.13 0.02Ad40 del.235 43 18 181 156 0.12
Ad40 del.235 46 21 203 178 0.12
Ad40 del.209 34 9 175 150 0.06
0.08 0.02Ad40 del.209 38 13 151 126 0.10
Ad40 del.209 42 17 232 207 0.08
Ad40 del. 166 40 15 429 202 0.04
0.10 0.05Ad40 del. 166 56 31 268 243 0.13
Ad40 del. 166 99 74 564 539 0.14
Ad40 del. 140 44 19 180 155 0.12
0.10 0.02Ad40 del. 140 36 11 169 144 0.08
Ad40 del. 140 42 17 178 153 0.11
Ad40 del.37 39 14 233 208 0.07
0.08 0.01Ad40 del.37 40 15 221 196 0.08
Ad40 del.37 41 16 201 176 0.09
Positive control 1733 1708 141 116 14
14 0.6Positive control 547 522 63 38 13
Positive control 893 868 85 60 14
Negative control 30 5 220 195 0.03
0.04 0.01Negative control 28 3 109 184 0.04
Negative control 31 6 154 129 0.05
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence assay background
RLL denotes Renilla luciferase luminescence
RLLAB denotes Renilla luciferase luminescence assay background
p denotes mean
5 denotes standard deviation
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Figure 4.1.8 Analysis of the intact and deleted Ad40 E l A promoter. The experiment was set 
up with triplicate 60mm plates of WS HeLa cells (seeded at lxlO 6 cells/plate), which were transfected 
with independently derived calcium phosphate precipitates containing lOpg experimental DNA plus 
200ng pRL-SV40, in parallel with a positive and negative control. The positive control contained the 
SV40 promoter, whilst the negative control was promoterless. The cells were harvested by using the 
dual-luciferase reporter assay system, then 20pl aliquots were assayed for firefly luciferase luminescence 
(TLU) then Renilla luciferase luminescence (TLU). A .  The intact and Bal 3 1  deleted Ad5 E l A and Ad40
B
o 1
Ad40
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Ad40 del.328
Ad40 del.268
FLL:RLL
2 3
J___________ L
H
Ad40 del.235
Ad40 del.209
Ad40 del.166 H
Ad40 del.140
Ad40 del.37
E l A promoters. Transcription factor binding sites are indicated by: 0  denotes ORP-A; O denotes
NF I; % denotes NF III; 0 denotes SP1; I  denotes ATF; i3 denotes EF-1 A; 0 denotes 
E2F; 0  denotes CAAT; I— ► denotes 24bp enhancer; denotes an Element II-like
sequence; □  denotes TATA; denotes cap s i t e ;  denotes hyphenated symmetry around cap
site. B. The p and 6 (capped lines) values for the ratio o f firefly luciferase luminescence (FLL) to Renilla 
luciferase luminescence are shown for the intact and Bal 31 deleted Ad5 and Ad40 E l A promoters.
Sum m ary
Basal transcription from the intact Ad40 El A promoter was concordant with 
observations made in section 4.1.4 and 4.1.6. Deletion of sequences from -416 to -328 
in the Ad40 El A promoter mediated an overall increase in the expression by a factor of 
2.5. Deletion of sequences from -328 to -268 and from -268 to -235 resulted in a 
promoter construct, which decreased expression of the firefly luciferase gene by a factor 
of 23, resulting in a promoter unable to support basal transcription. We can therefore 
conclude that sequences important for basal transcription from the Ad40 El A promoter 
lie between -328 to -235.
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4 . 2  P r e l i m i n a r y  c h a r a c t e r i s a t i o n  o f  f r a n s - a c t i v a t i o n  
b y  t h e  A d 4 0  E l  A  2 4 9 R  p r o t e i n .
Introduction
The Ad5 289R and 243R El A proteins are expressed from the El A gene at early times 
after infection (Perricaudet et al., 1979; van Ormondt et al., 1980). In the absence of the 
El A proteins, transcription from the E l A promoter is reduced approximately five fold 
suggesting a role for the E1A proteins in their own regulation (Montell et al., 1984a; 
Osborne et al., 1984). Indeed, El A has been shown to be capable of its own regulation 
at the level of transcription (Hearing and Shenk, 1985; Tibbetts et al., 1986). The E1A 
proteins, in particular the 289R protein, are able to trans-activate the El A promoter 
(Osborne et al., 1984; Hearing and Shenk, 1985), and both the E l A proteins have also 
been associated with negative regulation of their own promoter (Tibbetts et al., 1986; 
Cogan et al., 1992).
Previous studies of the adenovirus type 40 El A protein products revealed that 
fraws-activation of the Ad2 E4 promoter by the Ad40 El A proteins was significantly 
reduced when compared with trans-activation by the Ad5 El A proteins (van Loon et al., 
1987b). The fraws-activation of the Ad5 E2A and E3 promoters by the Ad40 El A 
proteins were also significantly reduced when compared with frans-activation by the 
Ad5 and the Adl2 E1A proteins (Ishino et al., 1988). Taken together these results 
suggest that the Ad40 El A proteins may well be implicated in the aberrant expression of 
El A, and therefore the growth restriction of Ad40. To investigate the involvement of 
the Ad40 E l A proteins in the restricted growth of Ad40, fraws-activation of the Ad40 
E l A promoter by the Ad40 El A proteins was compared with fra^s-activation of the 
Ad5 E1A promoter by the Ad5 E1A proteins. The sequences important in 
fraws-activation of the Ad40 El A promoter were then mapped by transient transfection 
analysis.
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4.2.1 Construction of a CMV expression plasmid containing the 
Ad40 E1A 13S equivalent cDNA
To investigate the involvement of the Ad40 El A proteins in the aberrant expression of 
the Ad40 El A region, the Ad40 El A equivalent 13S and 12S protein coding sequences 
were cloned into a CMV expression plasmid. The CMV expression plasmid used was 
pCMV19K (White and Cipriani, 1990), which had previously been modified to 
construct plasmids which expressed the Ad5 289R and 243R El A proteins (Morris and 
Mathews, 1991). Expression plasmids containing either the Ad5 or the Ad40 El A 
protein coding sequences were co-transfected with their homologous promoters to 
compare fraws-activation.
A library of Ad40 El A protein coding sequences was generated to retrieve the Ad40 
El A equivalent 13S and 12S protein coding sequences. The library was generated by 
reverse transcription-polymerase chain reaction (RT-PCR) of cytoplasmic RNA 
harvested 42h p.i. from 293 cells infected with 5ffu/cell Ad40 and blocked with 
20pg/ml araC 12 hourly (section 3.2.1, 3.2.2 and 3.5.3). lOOpmol of FS3 was used to 
prime the RT reaction, whilst lpM  FS2 was used to prime the PCR reaction using Taq 
DNA polymerase (Table 2.4; figure 4.2.1.1). The primers used in the RT-PCR (FS2 and 
FS3) were designed to generate protein coding sequences (from the El A start codon at 
nucleotide 486, to the El A stop codon at nucleotide 1311) of the Ad40 El A region, 
allowing efficient expression of the Ad40 El A protein coding sequences (in place of 
19K in pCMV19K) by the CMV promoter, which would be processed under the control 
of the SV40 poly A signal. Figure 4.2.1.1 A illustrates the position of the primers FS2 
and FS3 in relation to the Ad40 El A sequence. FS2 and FS3 were also designed to 
contain Eco RI and Hind m  restriction sites respectively, facilitating directional cloning 
of the Ad40 El A protein coding sequences into the CMV expression plasmid.
Figure 4.2.1.1 B illustrates the open reading frames contained within the Ad40 El A 
equivalent 13S, 12S and probable 9S mRNAs. The predicted size of the Ad40 E1A 
equivalent 13S, 12S and 9S protein coding sequences, which would be generated by 
RT-PCR are indicated to the right of the Ad40 E1A equivalent 13S, 12S and 9S 
mRNAs. Figure 4.2.1.1 C shows the Southern blot analysis of RT-PCR products
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Figure 4.2.1.1 Construction of expression plasmids containing the Ad40 E1A protein 
coding sequences. Two 60mm plates of 293 cells were infected with 5ffu/cell Ad40 or mock 
infected with (tris saline) then blocked with 20pg/jil ara C 12-hourly. Cytoplasmic RNA from 
Ad40 infected and mock infected cells was reverse transcribed with lOOpmol FS3, before being 
used to set up PCR reactions with IjliM FS2 and Taq DNA polymerase. A tenth of the RT-PCR 
reactions were then analysed by southern blot using pNM80 as a probe (section 2.1). The 
cDNAs generated were cloned into pCRQ (section 2.1) and characterised by 
dideoxy-sequencing with FS2 and FS3, then FS4 and FS5. A. Denotes position of primers used 
in RT-PCR of the Ad40 El A protein coding sequences (FS2 and FS3), and in sequencing (FS4 
and FS5) of cDNAs generated. B. Denotes the open reading frames of the Ad40 El A 
equivalent 13S, 12S and 9S mRNAs, marked with the predicted sizes of cDNAs which should 
be generated during RT-PCR (right-hand side). Solid lines denote RNA with introns indicated 
by carets; filled rectangles are open reading frames; rectangles with rounded comers are 
proteins, which have not yet been confirmed experimentally. C. Southern blot analysis of the 
Ad40 El A cDNAs generated by RT-PCR. 40 denotes Ad40 El A specific cDNAs; mi denotes 
RT-PCR of mock infected cytoplasmic RNA; lOObp denotes lOObp DNA ladder (Gibco BRL 
Life Technologies); * denotes predicted Ad40 El A equivalent 13S cDNA; ♦ denotes predicted 
Ad40 El A equivalent 12S cDNA product; • denotes predicted Ad40 El A equivalent 9S cDNA 
product.
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generated from Ad40 infected and mock infected 293 cells (see lanes marked 40, for 
Ad40 infected 293 cells; and m.i., for mock infected 293 cells). The RT-PCR products 
from Ad40 infected 293 cells (lane marked 40 in figure 4.2.1.1 C) contained eight 
distinct cDNA species which were Ad40 El A specific. Comparison of the eight cDNA 
species (in lane marked 40 in figure 4.2.1.1 C) with the predicted sizes of the Ad40 E l A 
13S, 12S and 9S protein coding sequences (see figure 4.2.1.1 B), revealed three cDNAs 
which corresponded to the predicted size of the 13S (indicated by * in figure 4.2.1.1 C), 
12S (indicated by ♦ in figure 4.2.1.1 C) and 9S (indicated by • in figure 4.2.1.1 C) 
cDNAs.
The RT-PCR products were then cloned into pCRU (figure 2.1.7) to maximise ligation 
efficiency, as only small quantities of products were available. The pCRII cloning 
vector is able to maximise ligation efficiency by utilising the A' overhang generated by 
Taq DNA polymerase during the PCR reaction. Plasmids containing the Ad40 El A 
cDNAs were identified by restriction analysis of miniprep DNA with Hind IQ and 
Eco RI. Clones containing Ad40 El A cDNAs were sequenced using primers FS2 and 
FS3 to confirm the absence of mutations which may have arisen during the PCR, and 
also to characterise the cDNAs produced in vivo, in particular the position of introns, 
and the splice donor and splice acceptor sites providing a map of El A mRNAs. 
Preliminary sequencing data was used to design a second set of primers, FS4 
(nucleotides 610-627) and FS5 (1201-1184) (Table 2. 4; indicated in figure 4.2.1.1 A), 
which were used to complete the characterisation of the cloned cDNAs. The primer 
FS4 was also used to screen clones for the Ad40 El A 12S splice junction.
Figure 4.2.1.2 A illustrates the Ad40 El A mRNAs which were isolated and 
characterised, whilst figure 4.2.1.2 B denotes the size of the cloned cDNA and the splice 
donor and splice acceptor sites. The splice donor and acceptor sites were defined on the 
basis of a matrix mean model which was derived from all known mammalian splice site 
signals held at GenBank up to that time (Stephens and Schneider, 1992). The Ad40 13S 
cDNA is denoted by a black line, with the intron indicated as a caret spanning 
nucleotides 1011 to 1088 (see figure 4.2.1.2 A). The cloned product size was as the 
predicted 749bp (see column 2 in figure 4.2.1.2 B), which contained a consensus splice 
donor site (TACA/gtaa, known henceforth as the 13S splice donor) and a consensus
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B Clone Cloned product size (bp)
Splice donor site Splice acceptor site
13S 749 TACA/gtaa ttag/GTCC
c.l 617 GATG/gtatTACA/gtaa
ctag/CGAT
ttag/GTCC
c.2 372 ATGT/gttt cagt/AAGT
c.3 585 GATG/gtatAACC/cgcg
ctag/GCGA
ttaa/AGCG
c.4 693 GATG/gtat ctag/CGAT
Figure 4.2.1.2 Analysis of the Ad40 E l A specific cDNAs. A. Solid lines denote RNA with 
introns indicated by carets; filled rectangles are open reading frames; rectangles with rounded 
comers are proteins, which have not been confirmed experimentally. B. Table o f sequences at 
the slice donor and splice acceptor site. Bold type denotes consensus splice donor or splice 
acceptor sites; normal type denotes non-consensus splice donor or splice acceptor sites.
splice acceptor site (ttag/GTCC, known henceforth as the 13S splice acceptor site) (see 
columns 3 and 4 in figure 4.2.1.2 B). The Ad40 cDNA clone 1 was 617bp in length, 
containing two introns from 669 to 802 nucleotides and from 1011 to 1088 nucleotides 
(figure 4.2.1.2 A). The consensus splice donor sequence at nucleotide 669 (GATG/gtat; 
known henceforth as the 9S splice donor site) (see column 3 in figure 4.2.1.2 B) splices 
to a consensus sequence (ctag/CGAT) at nucleotide 802. Clone 1 then utilises the 
consensus 13S splice donor and acceptor sites at nucleotides 1011 and 1088 respectively 
(see columns 3 and 4 figure 4.2.1.2 B). The Ad40 cDNA clone 2 was 372bp in length, 
and contained one intron spanning nucleotides 559 to 1013 (figure 4.2.1.2 A). The 
concensus splice donor sequence at nucleotide 559 (ATGT/gttt) (see columns 3 and 4 
figure 4.2.1.2 B) splices to a non-consensus splice acceptor at position 1013 
(cagt/AAGT) (see columns 3 and 4 figure 4.2.1.2 B). The Ad40 cDNA clone 3 was 
585bp in length, containing two introns, which spanned from nucleotides 669 to 22, 534 
and 22, 915 to 1292 (figure 4.2.1.2 A). This is remarkable as clone 3 utilises the 
predicted 9S splice donor at position 669, splicing to a consensus splice acceptor 
(ctag/GCGA) at position 22, 534 in the L4 lOOkDa exon (see columns 3 and 4 figure
4.2.1.2 B). The second splice donor site is a non-consensus sequence (AACC/cgcg) 
located at 22, 915 which splices to a non-consensus splice acceptor site (ttaa/AGCG) 
within the E1A region at position 1292 (see columns 3 and 4 figure 4.2.1.2 B). Finally, 
the Ad40 cDNA clone 4 was 693bp, containing one intron spanning nucleotides 669 to 
802 (figure 4.2.1.2 A). Clone 4 utilises the predicted 9S splice donor at position 669, 
splicing to a consensus splice acceptor at position 802 (ctag/CGAT) (see columns 3 and 
4 figure 4.2.1.2 B).
The Ad40 El A 13S cDNA which was characterised by dideoxy-sequencing was then 
substituted for the E1B 19kDa protein coding sequences in the expression vector 
pCMV19K (White and Cipriani, 1990). The Ad40 E1A 13S cDNA was generated by 
restriction digest of pCRII-Ad4013S with Eco RI and Hind HI, the cDNA fragment was 
then ligated into pCMV19K via Eco RI and Hind ID restriction sites which substituted 
the E1B 19kDa protein coding sequences. Candidate clones were then identified by 
restriction digest of miniprep DNA with Eco RI and Hind ID, prior to large-scale 
preparation of pCMVAd4013S and pCMV13S (which contains the Ad5 13S mRNA
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under the control of the CMV promoter; Morris and Mathews, 1991) for use in transient 
co-transfection assays (section 4.2.3).
Sum m ary
RT-PCR of Ad40 infected cells generated a library of Ad40 El A specific cDNAs, 
which contained eight distinct cDNA species ranging from approximately 400bp to 
1 lOObp in length. Dideoxy-sequencing of a number of cloned cDNAs identified the 
Ad40 E1A equivalent 13S cDNA, however the Ad40 E1A equivalent 12S and 9S 
cDNAs were not characterised. Several novel cDNA clones were identified by 
dideoxy-sequencing, three (c.l, c.3 and c.4) of which utilise the 9S splice donor at 
nucleotide 669 to produce three distinct mRNAs. Clones 1 and 4 also use the same non­
consensus splice acceptor at nucleotide 802 producing two distinct mRNAs. The most 
remarkable cDNA isolated is the cDNA clone 3 which splices to the L4 lOOkDa exon, 
then splices a second time into sequences containing the El A region.
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4.2.2 Qualitative analysis of the Ad40 E1A mRNAs in Ad40 
infected cells.
In section 4.2.1 the Ad40 E1A equivalent 13S cDNA and four novel Ad40 E1A cDNAs 
had been generated by RT-PCR (figure 4.2.1.1), then characterised by 
dideoxy-sequencing (figure 4.2.2.2). To establish the status of the Ad40 El A equivalent 
13S mRNA and the four novel Ad40 El A mRNAs in a productive Ad40 infection, 
primers were designed to span the splice junction/s contained within the aforementioned 
mRNAs, these would generate specific sized cDNA products in RT-PCR. The Ad40 
El A equivalent 12S mRNA was not detected in section 4.2.1 therefore, to establish 
whether the Ad40 12S mRNA was indeed present in a productive Ad40 infection, 
primers were designed to span the 12S splice junction.
The primers which would be used in the RT-PCR of Ad40 infected cells, known as 
ALEX 1-6, were designed to generate specific cDNA products which spanned the splice 
junction or junctions of the Ad40 El A equivalent 13S mRNA, the four novel Ad40 El A 
mRNAs and the Ad40 E1A equivalent 12S mRNA (figure 4.2.2). Figure 4.2.2 A and 
table 2.4, illustrates the position and direction of the primers ALEX 1-6 in relation to the 
Ad40 E1A sequence. Figure 4.2.2 B indicates the primer pairs used in RT-PCR of 
Ad40 infected cells (see column 2 in figure 4.2.2 B), to detect the specific splice 
junction/s contained within the cloned Ad40 El A cDNAs and the Ad40 E l A equivalent 
12S mRNA. Also indicated are the predicted sizes of cDNA and DNA products, which 
would be generated by RT-PCR or PCR of a plasmid containing the Ad40 El A 
sequences respectively (see columns 3 and 4 in figure 4.2.2 B).
Specific cDNA fragments were generated for the Ad40 El A 13S equivalent mRNA, the 
Ad40 El A equivalent 12S mRNA and the Ad40 El A mRNA clones one to four by 
RT-PCR of cytoplasmic RNA harvested 42h p.i. from 293 cells infected with 5ffu/cell 
Ad40 and blocked with araC (section 3.2.1, 3.2.2 and 3.5.3). Combinations of primers 
used in each RT-PCR reaction are outlined in figure 4.2.2 B, lOOpmol of primer was 
used within the RT reaction (primer for RT is denoted in bold type in column 2 of figure
4.2.2 B), whilst 1 pM primer was used in PCR with Taq DNA polymerase (primer for 
PCR is denoted in normal type in column 2 of figure 4.2.2 B). A tenth of the RT-PCR
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Figure 4.2.2 Qualitative analysis of Ad40 E1A mRNAs in Ad40 infected cells. Two 60mm 
plates of 293 cells were infected with 5 ffu/cell Ad40 or mock infected with tris saline, then 
blocked with ara C 12 hourly. Cytoplasmic RNA was harvested 42h p.i. to set up RT-PCR 
reactions with lOOpmol of the RT primer and l|iM of the PCR primer, in parallel with a positive 
PCR control (pNM80, section 2.1) and a negative PCR control. A tenth of the products along 
with a lOObp DNA ladder (Gibco BRL Life Technologies) and a 123bp DNA ladder (Gibco 
BRL Life Technologies) were visualised on an ethidium bromide stained gel. A. Position of 
primers used for RT-PCR. Arrow denotes direction of primer. B. Table of predicted DNA and 
cDNA sizes with different combinations of primers spanning the intron sequences of each 
clone. Normal type denotes primer used in RT reaction; bold type denotes primer used in PCR. 
C. Agarose gel analysis of RT-PCR products from Ad40 infected and mock infected cells. 13S 
denotes Ad40 13S El A equivalent cDNA fragment; 12S denotes Ad40 El A equivalent 12S 
cDNA fragment; c.l denotes Ad40 El A clone 1 cDNA fragment; c.2 denotes Ad40 El A clone 
2 cDNA fragment; c.3 denotes Ad40 E1A clone 3 cDNA fragment; c.4 denotes Ad40 E1A 
clone 4 cDNA fragment; 40 denotes Ad40 infected cells; mi denotes mock infected cells; +ve 
denotes positive PCR control; -ve denotes negative PCR control.
00
00o o  o
U __ L .1 L
A LEX l ALEX2
-►
ALEX4
ALEX5 ALEX6
ALEX3
Clone Primers Predicted DNA size 
(bp)
Predicted cDNA size 
(bp)
13S ALEX4, ALEX5 222 146
12S ALEX2, ALEX5 342 182
c.l ALEXl, ALEX5 639 431
c.2 ALEXl, ALEX5 639 186
c.3 ALEXl, ALEX6 - 196
c.4 ALEXl, ALEX3 323 189
B
products were then visualised on an ethidium bromide stained agarose gel (see 
figure 4.2.2 C).
Figure 4.2.2 C shows the RT-PCR products generated from Ad40 infected (denoted 40) 
and mock infected 293 cells (denoted mi), in parallel with a positive (denoted by +ve) 
and negative (denoted -ve) PCR control. The primers used in each RT-PCR or PCR are 
indicated above the lane markings. Figure 4.2.2 B indicates the size of the specific 
cDNA or DNA fragments generated for Ad40 El A equivalent 13S and 12S mRNAs, 
clone one, clone two, clone three and clone four. Figure 4.2.2 C indicates that a product 
of approximately 140bp was produced for primers, which spanned the Ad40 El A 
equivalent 13S cDNA, suggesting that the 13S cDNA is present early in Ad40 infection. 
However, a product of approximately 250bp in size, was produced when primers, which 
span the Ad40 El A equivalent 12S splice junction were used, suggesting that the Ad40 
El A 12S mRNA is either a minor species of Ad40 El A mRNA at early times in 
infection or is absent from Ad40 infected 293 cells. The cDNA clones one and four 
were predicted to produce cDNA products of 431 bp and 189bp respectively, indeed the 
RT-PCR products contain bands which approximate the predicted sizes, suggesting that 
clones one and four are present in a productive Ad40 infection. A number of 
alternatively sized RT-PCR products are observed in tracks containing clone one and 
four, which would suggest that a number of Ad40 El A mRNAs are produced which 
splice between 512 to 1150 nucleotides and 512 to 832 nucleotides respectively. The 
cDNA clones two and three are predicted to produce cDNA fragments of 186bp and 
196bp respectively however, neither product was observed. This suggests that the Ad40 
El A cDNA clones two and three are either minor species of Ad40 El A mRNA at early 
time in infection, or they may be absent from Ad40 infections in 293 cells, or the cDNA 
clones may have been unusual by-products of the RT-PCR.
The Ad40 El A 12S equivalent cDNA fragment, of predicted size 182bp, was not 
generated by RT-PCR of Ad40 infected 293 cells. This could possibly have resulted 
from RNA degradation therefore, the PCR reaction was repeated using the RT reaction 
which generated the Ad40 El A equivalent 13S cDNA fragment and lpM  ALEX2, in 
parallel with a positive and a negative PCR control. A tenth of the PCR products were 
then visualised on an ethidium bromide stained agarose gel. The Ad40 El A equivalent
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12S cDNA fragment of predicted size was not observed, which suggested that the 
previous observations made were not subject to experimental error, but were in fact real.
Sum m ary
Primers designed to produce specific cDNA fragments spanning the Ad40 El A 
equivalent 13S and 12S splice junctions, and spanning the Ad40 El A cDNA clones one 
to four, were used in RT-PCR of Ad40 infected 293 cells. The Ad40 E1A 13S mRNA 
and the Ad40 El A clones one and four were present at early times in Ad40 infected 
cells. Clones one and four are of particular interest as they produce a number of 
uniquely sized cDNA fragments by RT-PCR. The Ad40 El A 12S mRNA and the Ad40 
El A clones two and three were not observed at early times in Ad40 infected cells.
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4.2.3 Analysis of trans-activation by the Ad5 E1A 289R protein 
and the Ad40 E1A 249R protein upon their respective 
promoters
Previous studies of the adenovirus type 40 El A protein products, had revealed that the 
Jraws-activation of the Ad2 E4 promoter, the Ad5 E2A promoter and the Ad5 E3 
promoter by the Ad40 El A proteins was significantly lower when compared with 
fraws-activation by the Ad5 El A proteins (van Loon et al., 1987b; Ishino et al., 1988). 
These results suggested that the Ad40 El A proteins may well be implicated in the 
aberrant expression of El A, and therefore the growth restriction of Ad40. To 
investigate the involvement of the Ad40 El A proteins in their own aberrant expression, 
the Ad40 E l A equivalent 13S protein coding sequences were cloned into a CMV 
expression plasmid (section 4.2.1). The Ad40 El A equivalent 12S protein coding 
sequences were not detected in Ad40 infected 293 cells (section 4.2.1; 4.2.2). To 
compare fraws-activation by the Ad5 El A 289R protein on the Ad5 El A promoter with 
Jraws-activation by the Ad40 E1A equivalent 289R protein (known henceforth as the 
Ad40 El A 249R protein) on the Ad40 El A promoter, cells were co-transfected with the 
appropriate plasmids.
Before transient transfection of the aforementioned plasmids could take place, the 
conditions for transient transfection were optimised for the CMV expression vectors, 
pCMV13S and pCMVAd4013S. These co-transfections also established whether or not 
the CMV expression plasmid encoding the Ad40 El A 249R protein produced functional 
protein. Conditions for CaPCVmediated transient transfection in WS HeLa cells were 
optimised, with respect to the total amount of DNA transfected (optimum = lOpg), the 
incubation period of the CaP(> 4 precipitate with the cells (optimum = 6h) and whether a 
glycerol shock was required to enhance transfection (optimum = not required) in section 
4.1.2. The ratio of plasmid DNA to carrier DNA (10pg:0pg) had also been optimised 
for WS HeLa cells in section 4.1.4. The ratio of the experimental reporter plasmid to 
expression plasmid (lOpg pGL3-Ad5 or pGL3-Ad40 to 0.5pg, lpg, 2pg or 5pg 
pCMVAd4013S) was optimised in WS HeLa cells. Each experiment was set up with 
triplicate 60mm plates of WS HeLa cells (seeded at lx l0 6 cells/plate), which were 
transiently transfected with independently derived CaPC>4 precipitates (section 3.4.3).
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Cells were harvested using the dual luciferase reporter assay system (section 3.4.3.2), 
then 20pl aliquots of cell extract were assayed for firefly luciferase luminscence and 
Renilla luciferase luminescence (section 3.4.4.2). Sample firefly luciferase 
luminescence (FLL) and Renilla luciferase luminescence values were tabulated (see 
columns 2 and 4 in Table 4.2.3.1) then used to calculate the mean (p) and standard 
deviation (8) for each sample (see columns 7 and 8 in Table 4.2.3.1; see section 4.1.4).
Figure 4.2.3.1 A and B show the mean (p) and standard deviation (8) values for the ratio 
of firefly luciferase luminescence (FLL) to Renilla luciferase luminescence (RLL) for 
the Ad5 E l A promoter trans-activated by increasing amounts of the Ad5 El A 289R 
protein, and the Ad40 El A promoter /raws-activated by increasing amounts of the Ad40 
El A 249R protein. Expression from the Ad5 El A promoter increased steadily with the 
addition of 0.5pg, lpg, 2pg and 5pg expression plasmid pCMV13S, which contains the 
Ad5 El A 13S cDNA. Expression from the Ad40 El A promoter also increased steadily 
with the addition of 0.5pg, lpg, 2pg and 5pg expression plasmid pCMVAd4013S, 
which contains the Ad40 El A 13S cDNA. The dose dependent effect of both the Ad5 
El A 289R protein and the Ad40 El A 249R protein demonstrated that the corresponding 
expression plasmids pCMV13S and pCMVAd4013S express functional protein. The 
optimum ratio of experimental reporter plasmid to expression plasmid was lOpg 
pGL3-Ad5/pGL3-Ad40 to 5pg pCMV13S/pCMVAd4013S in WS HeLa cells. The two 
to one ratio of experimental reporter plasmid to expression plasmid was used in all 
subsequent co-transfections.
To establish whether trans-activation by the Ad5 El A 289R protein (pCMV13S) and 
the Ad40 El A 249R protein (pCMVAd4013S) were comparable, expression vectors 
containing the aforementioned protein coding sequences were transiently co-transfected 
with the Ad5 E1A promoter (pGL3-Ad5) or the Ad40 E1A promoter (pGL3-Ad40), in 
parallel with a positive (pGL3-control) and a negative (pGL3-basic) control. Each 
experiment was set up with triplicate 60mm plates of WS HeLa cells (seeded at 
lxlO6 cells/plate), which were transiently transfected with independently derived CaP0 4  
precipitates (section 3.4.3). Cells were harvested using the dual-luciferase reporter 
assay system (section 3.4.3.2), then 20pl aliquots of cell extract were assayed for firefly 
luciferase luminescence and Renilla luciferase luminescence (section 3.4.4.2). Sample
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Table 4.2.3.1 Transient co-transfection with increasing amounts of the Ad5 E1A 289R or 
the Ad40 E1A 249R protein with their corresponding promoters.
Sample FLLfl
(TLU)
FLL-
FLLAB*
(TLU)
RLLC
(TLU)
RLL-
RLLABrf
(TLU)
FLL/
RLL
Ad5 El A promoter 2128 2103 923 898 2.3
Ad5 El A promoter 2999 2974 1024 999 3.0 2.5 0.36
Ad5 El A promoter 1875 1850 875 850 2.2
Ad5 E1A + 0.5|ug 13S 5885 5860 359 334 18
Ad5 E1A + 0.5pg 13S 5626 5601 298 273 21 21 2.1
Ad5 El A + 0.5jng 13S 38431 38406 1672 1647 23
Ad5 E 1A + lpg 13S 21268 21243 1057 1032 21
Ad5 El A + lpg 13S 22709 22684 790 765 30 25 3.9
Ad5 E1A + lpg 13S 6141 6116 295 270 23
Ad5 El A + 2pg 13S 13270 13245 422 397 33
Ad5 El A + 2|ig 13S 7383 7358 239 214 34 32 2.6
Ad5 E1A + 2pg 13S 13393 13368 503 478 28
Ad5 E1A + 5pg 13S 1656 1631 57 32 51
Ad5 E1A + 5pg 13S 3267 3242 115 90 36 43 6.1
Ad5 E1A + 5pg 13S 5057 5032 142 117 43
Ad40 El A promoter 273 248 1067 1042 0.24
Ad40 El A promoter 252 227 870 845 0.27 0.24 0.02
Ad40 El A promoter 498 473 2291 2266 0.21
Ad40 E1A + 0.5pg 13S 381 356 882 857 0.42
Ad40 E1A + 0.5pg 13S 445 420 827 802 0.52 0.47 0.04
Ad40 E1A + 0.5pg 13S 300 275 593 568 0.48
Ad40 E1A + lpg 13S 330 305 657 632 0.48
Ad40 E1A + lpg 13S 141 116 306 281 0.41 0.48 0.06
Ad40 E 1A + lpg 13S 321 296 550 525 0.56
Ad40 E l A + 2pg 13S 535 510 956 931 0.55
Ad40 E1A + 2pg 13S 408 383 782 757 0.51 0.56 0.04
Ad40 E1A + 2pg 13S 216 191 336 311 0.61
Ad40 E1A + 5pg 13S 145 120 259 234 0.51
Ad40 E1A + 5pg 13S 203 178 373 348 0.51 0.54 0.04
Ad40 E1A + 5pg 13S 207 182 331 306 0.59
Sample FLLfl
(TLU)
FLL-
FLLAB*
(TLU)
RLLC
(TLU)
RLL-
RLLABrf
(TLU)
FLL/
RLL
e
V
Positive control 26951 26926 4610 4585 5.9
5.0 0.67Positive control 8551 8526 1875 1850 4.6
Positive control 7020 6995 1629 1604 4.4
Negative control 36 11 2603 2578 0
0 0Negative control 38 13 3252 3227 0
Negative control 26 1 1518 1493 0
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence assay background
RLL denotes Renilla luciferase luminescence
RLLAB denotes Renilla luciferase luminescence assay background
jj. denotes mean
8 denotes standard deviation
60 -
20  -
0 0.5pg lpg 2 Mg
Ad5 E1A 289R
1.00
0.75 -
^  0.50 - 
&
0.25 | |
0.00
0 o.5|jg lp g 2pg 5pg
Ad40 E1A 249R
Figure 4.2.3.1 7>a//s-activation of the Ad5 and the Ad40 E1A promoters with increasing 
amounts of the Ad5 E1A 289R protein and the Ad40 E1A 249R protein respectively. The
experiment was set up with triplicate 60mm plates of WS HeLa cells (seeded at 
lxlO6 cells/plate), which were co-transfected with independently derived calcium phosphate 
precipitates containing lOjug Ad5 or Ad40 promoters with either 0.5pg, lpg, 2pg or 5pg Ad5 
El A 13S cDNA or Ad40 El A equivalent 13S cDNA, in parallel with a positive and negative 
control (section 3.4.3). The positive control (pGL3-control; figure 2.1.4) contained the SV40 
promoter, whilst the negative control (pGL3-basic; figure 2.1.3) was promoterless. The cells 
were harvested using the dual luciferase reporter assay system (section 3.4.3.2), then 20pl 
aliquots were assayed for firefly luciferase luminescence (TLU) then Renilla luciferase 
luminescence (section 3.4.4.2). The p (■) and 8 (capped lines) values for the ratio of firefly 
luciferase luminescence (FLL) to Renilla luciferase luminescence (RLL) are shown for the Ad5 
and the Ad40 El A promoters with increasing amounts of the Ad5 El A 289R protein and the 
Ad40 El A 249R protein respectively.
firefly luciferase luminescence (FLL) and Renilla luciferase luminescence (RLL) values 
were tabulated (see columns 2 and 4 in Table 4.2.3.2) then used to calculate the mean 
(p) and standard deviation (8) for each sample (see columns 7 and 8 in Table 4.2.3.2; 
see section 4.1.4).
Figure 4.2.3.2 shows the mean (p) and standard deviation (5) values for the ratio of 
firefly luciferase luminescence (FLL) to Renilla luciferase luminescence (RLL) for the 
Ad5 El A promoter and the Ad40 El A promoter frans-activated by the Ad5 El A 289R 
protein and the Ad40 El A 249R protein. The Ad5 El A 289R protein Jraws-activates 
the Ad5 El A promoter by a factor of 10.4, it is also able to trans-activate the Ad40 El A 
promoter by a factor of 40, which gives an expression level comparable to Ad5. The 
Ad40 El A 249R protein fraws-activates the Ad40 El A promoter by a factor of 1.7 fold, 
but is unable to fra/w-activate the Ad5 E l A promoter. 7ra«s-activation from the Ad40 
El A promoter by the Ad40 El A 249R protein was activated 6.2 fold less when 
compared to ?ra«s-activation of the Ad5 El A promoter by the Ad5 E1A 289R protein; 
this value was calculated by dividing the ratio of fraws-activation from the Ad5 E l A 
promoter by the Ad5 El A 289R protein, by the ratio of fraws-activation from the Ad40 
El A promoter by the Ad40 El A 249R protein.
Summary
The Ad5 E1A 289R protein is a strong trans-activator, which is able to fraws-activate 
both the Ad5 and the Ad40 El A promoters to similar expression levels. On the other 
hand the Ad40 E l A 249R protein is an extremely weak /raws-activator, which is able to 
trans-&cX\vdXQ its own promoter but unable to trans-activate the Ad5 El A promoter. 
Overall /rans-activation by the Ad40 El A 249R protein on the Ad40 El A promoter is 
approximately 6.2 fold less than /raws-activation by the Ad5 El A 289R protein on the 
Ad5 El A promoter.
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Table 4.2.3.2 Transient co-transfection of the intact Ad5 or Ad40 E1A promoters with 
either the Ad5 E1A 289R protein or the Ad40 E1A 249R protein.
Sample FLLfl
(TLU)
FLL-
FLLAB*
(TLU)
RLLC
(TLU)
RLL-
RLLAB*
(TLU)
FLL/
RLL H-* 5f
Ad5 El A promoter 1765 1740 138 113 15
15 1.7Ad5 El A promoter 3035 3010 203 178 17
Ad5 El A promoter 3062 3037 247 222 14
+Ad5 13S 48966 48941 307 282 174
156 15+Ad5 13S 62925 62900 429 404 156
+Ad5 13S 65144 65119 498 473 137
+ Ad40 13S 19639 19614 1173 1148 17
16 1.0+ Ad40 13S 14205 14180 834 809 17
+ Ad40 13S 4256 4231 311 286 15
Ad40 El A promoter 197 172 82 57 3.0
3.4 0.26Ad40 El A promoter 186 161 71 46 3.5
Ad40 El A promoter 202 177 74 49 3.6
+Ad5 13S 11773 11748 104 79 149
137 27+Ad5 13S 15667 15642 183 158 99
+Ad5 13S 1656 1631 35 10 163
+ Ad40 13S 1552 1527 317 292 5.2
5.7 0.41+ Ad40 13S 4329 4304 721 696 6.2
+ Ad40 13S 114 89 41 16 5.6
Positive control 229 204 53 28 7.3
7.4 1.4Positive control 171 146 41 16 9.1
Positive control 224 199 60 35 5.7
Negative control 25 0 1190 1165 0.0
0.0 0.0Negative control 24 0 960 935 0.0
Negative control 26 1 1369 1344 0.0
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence array background
RLL denotes Renilla luciferase luminescence
RLLAB denotes Renilla luciferase luminescence array background
jn denotes mean
5 denotes standard deviation
FLL:RLL
Ad5 El A promoter
+A d513S
+Ad4013S
Ad40 E l A promoter
+Ad513S
+Ad40 13S a
Figure 4.2.3.2 Analysis of fra/is-activation by the Ad5 E1A 289R protein and the Ad40 
E1A 249R protein on the Ad5 and the Ad40 E1A promoters. The experiment was set up
with triplicate 60mm plates of WS HeLa cells (seeded at lx l0 6 cells/plate), which were 
co-transfected with independently derived calcium phosphate precipitates containing 5 fig Ad5 
or Ad40 El A promoters with either 5pg Ad5 E l A 13S cDNA or Ad40 E l A 13S equivalent 
cDNA, in parallel with a positive (pGL3-control; figure 2.1.4) and negative control (pGL3- 
basic; figure 2.1.3). The positive control contained the SV40 promoter whilst the negative 
control was promoterless. The cells were harvested by using the dual-luciferase reporter assay 
system (section 3.4.3.2), then 20pl aliquots were assayed for firefly luciferase luminescence 
then Renilla luciferase luminescence (section 3.4.4.2). The p. and 5 (capped lines) values are 
shown for the Ad5 and the Ad40 El A promoters with the Ad5 El A 289R protein and the Ad40 
El A 249R protein.
4.2.4 Analysis of trans-activation by the Ad5 E1A 289R protein 
and the Ad40 E1A 249R protein upon the intact and deleted 
Ad5 and Ad40 E1A promoters
The Ad40 El A 249R protein is a weak activator of Ad40 El A transcription when 
compared with /ra«s-activation of the Ad5 E1A promoter by the Ad5 E1A 289R 
protein. Suggesting that /raws-activation of the Ad40 El A promoter may be implicated 
in the growth restriction of Ad40. To map sequences which were important for 
rraws-activation from the Ad40 El A promoter, WS HeLa cells were transiently 
co-transfected with a CaPC>4 precipitate containing the intact or deleted Ad5 or Ad40 
El A promoters (section 4.1.5 and 4.1.7) with expression vectors containing either the 
Ad5 El A 13S coding sequences (pCMV13S) or the Ad40 equivalent El A 13S protein 
coding sequences (pCMVAd4013S), in parallel with a positive (pGL3-control; 
figure 2.1.4) and a negative (pGL3-basic; figure 2.1.3) control. The experiment was set 
up with duplicate 60mm plates of WS HeLa cells (seeded at lx l0 6 cells/plate), 
transiently co-transfected with independently derived CaPC>4 precipitates (section 3.4.3). 
Cells were harvested using the dual-luciferase reporter assay system (section 3.4.3.2), 
then 20pl aliquots of cell extract were assayed for firefly luciferase luminescence and 
Renilla luciferase luminescence (section 3.4.4.2). Sample firefly luciferase 
luminescence (FLL) and Renilla luciferase luminescence (RLL) values were tabulated 
(see columns 2 and 4 in Table 4.2.4) then used to calculate the mean (p) and standard 
deviation (5) for each sample (see columns 7 and 8 in Table 4.2.4; see section 4.1.4).
Figure 4.2.4 A shows a diagrammatic representation of the intact and deleted Ad5 and 
Ad40 El A promoters used in the co-transfection, whilst B shows the mean (p) and 
standard deviation (5) values for the ratio of firefly luciferase luminescence (FLL) to 
Renilla luciferase luminescence (RLL) for the intact and deleted Ad5 and Ad40 El A 
promoters fraws-activated by the Ad5 289R El A protein. The equivalent Ad5 and Ad40 
El A promoters fraws-activated by the Ad40 El A 249R protein were not obtained as an 
error occurred within the incubator, rendering the co-transfections null and void. 
Figure 4.2.4 B illustrates that the overall expression levels within this experiment were 
adversely affected by the error which occurred within the incubator during the 
experiment however, the results were still valid from this half of the experiment as the
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Table 4.2.4 Transient co-transfection of the intact and deleted Ad5 or Ad40 E1A
promoters with the Ad5 E1A 289R protein
Sample FLLfl(TLU)
FLL-
FLLAB*
(TLU)
RLLC
(TLU)
RLL-
RLLABrf
(TLU)
FLL/
RLL
e
V
Ad5 El A promoter 205 180 44 19 9.5 10 0.8Ad5 El A promoter 209 184 41 16 11
Ad5 El A promoter +13S 1325 1300 43 18 72 97 25Ad5 El A promoter +13S 1494 1469 37 12 122
Ad5 del.428 + 13S 8192 8167 131 106 77 81 3.0Ad5 del.428 + 13S 5547 5522 91 66 84
Ad5 del.321 + 13S 231 206 37 12 17 13 4.1Ad5 del.321 + 13S 174 149 40 15 9.9
Ad5 del. 171 + 13S 209 184 43 18 10 12 1.6Ad5 del. 171 + 13S 204 179 39 14 13
Ad5 del.42 + 13S 39 14 37 12 1.2 0.85 0.35Ad5 del.42 + 13S 35 10 45 20 0.50
Ad40 El A promoter 128 103 51 26 4.0 2.3 1.7Ad40 El A promoter 40 15 52 27 0.56
Ad40 El A promoter + 13S 56 31 29 4 7.8 7.4 0.4Ad40 El A promoter + 13S 95 70 35 10 7.0
Ad40 del.349 + 13S 972 947 66 41 23 24 1.0Ad40 del.349 + 13S 1627 1602 89 64 25
Ad40 del.328 + 13S 646 621 54 29 21 24 3.0Ad40 del.328 + 13S 505 480 43 18 27
Ad40 del.268 + 13S 3474 3449 278 253 14 15 0.7Ad40 del.268 + 13S 581 556 61 36 15
Ad40 del.235 + 13S 39 14 42 17 0.82 0.91 0.09Ad40 del.235 + 13S 34 9 34 9 1.00
Ad40 del.209 + 13S 30 5 43 18 0.28 0.39 0.11Ad40 del.209 + 13S 37 12 49 24 0.50
Ad40 del. 166 + 13S 38 13 42 17 0.76 0.55 0.22Ad40 del. 166 + 13S 30 5 40 15 0.33
Ad40 del.140 + 13S 66 41 112 87 0.47 0.50 0.03Ad40 del.140 + 13S 69 44 108 83 0.53
Sample FLLa(TLU)
FLL-
FLLAB*
(TLU)
RLLC
(TLU)
RLL-
RLLABrf
(TLU)
FLL/ 
RLL
e
V
Ad40 del.37 + 13S 35 10 54 29 0.34 0.48 0.14Ad40 del.37 + 13S 36 11 43 18 0.61
Positive control 254 229 52 27 8.5 8.6 0.1Positive control 276 251 54 29 8.7
Negative control 25 0 659 634 0.00 0.0 0.0Negative control 26 1 635 610 0.00
FLL denotes firefly luciferase luminescence
FLLAB denotes firefly luciferase luminescence assay background
RLL denotes Renilla luciferase luminescence
RLLAB denotes Renilla luciferase luminescence assay background
p, denotes mean
5 denotes standard deviation
-500
I_
-400
I
-300 
__ l_
-200
- I
-100 
__ l_
-1 +100
I____________ I
Ad5 -498
ITR
-428
-321
► ►
§0@— 0-0-
-171
TATAcap
TATAcap
1 0
TATAcap
■ H O - r ?
TATAcap
M h ?
TATAcap
■“ -n - r ?
Ad40
-416
-349
-328
-268
-209
fl-HJ-0-0 l-f-O-
- f F h O-O-------- 1— 1 — D -^ ?
235—CH]------- 1—I —
0 - 0  1 - 1 - 0 - = * ?
— I —
— M - 0 - = *  
-370 > ^
-166 —  
-140
Figure 4.2.4 Analysis of fra/is-activation by the Ad5 E1A 289R protein on the intact and 
deleted Ad5 and the Ad40 E1A promoters. The experiment was set up with duplicate 60mm 
plates o f WS HeLa cells (seeded at lxlO 6 cells/plate), which were co-transfected with independently 
derived calcium phosphate precipitates (section 3.4.3) containing 5pg intact or deleted Ad5 or Ad40 E l A 
promoters with 5pg Ad5 E l A 289R protein, in parallel with a positive and negative control. The positive 
control contained the SV40 promoter (pGL3-control; figure 2.1.4), whilst the negative control 
(pGL3-basic; figure 2.1.3) was promoterless. The cells were harvested by using the dual-luciferase 
reporter assay system (section 3.4.3.2), then 20pl aliquots were assayed for firefly luciferase
FLL:RLL
400 20 60 80 100 120
Ad5 El A promoter
+Ad5 13S
del.428 + Ad5 13S
del.321 + Ad5 13S
del.171 + Ad5 13S
del.42 + Ad5 13S
Ad40 El A promoter
H+Ad5 13S
del.349 + Ad5 13S
del.328 + Ad5 13S
del.268 + Ad5 13S
del.235 + Ad5 13S
del.209 + Ad5 13S
del. 166 + Ad5 13S
del.140 + Ad5 13S
del.37 + Ad5 13S
luminescence then Renilla luciferase luminescence (section 3.4.4.2). A. The Ad5 and the Ad40 E1A full 
length and deleted promoters. B. The p and 5 (capped lines) values are shown for the intact and deleted 
Ad5 and Ad40 E l A promoters with/without the Ad5 E l A 289R protein. Transcription factor binding 
sites are indicated by: §  denotes ORP-A; #  denotes NF I; O  denotes NF III; 0 denotes
SP1; I  denotes ATF; [] denotes EF-1A; O denotes E2F; 0  denotes CAAT; ► denotes
Element I; denotes Element II in the Ad5 sequence and an Element II-like sequence in the Ad40
sequence; I— ► denotes 24bp enhancer; D  denotes TATA; f- ^  denotes the cap s i t e ; ---denotes
the hyphenated symmetry around the cap site.
Ad5 El A 289R protein was a strong /raws-activator of transcription. Basal transcription 
from the Ad40 El A promoter when compared with the Ad5 El A promoter is reduced 
by approximately the same levels as observed in previous experiments in sections 4.1 
and 4.2. The Ad5 El A 289R protein £ra/«-activated both the intact Ad5 and the intact 
Ad40 El A promoters however, not to the same level as was previously demonstrated 
(Figure 4.2.3.2). This may have been related to the equipment problem mentioned 
above, and given more time it would have been beneficial to repeat these experiments.
Deletions within the Ad5 and the Ad40 El A promoter demonstrated similar patterns of 
expression. Deletion of sequences from -498 to -428 (relative to the cap site) in the Ad5 
El A promoter resulted in a 1.2 fold decrease in fraws-activated expression however, the 
decrease is within the range for standard deviation and therefore is not significant. The 
largest decrease in fraws-activated expression within the Ad5 El A promoter came with 
the deletion of sequences from -428 to -321, and resulted in a decrease by a factor of 
6.2. Deletion of sequences from -321 to -171 did not affect fraws-activated expression 
from the Ad5 El A promoter, the final decrease in /ra/w-activated expression resulted 
from deletion of sequences from -171 to -42, with an approximated value of 14 fold.
Deletion of sequences within the Ad40 El A promoter demonstrated a similar pattern of 
expression to that observed within the Ad5 E1A promoter i.e. deletion of sequences 
resulted in a sequential decrease in fraws-activated transcription from the Ad40 El A 
promoter. There was however one difference to the pattern of expression observed 
within the deletion analysis of the Ad40 El A promoter, namely deletion of sequences 
from -416 to -349 relative to the Ad40 El A cap site, effected an increase in trans- 
activated levels of expression from the Ad40 El A promoter. Deletion of sequences 
from -349 to -328 mediated a slight decrease in fraws-activated expression. Deletion of 
sequences from -328 to -268 and -268 to -235 reduced fraws-activated expression to the 
level observed from the Ad40 El A TATA box deletion construct (del.37). The decrease 
in £ra«s-activated expression within these sequences was mediated in two stages, with 
the deletion of -328 to -268 resulting in a 17 fold decrease, whilst deletion of the region 
-268 to -235 resulted in a- 2.3 fold decrease. Overall the deletion of sequences from the 
Ad40 E1A promoter in the region of -328 to -235 mediated a decrease in /raws-activated
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expression by a factor of 39. Subsequent deletion of sequences from -235 to -37 had no 
real effect on fra«s-activated expression from the Ad40 El A promoter.
Sum m ary
The Ad5 E1A 289R protein /raws-activated both the intact Ad5 E1A promoter and the 
intact Ad40 El A promoter however, this was not consistent with the previous 
experiment (section 4.2.3) where the Ad5 E1A 289R protein was shown to trans- 
activate the Ad40 El A promoter to the same level as the Ad5 El A promoter (Table 
4.2.3.2; figure 4.2.3.2). This may be accounted for by the equipment filure mentioned 
above. Deletions within the Ad5 and the Ad40 El A promoters demonstrated similar 
patterns of expression. Deletion of sequences from the ITR to the TATA box in the 
Ad5 E l A promoter resulted in a decrease in /raws-activated expression with each 
deletion, the greatest decrease being mediated by a region between -428 to -321. Trans- 
activation of the Ad40 El A promoter deletion constructs also mediated a sequential 
decrease in fr*<z«s-activated expression from the ITR to the TATA box. The region from 
-328 to -235 mediating the greatest decrease in /raws-activated expression by the Ad5 
El A 289R protein.
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4 . 3  C h a r a c t e r i s a t i o n  o f  b r a n c h e d  c h a i n  a n t i - p e p t i d e  
a n t i b o d i e s  d i r e c t e d  a g a i n s t  t h e  A d 4 0  E 1 A  p r o t e i n s
Introduction
The Ad5 El A region has been shown to produce a number of proteins (figure 1.1.4.2). 
The major Ad5 El A proteins are the 289R and 243R proteins, which contain three 
highly conserved regions, designated CR1, CR2 and CR3 (Kimelman et al., 1985; 
Moran and Mathews, 1987). CR1 is required for transcriptional repression, 
transformation and induction of DNA synthesis (Lillie et al., 1987; Schneider et al., 
1987; Jelsma et al., 1989; reviewed in Jones, 1995). CR2 is required for transformation 
and induction of DNA synthesis, but may be dispensable for transcriptional repression 
((Lillie et al., 1986; Moran et al., 1986a; Howe et al., 1990; Stein et al., 1990). CR3 
possesses a potent fraws-activation function (Shenk and Flint, 1991; Jones, 1992; Bayley 
and Mymrk, 1994). The non-conserved C-terminal region of El A is also required as an 
enhancer of CR3-mediated fraws-activation (Bondesson et a l,  1992; Strom et al., 1998). 
The functions of the El A proteins have been well documented, and include their 
abilities for autoregulation, fraws-activation, /ra«5-repression and transformation 
(section 1.2). The El A proteins ability to mediate these functions is dependent upon 
their interaction with a number of viral and cellular proteins (see section 1.2.3, in 
particular figure 1.2.3; reviewed in Mymrk, 1996).
Expression from the Ad40 El A region in plasmid transformed cells results in a 249R 
protein and a 221R protein equivalent to the Ad5 El A 289R and 243R proteins 
(van Loon et al., 1987a). The mRNA encoding the 249R protein was demonstrated in 
Ad40 infected cells, however the 221R protein was not demonstrated at early times in 
Ad40 infected cells (section 4.2.2). The Ad40 El A 135R protein has also been 
predicted but has not been demonstrated experimentally (van Loon et al., 1987a). These 
results suggest that perhaps like the Ad5 El A region the Ad40 El A region encodes a 
number of proteins. To determine the number and size of the respective Ad40 El A 
proteins, infected cell extracts were analysed in western blot experiments with anti­
peptide antibodies raised against the Ad40 El A 249R protein.
- 1 0 8 -
4.3.1 Production of branched chain anti-peptide antibodies 
directed against the N-terminal, CR3 and C-terminal 
regions of the Ad40 E1A 249R protein
To investigate the number and size of Ad40 El A proteins and the interactions with 
other cellular and viral proteins during an Ad40 infection in vitro and in vivo, antisera 
were generated to the Ad40 El A proteins. Two of these sera would be expected to 
contain antibodies which recognise the N-terminus and the C-terminus sequences, 
which would detect both the 249R and the 221R El A proteins, while the third would 
recognise CR3, and therefore would be specific to the 249R protein.
Ad40 El A specific anti-peptide antibodies were generated using branched-chain 
peptides to the first 15 amino acids of the N-terminus (peptide denoted 1051C), CR3 
between amino acids 162 to 176 (peptide denoted 105ID) and the last 12 amino acids of 
the C-terminus of the Ad40 E l A 249R protein (peptide denoted 105 IE) (see Table 2.10 
for details of the peptide sequences used). The branched-chain peptides 1051C, 105 ID 
and 105IE were synthesised in house by Mrs K. McAulay using a Shimadzu Europa 
PSSM-8 peptide synthesiser, then each peptide was used to raise antibodies in pairs of 
rabbits. Peptides corresponding to the N-terminus, CR3 and the C-terminus of the Ad40 
E1A 249R protein were initially injected at 50pg 1051C, 1051D or 1051E in 0.5ml 
Freund’s complete adjuvant, then subsequent boosts were made with 50pg of peptide in 
0.5ml Freund’s incomplete adjuvant. Before the rabbits were boosted, test bleeds were 
taken from each rabbit to establish whether or not the rabbits were raising antibodies to 
the peptide, and to establish whether subsequent boosts were required, and finally to 
decide when the rabbits should be bled out. The test bleeds were processed, then tested 
undiluted or diluted at concentrations of 1 in 10, 1 in 100, 1 in 1, 000 and 1 in 10, 000, 
against lOOng and lpg  of the appropriate peptide in ELISA assays.
Figures 4.3.1 illustrates the immune response of rabbits 228 and 229 to the N-terminus 
branched-chain peptide 1051C, rabbits 230 and 231 to the CR3 branched-chain peptide 
105ID and rabbits 232 and 233 to the C-terminus branched-chain peptide 105IE, at 
antibody dilutions of 1 inlO, 1 in 100, 1 in 1, 000 and 1 in 10, 000, across six test bleeds. 
Rabbits 228 and 229 did not appear to raise antibodies to the Ad40 El A 249R
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N-terminus branched-chain peptide 1051C. However, antibodies were produced in 
rabbits 230 and 231 against the Ad40 El A 249R CR3 branched-chain peptide 105 ID, 
and in rabbit 232 against the Ad40 E1A 249R C-terminus branched-chain peptide. 
Rabbits 230 and 232 produced antibodies, which increased in titre over the 
immunisation period and appeared to plateau by the sixth test bleed, whereas rabbit 231 
raised antibodies by the second test bleed and the titre remained constant over the 
immunisation period. Rabbit 233 did not produce antibodies, which recognised the 
C-terminus branched-chain peptide 105IE.
Sum m ary
Rabbits 230 and 231 raised antibodies against the Ad40 El A 249R CR3 sequences, 
whilst rabbit 232 raised antibodies against the Ad40 E l A 249R C-terminus. An 
antibody was not raised against the Ad40 El A 249R N-terminus. The antibodies 
generated were subsequently tested in Western blot analysis and immunoprecipitations.
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4.3.2 Western blot analysis of Ad5 and Ad40 infected cells
Antibodies raised against the Ad40 El A 249R CR3 and the C-terminus were used in 
western blot analysis of Ad40 infected cells to characterise the antibodies generated and 
determine the number and size of Ad40 El A proteins which are produced during an 
Ad40 infection. To characterise the anti-peptide antibodies in western blot analysis, 
duplicate 60mm plates of WS HeLa cells (seeded at lx l0 6 cells/plate) were infected 
with 5pfu/cell Ad5 WT, 5ffu/cell Ad40 (strain Dugan) or mock infected, then blocked 
with 20 pg/ml araC 12 hourly (section 3.5.3), which prevented DNA replication, 
allowing accumulation of the early proteins in both Ad5 and Ad40 infected cells. 
Duplicate plates were harvested 42h p.i., then one tenth of the whole cell extract was 
analysed by western blot analysis (section 3.3.4; section 3.3.5) using either an Ad5 E1A 
monoclonal antibody (denoted M58) to detect Ad5 El A proteins, or an Ad40 El A 249R 
CR3 anti-peptide antibody (denoted as 230 or 231) or an Ad40 El A 249R C-terminus 
anti-peptide antibody (denoted 232).
Figure 4.3.2 shows the Western blot analysis of Ad5 and Ad40 infected cells probed 
with the Ad5 El A 13S C-terminus monoclonal antibody M58, the Ad40 El A 249R 
CR3 and C-terminus anti-peptide antibodies or the Ad40 E1B 19kDa C-terminus 
antibody (Mautner et al., 1990). The track probed with Ad5 E1A 13S C-terminus 
monoclonal antibody M58 contains bands which correspond with the expected size of 
the Ad5 El A proteins in the infected cell extract, but the track with the uninfected cell 
extract did not. However, the tracks containing Ad40 infected cell extracts probed with 
the Ad40 El A 249R CR3 and C-terminus anti-peptide antibodies, when compared with 
mock infected cell extracts contained no infection-specific bands, suggesting that either 
the antibodies were not functional within the western blot or that there had been no 
Ad40 infection. To establish whether or not an Ad40 infection had taken place the blot 
was stripped, then reprobed with the Ad40 E1B 19kDa C-terminus antibody. A band 
was observed between the 21.5kDa and 14.3kDa rainbow markers in the Ad40 infected 
cells, which corresponded with the predicted size of the E1B 19kDa protein. This 
suggests that a productive Ad40 infection had in fact occurred, although the amount of 
the E1B 19kDa polypeptide was apparently very low. Therefore the Ad40 infected 
samples used in these experiments may have come from an inefficient infection, and the 
affinities of the antibodies raised against the Ad40 El A proteins may have been
- I ll  -
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Figure 4.3.2 Western blot analysis of Ad5 and Ad40 infected cells. WS HeLa cells were 
infected with Ad5 (5pfu/cell), Ad40 (5ffu/cell) or mock infected (tris saline), and DNA 
replication blocked with 20pg/ml araC every 12h (section 3.5.3). Cells were harvested into IX 
boiling mix 42h p.i. (section 3.3.1), then a tenth of the whole cell extract was separated, in 
parallel with high molecular weight rainbow markers (Amersham Life Science) on a 12% 
polyacrylamide gel (section 3.3.4). Proteins resolved on the gel were then transferred to 
nitrocellulose, which was probed with an Ad5 El A 289R C-terminus monoclonal antibody 
M58, Ad40 El A 289R CR3 anti-peptide antibodies 230 and 231, and an Ad40 El A 289R 
C-terminus anti-peptide antibody 232; bands were visualised with ECL system (Amersham Life 
Science) (section 3.3.5). The blot was then stripped and reprobed with an Ad40 E1B 19kDa 
C-terminus antibody (Mautner et al., 1990). Line denotes the position of the Ad5 El A 
proteins; star denotes the position of the Ad40 El B 19kDa protein.
insufficient to detect the low amounts of viral proteins in these extracts. Unfortunately, 
time constraints did not allow further analysis using different infected cell samples.
Sum m ary
Bands in the region of 46kDa were detected in Ad5 infected cell extracts, which 
correspond with the Ad5 El A proteins. However, no bands were detected in Ad40 
infected cell extracts. Although the Ad40 infection was productive very little 
E1B 19kDa protein was detectable, suggesting that the apparent lack of Ad40 El A 
proteins may be because they are present below the level of detection. To eliminate this 
possibility it would be necessary to repeat the western blot experiments using cell 
extracts expressing high levels of Ad5 and Ad40 El A proteins.
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4.3.3 Western blot analysis of the Ad5 E1A 289R protein and the 
Ad40 El A 249R protein in transfected cells.
The Ad40 El A 249R CR3 and C-terminus anti-peptide antibodies had been unable to 
detect Ad40 E l A proteins in infected cells, which was likely to have been due to the 
poor expression of Ad40 El A in the infected cell samples used. In an attempt to 
establish whether or not the low level of Ad40 E l A proteins in infected cells was an 
issue, 60mm plates of WS HeLa cells (seeded at lxlO6 cells/plate) were transiently 
transfected with independently derived calcium phosphate precipitates (section 3.4.3) 
containing lOpg pCMV13S, pCMVAd4013S or pUC9 (which acted as a negative 
control). Cells were harvested 48h after transfection (section 3.3.1), then one tenth of 
the resultant whole cell extract was analysed by western blotting (section 3.3.4; section 
3.3.5) using the Ad5 E1A monoclonal antibody M58, anti-Ad40 E1A CR3 antibodies 
230 and 231, or an anti-Ad40 El A C-terminus antibody 232.
Figure 4.3.3 shows the western blot analysis of WS HeLa cells transfected with the Ad5 
El A 13S cDNA and the Ad40 El A equivalent 13S cDNA probed with the Ad5 El A 
13S C-terminus monoclonal antibody M58, the Ad40 El A 249R CR3 anti-peptide 
antibody or the Ad40 El A 249R C-terminus anti-peptide antibody. The track probed 
with Ad5 El A 13S C-terminus monoclonal antibody M5 8 contains several bands, which 
range in size from approximately 54kDa to 43kDa; these correspond to the expected 
sizes of the Ad5 El A proteins. However, cells which were transfected with expression 
plasmid containing the Ad40 El A 13S cDNA and probed with either the Ad40 E l A 
249R CR3 anti-peptide antibody (230 and 231) or the Ad40 El A 249R C-terminus 
anti-peptide antibody (232) appeared to contain no bands which differed from those 
present in extracts from mock transfected cells.
Summary
Several bands were detected in Ad5 transfected cell extracts which ranged in size from 
approximately 54kDa to 43kDa, corresponding to the pattern of Ad5 El A proteins 
observed in section 4.3.2. However, no bands were detected in Ad40 transfected cell 
extracts. This raises two questions: firstly, do the anti-peptide antibodies recognise the 
Ad40 El A proteins, and secondly is the Ad40 El A equivalent 13S cDNA being
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Figure 4.3.3 Western blot analysis of overexpressed Ad5 E1A 289R protein and Ad40 
El A 249R protein. WS HeLa cells were transfected with 10 pg pCMV13S, pCMVAd4013S 
or pUC9 (section 3.4.3), then harvested into IX boiling mix (section 3.3.1). A tenth of whole 
cell extract was separated, in parallel with high molecular weight rainbow markers (Amersham 
Life Science) on a 12% polyacrylamide gel (section 3.3.4). Proteins which were resolved were 
transferred to nitrocellulose, which was probed with an Ad5 El A 289R C-terminus monoclonal 
antibody (M58), anti-peptide Ad40 El A 249R CR3 antibodies (230 or 231) and an anti-peptide 
Ad40 El A 249R C-terminus antibody (232); bands were visualised with ECL system 
(Amersham Life Science; section 3.3.5). Dot denotes the position of the Ad5 El A 289R 
protein.
correctly expressed from the pCMV expression plasmid. The pCMVAd4013S plasmid 
appears to express a functional Ad40 El A 249R protein, as demonstrated by the 
enhanced promoter activity in transfection analysis described in section 4.2.3. It is 
likely that the protein is expressed and functional since comparison of the trans- 
activation achieved by the Ad5 El A 289R and the Ad40 El A 249R proteins on their 
respective promoters is comparable with that determined by other groups (van Loon et 
al., 1987b; Ishino et al., 1988), and the effect is dose dependent (section 4.2.3). It is 
therefore more likely that the anti-peptide antibodies are unable to recognise efficiently 
the Ad40 El A proteins.
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4.3.4 Immunoprecipitation of E1A proteins from Ad5 and Ad40 
infected cells
It is possible that rabbit antibodies, even those raised against branched peptide antigens, 
could recognise conformational epitopes which could be lost from the denatured 
proteins present in western blotting experiments. Such conformation-specific epitopes 
would be maintained in native proteins in crude cell extracts. To test this possibility, the 
anti-peptide antibodies to the Ad40 El A CR3 (230 and 231) and to the Ad40 C- 
terminus were used in immunoprecipitation experiments. WS HeLa cells (seeded at 
lxlO6 cells per 100mm plate) were infected with Ad5 WT (5pfu/cell), Ad40 (5ffu/cell) 
or mock infected (Tris saline), labelled for 2h at 42h p.i. with 100 pCi [35S]L- 
methionine (section 3.3.2), then harvested into high salt extraction buffer. Aliquots 
were then pre-cleared before being incubated with pre-immune (pre-bleed of rabbit) or 
immune serum (either Ad5 El A 13S C-terminus monoclonal M58, anti-Ad40 El A 13S 
CR3 (230 or 231) or anti-Ad40 E1A 13S C-terminus (232)) before being processed as 
described in section 3.3.3. Immune complexes were then separated on a 12% 
polyacrylamide gel (section 3.3.4), and the radiolabelled proteins were visualised by 
autoradiography on Kodak X-OMAT S film.
Figure 4.3.4 shows immunoprecipitations of Ad5 and Ad40 infected cells using the Ad5 
E1A 13S C-terminus monoclonal antibody M58, the Ad40 E1A 249R CR3 and 
C-terminus anti-peptide antibodies or the Ad40 El A C-terminus antibody. The track 
containing Ad5 infected cell proteins immunoprecipitated with Ad5 El A 13S C- 
terminus monoclonal antibody M58 contains several bands ranging in size from 
approximately 43kDa to 50kDa, which correspond with the expected size and pattern of 
Ad5 El A proteins previously observed in the infected cell extract. However, the tracks 
containing Ad40 infected cell proteins precipitated with the Ad40 El A 249R CR3 or C- 
terminus anti-peptide antibodies showed no bands specific to Ad40 infection, suggesting 
that either the same detection problem had arisen as in the western blots or that the 
anti-peptide antibodies were unable to detect folded Ad40 El A proteins in crude cell 
extracts.
-115-
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Sum m ary
The Ad5 El A proteins were immunoprecipitated with the Ad5 El A 13S C-terminus 
monoclonal antibody M58, but the Ad40 El A proteins could not be precipitated with 
either the Ad40 El A CR3 anti-peptide antibodies 230 or 231, or the Ad40 El A 
C-terminus anti-peptide antibody 232. It can be concluded that the branched chain 
anti-peptide antibodies produced using the CR3 and C-terminus regions of the Ad40 
249R protein were functional against peptide in ELISA, but they were not sufficiently 
active in western blots of infected cell extracts, cell extracts overexpressing the Ad40 
El A 249R protein, or in immunoprecipitations of Ad40 infected cells, using the extracts 
that were available for these studies.
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DISCUSSION
5. Discussion
I n t r o d u c t i o n
The enteric adenoviruses were first identified from the stool samples of infants with 
acute gastroenteritis (Flewett et al, 1973). Although enteric adenovirus particles are 
shed in large numbers from the gut, they fail to propagate in cells such as HEK, KB, 
HeLa, HEP-2 and WI-38, which are normally used to propagate other adenovirus 
serotypes in tissue culture (Madeley et al., 1977; Retter et al., 1979). They will however 
propagate in 293 cells, a human embryo kidney (HEK) cell line which has been 
transformed with the Ad5 El region (Graham et al., 1977; Takiff et al., 1981), albeit at 
reduced levels compared with other serotypes. This observation suggests that the El 
function is poorly expressed or of intrinsically lower activity in certain cell types, 
therefore implicating the El region in the restrictive growth properties of the enteric 
adenoviruses. Previous work had demonstrated that the Ad40 E1B region played a 
significant role in this phenotype (Mautner et al., 1989; Steinthorsdottir, 1991; Gomes et 
al., 1992), however the Ad40 El A region was also implicated. The E l A region was 
implicated for two reasons firstly, a delay in the onset of Ad40 El A mRNA expression 
was observed compared to Ad5 El A mRNA expression (Ullah, 1997); and secondly, the 
Ad40 El A proteins were observed as weaker /ra«s-activators when compared to the 
Ad5 El A proteins (van Loon et al., 1987b; Ishino e ta l., 1988). Taken together these 
observations suggested that the Ad40 El A region is of intrinsically lower activity in 
tissue culture, which would considerably affect progression of Ad40 into the late phase 
of the infectious cycle. A preliminary characterisation of the Ad40 El A region involved 
analysis of basal transcription (sections 4.1 and 5.1) and fraws-activated transcription 
from the Ad40 E1A promoter (sections 4.2 and 5.3) compared to the Ad5 E1A 
promoter. A preliminary map of Ad40 El A cDNAs was also determined (sections 4.2 
and 5.2).
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5.1 Analysis of basal transcription from the Ad40 
El A promoter
The aberrant expression of the Ad40 El region (Takiff et a l, 1981; Kidd and Madeley, 
1981) had mainly been attributed to E1B (Mautner et a l,  1989; Steinthorsdottir and 
Mautner, 1991; Gomes et a l,  1992) however, E l A was also implicated (Ullah, 1997; 
van Loon et a l,  1987b; Ishino et a l, 1988). Ad40 E l A mRNA was expressed 36h p.i. 
(Ullah, 1997) compared with Ad5 E l A mRNA expression at 1.5-2h p.i.. These data 
suggest that the Ad40 El A region is either aberrantly expressed or of intrinsically lower 
activity when compared to Ad5 in tissue culture. Therefore, to investigate the 
involvement of the E l A region in the restricted growth of Ad40, a preliminary 
characterisation of sequences important for basal transcription (section 4.1) was 
undertaken.
The E l A promoter sequences of Ad5 (van Ormondt et a l,  1978) and Ad40 (van Loon 
e ta l ,  1987a) had previously been determined, allowing comparison of the Ad5 E l A 
upstream enhancer and core promoter sequences (Yoshida et a l,  1995), with the Ad40 
E l A promoter (figure 5.1). To identify possible transcription factor binding sites within 
the Ad40 El A promoter, sequences from the ITR (nucleotide 1) to the core promoter 
(as identified in Ad5 (Hearing and Shenk, 1983a); nucleotide 452) were compared with 
the transcription factor database held at EMBL (using a single mismatch algorithm; 
Ghosh, 1990). This revealed a number of possible transcription factor binding sites 
within the Ad40 E l A promoter (figure 5.1). The known Ad5 E l A core promoter and 
upstream enhancer sequences (Yoshida et a l ,  1995) were then compared with the 
proposed map of the Ad40 El A promoter (figure 5.1). This revealed a number of 
potential similarities and differences between the Ad5 and the Ad40 E1A promoters. 
Sequences within the ITRs were relatively well conserved between the promoters, with 
Ad40 containing predicted ORPA, NFI, NFIII, two Spl and two ATF binding sites 
conserved in the same relative order as Ad5 (Hatfield and Hearing, 1991). Ad40 was 
also predicted to map an enhancer region like Ad5, comprising of two distinct elements 
(Hearing and Shenk, 1986; Bruder and Hearing, 1989, 1991). Two copies of element I 
or EF-1A binding sites (sites 1 and 2 in figure 5.1), and three EF-1 A-like sequences are
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predicted (sites 3, 4 and 5 in figure 5.1). The three EF-lA-like elements were not 
obvious from initial comparisons with the transcription factor database held at EMBL, 
therefore the sequence was re-analysed using TRANSFAC (http://transfac.gbf.de; 
Quandt et a l,  1995), which identified three binding sites for Elk 1, Elk 1 and GABP 
respectively (sites 5, 4 and 3 respectively, figure 5.1), members of the ets oncogene 
family (Wasylyck, 1993).
An element II-like sequence was also identified within the Ad40 E l A promoter, which 
had 75% homology to the Ad5 element II sequence. One copy of element III (the E2F 
binding site) and two ATF binding sites are also predicted, although the ATF sites are 
not conserved in the same relative order between the promoters. The core promoter is 
well conserved between Ad5 and Ad40, containing a CAAT homology, TATA box and a 
cap site within a hyphenated symmetry (Hearing and Shenk, 1983a). The CAAT 
homology strongly resembles the Ad5 E l A CAAT homology (Hearing and Shenk, 
1983a). Situated downstream of the CAAT homology lies the Ad40 E l A TATA 
homology showing one nucleotide difference from the Ad5 TATA homology and four 
nucleotide difference from the TATA homology (Benoist et al., 1980). This may be 
significant as mutational analysis of the TATA homology within the adenovirus MLP 
conferred differences to transcription (Hoopes et a l,  1998). A cap site for Ad40 E l A 
mRNAs was identified at nucleotide position 418 from the left end of the viral genome 
(Hearing and Shenk, 1983a). The cap site occurs within a hyphenated symmetry which 
strongly resembles the Ad5 E l A cap sequence (Hearing and Shenk, 1983a).
The intact Ad5 and Ad40 E l A promoters were cloned upstream of a modified firefly 
luciferase gene then analysed by transient transfection in HeLa cells. The mean and 
standard deviation were then calculated. The methods used to calculate the mean and 
standard deviations, for the replicates within each independent experiment, assumed a 
normal distribution for a large number of replicates. However, it should be noted that 
only a small number of replicates were actually made and therefore the mean (p) and 
standard deviation (8) obtained are estimated values. In addition, although comparisons 
within a single experiment are valid, there may be problems in comparing between 
experiments. For example, measurement of ratios of Renilla to firefly luciferase between 
experiments might show an inherent variability due to differences in the activity or
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stability of the different substrates. For this reason, interpretation and discussion of the 
data focuses upon the major qualitative trends seen within single experiments. In almost 
all instances (and unless discussed otherwise) the same general trends were consistently 
observed between experiments. Baring this in mind the analysis of the Ad5 and the Ad40 
E l A promoters revealed that basal transcription from the Ad40 E l A promoter was 
lowered by approximately 6.5 fold when compared with expression from the Ad5 E l A 
promoter (section 4.1.4), demonstrating that expression from the Ad40 E l A promoter is 
indeed of intrinsically lower activity when compared to the Ad5 E l A promoter. To map 
sequences important for basal transcription from the Ad40 E l A promoter, a series of Bal 
31 deletions were constructed for the Ad5 and the Ad40 E l A promoters.
Transient transfection of the intact and Bal 31 deleted Ad40 E l A promoters compared 
with the equivalent Ad5 E l A promoter constructs revealed an almost identical pattern of 
expression between the two promoters, albeit at reduced levels from the Ad40 E l A 
promoter. Interestingly, deletions of sequences within the ITR from -498 to -428 
relative to the Ad5 E1A cap site, and from -416 to -349 relative to the Ad40 E1A cap 
site, resulted in increased expression levels from both promoters. This was unexpected, 
as previously the Ad5 ITR had demonstrated intrinsic promoter and enhancer activities 
when the Ad5 ITR was placed adjacent to the E1A TATA box (Hatfield and Hearing, 
1991). The simplest model, which would account for the increase in transcription from 
both the Ad5 and Ad40 E l A promoters, would be that the sequences deleted from each 
promoter contained a binding site for a transcriptional repressor. However, no such 
sequences have previously been demonstrated within the Ad5 E l A promoter.
Deletion of sequences from -428 to -321 in the Ad5 E l A promoter resulted in a decrease 
in expression levels by a factor of 5.5, this was the largest decrease observed within the 
Ad5 E l A promoter. This observation was expected as the region from -428 to -321 
contains two copies of an element I-related sequence (EF-1A sites 4 and 5), deletion of 
which effects a decrease in Ad5 E l A mRNA levels (Bruder and Hearing, 1991). The 
region -428 to -321 also contains three Spl binding sites, three ATF binding sites and a 
24bp enhancer. These sites have been demonstrated to increase transcriptional activity, 
although it is not clear the extent of the role they play within the context of basal 
transcription from the E1A promoter (Sassone-Corsi et al., 1983; Jones et al., 1988;
- 1 2 0 -
Hatfield and Hearing, 1991). An E2F binding site (also described as element III) is also 
contained within the deleted region -428 to -321, however this will not be discussed 
further within this section as basal transcription from the E l A transcriptional control 
region is unaffected by deletion of either or both copies of element III (Bruder and 
Hearing, 1989).
Further deletion of sequences from -321 to -171 within the Ad5 E l A promoter resulted 
in an approximated 3-fold decrease in expression. This region contains two EF-1A 
binding sites and an EF-lA-related sequence, which demonstrate co-operative binding of 
EF-1A resulting in synergistic activation of E l A transcription (Bruder and Hearing, 
1991). Nested between the two EF-1A elements is a second control region known as 
element II, which regulates transcription from all early regions within the viral genome 
(Hearing and Shenk, 1986). Finally, deletion of sequences from -171 to -42, which 
included the CAAT homology and an ATF binding site, rendered the Ad5 E l A promoter 
inactive. Previous studies had found that partial deletions within this region had no 
effect on transcription in vitro or in vivo, but in this study the deletions were more 
extensive (Hearing and Shenk, 1983a; Jones et al., 1987).
Transient transfection of the intact and Bal 31 deleted Ad40 E l A promoter constructs 
revealed that apart from the initial increase in transcription which resulted from the 
deletion of sequences from -416 to -349, the series of deletions from -349 to -37 resulted 
in decreasing expression levels, which were comparable with the pattern of expression 
observed within the Bal 31 deleted Ad5 El A promoter. Sequences from -349 to -140 
mediated the greatest decrease in expression from the Ad40 El A promoter. To further 
map sequences important for basal transcription, a second series of Ad40 E l A promoter 
deletions were constructed (section 4.1.7).
Transient transfection analysis of the intact and deleted Ad40 E l A promoter revealed a 
further 1.3 fold increase in expression with the deletion of sequences from -349 to -328, 
giving an overall increase in expression by a factor of 2.5 with the deletion of sequences 
from -416 to -328. Further deletion of sequences from -328 to -268 mediated a 5-fold 
decrease in expression. This region is predicted to contain three EF-lA-related 
sequences, which would bind alternative members of the ets oncogene family known as
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Elk 1, Elk 1 and GABP (sites 5, 4 and 3 respectively, figure 5.1). The ets family of 
transcription factors comprises of seven subfamilies including Etsl and Ets2, Erg, 
GABP, PE A3, Elk, Elf and PU.l, which show tissue specificity between themselves and 
the cofactors which regulate their biological function (reviewed in Wasylyk et at., 1993). 
This suggests a role for transcription factor tissue specificity within the Ad40 El A 
promoter. If the EF-lA-related sequences were functional within the Ad40 El A 
promoter, deletion of the region -328 to -268 would be expected to mediate a decrease 
in expression levels as observed within the Ad5 E l A promoter deletions (Bruder and 
Hearing, 1991).
Deletion of the region -268 to -235 mediated a further 4.6-fold decrease in expression 
rendering the promoter inactive. This region is predicted to contain an ATF binding site, 
one copy of element I and an element II-related sequence. The element Il-related 
sequence shows 75% homology to the Ad5 element II, deletion of which mediates a 
decrease in Ad5 E l A mRNA expression (Hearing and Shenk, 1986). Subsequent 
deletion of sequences from -235 to -209, -209 to -166, -166 to -140 and -140 to -37, 
which contained one copy of element I, one copy of element II, an ATF binding site and 
the CAAT homology, did not affect basal transcription from the Ad40 E l A promoter. 
The deletion construct containing only the Ad40 E l A TATA box was unable to support 
basal transcription. Therefore it was concluded that the Ad40 E l A enhancer region 
maps to sequences within -328 to -235 relative to the Ad40 E l A cap site at +1. 
Alternative mechanisms for basal transcription from the Ad40 E l A promoter in vivo can 
not be ruled out, as sequence comparison of the Ad40 E l A promoter with TRANSFAC 
(Quandt et a l,  1995) revealed that the Ad40 E l A promoter contains motifs related to 
the binding sites of gut-specific transcription factors from the HNF and HFH families 
within the region -209 to -37. It is therefore possible that Ad40 has evolved to utilise 
gut specific transcription factors, and therefore it would be interesting to analyse basal 
transcription from the intact and deleted promoter constructs in the context of gut biopsy 
samples.
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5.2 Preliminary characterisation of the Ad40 
El A cDNA map
To characterise /ra/ts-activated expression from the Ad40 El A promoter an expression 
plasmid containing the Ad40 El A equivalent 13S protein coding sequence was 
constructed. The 12S mRNA protein coding sequences were not isolated from Ad40 
infected 293 cells blocked with ara C. Ara C blocked DNA replication therefore 
allowing only early viral proteins to accumulate. It is therefore possible that the Ad40 
E l A 221R protein is only present at late times in infection. Previously the 12S mRNA 
was reported in plasmid transformed cells (van Loon et al., 1987a). A number of other 
Ad40 El A specific cDNAs were also characterised from the early stage of Ad40 
infected 293 cells. These included the Ad40 cDNA clones one to four, which are 
described in section 4.2.1. Repeat RT-PCR of Ad40 infected 293 cells revealed that 
clones one and four were produced during an Ad40 infection. This was surprising as 
clones one and four appear to encode truncated products or proteins unrelated to the 
previously characterised El A region proteins. Furthermore, if  these cDNAs arose from 
aberrantly spliced mRNAs, it would be expected that they might be more common in the 
heterogeneous nuclear mRNA fraction and not efficiently exported to the cytoplasm.
The failure to find a cDNA expressing the Ad40 12S El A message and the presence of 
a family of apparently aberrant El A mRNAs which express non-functional truncated 
E l A proteins suggests a further significant reason for the failure of Ad40 to grow well 
in cultured cells. It is possible that the correct splicing of Ad40 primary transcripts is 
influenced by factors present in different cell types. Differential splicing of transcripts is 
a well established regulatory mechanism, so it is possible that Ad40 has evolved to 
utilise the splicing machinery present in gut cells. If so, it would be of great interest to 
analyse the pattern of Ad40 El A mRNA transcripts in biopsy samples of infected 
human tissue.
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5.3 Analysis of fra/is-activation within the Ad40 
El A promoter
The aberrant expression of the El region (Takiff et al., 1981; Kidd and Madeley, 1981) 
had in part been attributed to the delayed expression of the Ad40 El A mRNAs (Ullah, 
1997) and the intrinsically lower activity observed in basal transcription from the Ad40 
El A promoter (section 4.1 and 5.1). Previous studies of the Ad40 El A protein products 
had also revealed that the trans-activation of the Ad2 E4 promoter by the Ad40 El A 
proteins was significantly reduced when compared with /raws-activation by the Ad5 
E l A proteins (van Loon et al., 1987b). The trans-activation of the Ad5 E2A and E3 
promoters by the Ad40 El A proteins was also significantly reduced when compared 
with /ra«s-activation by the Ad5 and the Ad 12 El A proteins (Ishino et al., 1988). As 
the Ad40 El A proteins are weaker frawj-activators of other early adenovirus promoters 
they are also likely to be weaker /raws-activators of their own promoter, which would 
contribute to the aberrant expression of the El region. To investigate the involvement 
of the Ad40 El A proteins in the aberrant expression of Ad40, the Ad40 El A equivalent 
13S protein coding sequences were cloned into a CMV expression plasmid 
(section 4.2.1.). The Ad40 El A equivalent 12S protein coding sequences were not 
isolated from Ad40 infected 293 cells (sections 4.2.1; 4.2.2) therefore, /ra/w-activation 
was only analysed with reference to the Ad40 El A 249R protein. The Ad5 and the 
Ad40 El A promoters were co-transfected with expression vectors encoding either the 
Ad5 El A 289R protein or the Ad40 El A 249R protein.
The Ad5 El A 289R protein fra«s-activates the Ad5 El A promoter by a factor of 10.4, 
whereas the Ad40 El A 249R protein trans-activates the Ad40 El A promoter by a factor 
of 1.7. Therefore, fraws-activation by the Ad40 El A 249R protein is lowered by a factor 
of 6.2 when compared to fraws-activation by the Ad5 El A 289R protein. Published data 
revealed that trans-activation of the Ad2 E4 promoter by the Ad40 El A proteins was 
lowered by an approximated factor of 4.6 when compared to fra«s-activation by the Ad5 
El A proteins (van Loon et al 1987b). 7><ms-activation of the Ad5 E2A and E3 
promoters by the Ad40 El A proteins was also lowered when compared to trans- 
activation by the Ad5 El A proteins. However, this data was not quantified therefore we
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can only conclude that the overall reduction in expression was comparable with 
previously published data (Ishino et al., 1988). The published data are concordant with 
the data produced in section 4.2, any differences are likely to arise from the differences 
in E1A proteins produced within the co-transfections i.e. the Ad40 E1A 249R protein 
/raws-activated the Ad40 El A promoter (section 4.2) whereas the Ad40 El A 249R and 
221R proteins trans-activaied the Ad2 E4 promoter (van Loon et al, 1987b).
Interestingly, the Ad5 El A 289R protein was able to /raws-activate the Ad40 E l A 
promoter by a factor of 40, which brought firefly luciferase expression levels from the 
Ad40 El A promoter to levels measured within the trans-activated Ad5 El A promoter. 
This suggests that the Ad40 El A promoter contains transcription factor binding sites 
necessary for trans-activation by the Ad5 El A 289R protein. In the light of sequence 
analysis of the Ad40 El A promoter, which predicts an E2F binding site, four ATF 
binding sites and the TATA box this is reasonable. The reciprocal is not true for 
fraws-activation of the Ad5 El A promoter by the Ad40 El A 249R protein, suggesting 
that either the Ad40 E1A 249R protein is aberrantly expressed or fra/w-activates via 
different mechanisms. Section 4.2.3 established that functional Ad40 El A 249R protein 
was produced in vitro from the CMV expression vector, albeit a weaker trans-activator 
than the equivalent Ad5 El A 289R protein. In principle there could be a difference 
between functionality of the Ad40 El A 249R protein in vitro and in vivo. This principle 
was demonstrated by the expression of the Ad 12 El A proteins from bacterial cells, 
whereby the conditions for protein formation were shown to affect protein function 
(Grand et ah, 1998). Post-translational modification is an established regulatory 
mechanism of E l A protein function, so it is possible that Ad40 has evolved to utilise the 
post-translational modification system present in gut cells. If so, it would be of great 
interest to analyse trans-activation of the Ad40 El A promoter by the 249R protein in 
biopsy samples of infected human tissue.
To map sequences which are important in /raws-activation from the Ad40 El A 
promoter, cells were co-transfected with the reporter constructs containing intact or 
deleted Ad5 and Ad40 El A promoters along with CMV expression vectors containing 
either the Ad5 El A 13S protein coding sequences or the Ad40 El A equivalent 13S 
protein coding sequences. Table 5.3 illustrates the mean (p) value obtained for basal
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Table 5.3 Basal and trans- activation of the Ad5 and the Ad40 E1A promoters.
Sample Basal expressiona Trans-activated expression b
Fold activation of 
expression by the 
Ad5 El A 289R 
proteinc
Ad5 El A promoter 12 97 12.5
Ad5 El A promoter del.428 12 81 6.7
Ad5 El A promoter del.321 2.2 13 5.9
Ad5 El A promoter del. 171 0.71 12 16.9
Ad5 E1A promoter del.42 0.06 0.85 14.2
Ad40 El A promoter 1.2 7.4 6.2
Ad40 E1A promoter del.349 2.3 24 10.4
Ad40 El A promoter del. 328 3.0 24 8
Ad40 E1A promoter del.268 0.6 15 25.0
Ad40 El A promoter del.235 0.13 0.91 7.0
Ad40 El A promoter del.209 0.08 0.39 4.9
Ad40 El A promoter del. 166 0.10 0.55 5.5
Ad40 El A promoter del. 140 0.10 0.50 5.0
Ad40 E1A promoter del.37 0.08 0.48 6.0
“ Basal expression denotes the mean (p.) calculated in Table 4.1.6 and Table 4.1.8 
b Trans-activated expression denotes the mean (p) calculated in Table 4.2.4
c Fold activation of expression by the Ad5 E1A 289R protein was calculated by dividing the 
/ram-activated expression (column 3) by the basal expression (column 2).
expression from the intact and deleted Ad5 and Ad40 El A promoters (see column 2 
Table 5.3); the mean (p) value obtained for trans-activated expression from the intact 
and deleted Ad5 and Ad40 El A promoters by the Ad5 El A 289R protein (see column 3 
Table 5.3); and the ratio of trans-activated to basal activity (column 4 Table 5.3). 
Trans-activated expression of the Ad5 and Ad40 El A promoters by the Ad40 El A 
249R protein are not discussed, due to an equipment (incubator) problem which 
rendered the experimental data unreliable.
Previously the Ad5 El A 289R protein was shown to trans-activate the Ad40 El A 
promoter to the same level as the Ad5 E1A promoter (Table 4.2.3.2; Figure 4.2.3.2) 
however, this was not the case within this experiment (Table 5.3). This may have been 
related to the equipment problem mentioned above and given more time it would have 
been beneficial to repeat these experiments
Deletions within the Ad5 and the Ad40 El A promoter demonstrated similar patterns of 
expression. Deletion of sequences from -498 to -428, -428 to -321, -321 to -171 and 
-171 to -42 relative to the Ad5 El A cap site resulted in a sequential decrease in 
trans-activated expression from the Ad5 El A promoter. The largest decreases in 
trans-activated expression from the Ad5 E l A promoter were effected by sequences 
contained within the regions -428 to -321 and -171 to -42 relative to the Ad5 E1A cap 
site, which contained two copies of ATF and Spl transcription factor binding sites, and 
a single copy of the ATF transcription factor binding site respectively. Previously 
trans-activation by the Ad5 El A 289R protein was demonstrated to involve both ATF 
and Spl (reviewed in Flint and Shenk, 1997; see section 1.2). It was therefore not 
surprising that deletion of sequences corresponding to Spl and ATF transcription factor 
binding sites would cause a decrease in ^raws-activated expression from the Ad5 El A 
promoter. Deletion of sequences from -321 to -171 had little effect on trans-activated 
expression, which was surprising as this region contains two copies of the E2F 
transcription factor binding site, which is known to be involved in /raws-activation by 
the Ad5 El A 289R protein (reviewed in Flint and Shenk, 1997). Finally, expression 
from the Ad5 El A promoter construct containing the TATA box alone (del.42) was not 
abolished, expression probably resulting from fraws-activation of the TATA box 
through TBP and/or through a number of TAFs which are components of a larger
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complex known as TFIID (reviewed in section 1.2).
Deletion of sequences within the Ad40 El A promoter demonstrated a similar pattern of 
expression to that observed within the Ad5 E1A promoter i.e. deletion of sequences 
from -349 to -328, -328 to -268, -268 to -235, -235 to -209, -209 to -166, -166 to -140 
and -140 to -37 relative to the Ad40 El A cap site resulted in a sequential decrease in 
trans-activated expression from the Ad40 El A promoter. There was however one 
difference to the pattern of expression observed within the deletion analysis of the Ad40 
El A promoter, namely deletion of sequences from -416 to -349 relative to the Ad40 
El A cap site effected an increase in /rans-activated levels of expression from the Ad40 
El A promoter. This result should, however, be interpreted with caution since 
previously the Ad5 El A 289R protein had trans-activated the Ad40 El A promoter to 
the same level as the trans-activated Ad5 E1A promoter (section 4.2.3). It is therefore 
possible that the /raws-activated level of expression observed with the intact Ad40 El A 
promoter in this experiment is an aberrantly low value, possibly associated with the 
equipment problems. In order to confirm whether this is the case the experiment needs 
to be repeated.
The largest decrease in trans-activated expression from the Ad40 El A promoter was 
effected by sequences contained within the region -268 to -235, which are predicted to 
contain a single copy of the ATF transcription factor binding site. Deletion of 
sequences from -328 to -209, which are predicted to contain two ATF and one Spl 
transcription factor binding sites, reduced ^raws-activated expression to the level 
observed from the Ad40 E1A TATA box deletion construct. Sequences contained 
within the region -209 to -37 did not appear to be important for trans-activation by the 
Ad5 El A 289R protein, suggesting that the predicted ATF and E2F transcription factor 
binding sites are not important. Finally the del.37 construct was trans-activated by the 
Ad5 El A 289R protein presumably through the TATA box (reviewed in section 1.2). 
From comparisons of the ratios of trans-activated to basal expression for both the Ad5 
and Ad40 promoter constructs (table 5.3) no single sequence element can be identified 
which is uniquely important for trans-activation. Rather, those elements which affect 
the level of basal expression seem also to have an effect on the level of trans-activated 
expression observed in the presence of the Ad5 El A 289R protein. Thus the Ad5 El A
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289R protein probably activates gene expression through an effect on the basal 
transcription apparatus. It would be interesting to analyse trans-activated expression of 
the Ad40 El A promoter constructs by the Ad40 El A 249R protein in WS HeLa cells 
and biopsy samples of gut tissue to map sequences important for /ra«s-activation and to 
allow comparison with the Ad5 El A 289R protein.
In summary, the work in this thesis suggests that, in addition to the previously observed 
defects in E1B region function, the failure of Ad40 to propagate in HeLa and other 
similar cultured cell lines can in part be attributed to: (i) intrinsically poor activity of the 
Ad40 El A promoter region; (ii) apparently aberrant splicing of El A mRNAs; (iii) 
intrinsically low activity of the Ad40 major El A trans-activator protein encoded by the 
13S El A mRNA. Each of these factors may be modulated by the environment in 
different cell types, and future studies could seek to determine differences in El A 
promoter- and El A protein-binding factors between cultured cells and gut tissue.
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** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * **
** * * * * * * * * * * * * * * **** * * * * * * * * * * * * * * * * * * * *
** * * * * * * * * * * * * * * * * * * * * * * * * **** * * * * * * * * * * * * * * * * * * * *
** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * **
** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *■ ★
** * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * k k
** * * * * * * * * * * * * * * * * * * * * * * * * **** * * * * * * * * * * * * * * * * * * kk
IT R
SP1 ATF SP1
-4 1 6 GGGAGGAGGG ACTAG GGGTG GTGTAAG GTG ACGT AGAGGC GGGCGG 3GTG
-3 4 9 * * * * * * * * * * * * * * * ** g tg GTGTAAG GTG ACGT AGAGGC GGGCGG 3GTG
-3 2 8 * * * * * * * * * * *  *  *  *  * * * * * * * * * * * * * * * * * * * * ****GC GGGCGG 3GTG
* * * * * * * * * * *  *  *  *  * * * * * * * * * * * * * *  *  * *  *  *  * * * * * * * * * * * * * *  *  *  *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *  *  *  * * * * * * * * * * * * * *  *  *  *
* * * * * * * * * * *  *  *  *  * *  *  *  *  * * * * * * * * * * * *  *  *  * * * * * * * * * * * * * *  *  *  *
* * * * * * * * * * *  *  *  *  * *  *  *  *  * * * * * * * * *  *  * *  *  *  * * * * * * * * * * * * * k  *  *  *
* * * * * * * * * * *  *  *  *  * * * * * * * * * * * * * *  *  * *  *  *  * * * * * * * * * * * * * k  *  *  *
* * * * * * * * * * * * * * * *  *  *  *  * * * * * * * * *  *  * *  *  *  * * * * * * * * * * * * * * * * *
IT R
ATF
-4 1 6 GGAAAGGGTG GAGGCGG2 TG
-3 4 9 GGAAAGGGTG GAGGCGG2 TG
-3 2 8 GGAAAGGGTG GAGGCGG2 TG
-2 6 8 * * * * * * * * * * * * * * * * * * **
* * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * *
* * * * * * * * * * * * * * * * * * * *
ACGT 
ACGT 
ACGT 
****  
* * * * 
* * * * 
****  
* * * * 
*  *  *  *
GTGGGG
GTGGGG
GTGGGG
* * * * * *
* * * * * *
* * * * * *
* * * * * *
* * * * * *
* * * * * *
TCGGAGGACG
TCGGAGGACG
TCGGAGGACG
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
GGCGCGGTGC 
GGCGCGGTGC 
GGCGCGGTGC 
* * * * * * * *  QC 
* * * * * * * * * *  
* * * * * * * * * *  
* * * * * * * * * *  
* * * * * * * * * *  
* * * * * * * * * *
IT R
416
349
328
268
235
416
349
328
268
235
2 0 9
41 6
349
328
268
235
2 0 9
166
140
41 6
3 4 9
328
268
235
209
166
140
EF - 1A ATF
rc
rc
rc
rc
ACGGAAAA
ACGGAAAA
ACGGAAAA
ACGGAAAA
* * * * * * * *
GGCGGAAGl
GGCGGAAG1
GGCGGAAGl
GGCGGAAG1
* * * * * * * * *
TGGTGTATTG
TGGTGTATTG
TGGTGTATTG
TGGTGTATTG
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
GGCGGGTTTT
GGCGGGTTTT
GGCGGGTTTT
GGCGGGTTTT
*GCGGGTTTT
**********
* * * * * * * * * *
* * * * * * * * * *
* * * * * * * * * *
TGTAACTTTT
TGTAACTTTT
TGTAACTTTT
TGTAACTTTT
TGTAACTTTT
* * * * * * * * * *
* * * * * * * * * *
**********
* * * * * * * * * *
ITR E lem en t I I - l i k e  seq u en c e
E2F E F -1A
3GGA CGAACTTTGG 
3GGA CGAACTTTGG 
3GGA CGAACTTTGG 
3GGA CGAACTTTGG 
3GGA CGAACTTTGG 
3GGA CGAACTTTGG 
**** * * * * * * * * * *  
****  * * * * * * * * * *  
* * * *  * * * * * * * * * *
  M-----------
GGCCA'
GGCCA'
GGCCA
GGCCA'
GGCCA'
* * * * * *
* * * * * *
* * * * * *
* * * * * *
TT
TT
TT
.TT
.TT
TTG
TTG
TTG
TTG
TTG
*t t g  
* * * * 
* * * * 
* * * *
GC 
GC 
GC 
GC 
GC 
GC 
* * * 
* * * 
* * *
G3
GC
GC
GC
GC
GC
GAAAAC
GAAAAC
GAAAAC
GAAAAC
GAAAAC
GAAAAC
* * * * * * *
* * * * * * *
* * * * * * *
TGAGTAA1
TGAGTAAT
TGAGTAAT
TGAGTAAT
TGAGTAAT
TGAGTAAT
* * * * * * * *
* * * * * * * *
* * * * * * * *
GA 
GA 
GA 
GA 
GA 
GA 
* * 
* * 
*  *
GGACGT
GGACGT
GGACGT
GGACGT
GGACGT
GGACGT
* * * * * *
* * * * * *
* * * * * *
ACTTTTGTGT
ACTTTTGTGT
.ACTTTTGTGT
ACTTTTGTGT
ACTTTTGTGT
ACTTTTGTGT
ACTTTTGTGT
* * * * * * * * * *
* * * * * * * * * *
TTATGGAGGA
TTATGGAGGA
TTATGGAGGA
TTATGGAGGA
TTATGGAGGA
TTATGGAGGA
TTATGGAGGA
**********
* * * * * * * * * *
AAAACTGCTG
AAAACTGCTG
AAAACTGCTG
AAAACTGCTG
AAAACTGCTG
AAAACTGCTG
AAAACTGCTG
******QCPG
* * * * * * * * * *
ATTATTACTG
ATTATTACTG
ATTATTACTG
ATTATTACTG
ATTATTACTG
ATTATTACTG
ATTATTACTG
ATTATTACTG
* * * * * * * * * *
AACTTTGGC
AACTTTGGC
AACTTTGGC
AACTTTGGC
AACTTTGGC
AACTTTGGC
AACTTTGGC
AACTTTGGC
* * * * * * * * *
ATF CAAT h o m o lo g y
CATGACGAAC
CATGACGAAC
CATGACGAAC
CATGACGAAC
CATGACGAAC
CATGACGAAC
CATGACGAAC
CATGACGAAC
* * * ★ ★ ★ * * * ★
C GGTTTTTCT 
C GGTTTTTCT 
C GGTTTTTCT 
C GGTTTTTCT 
CGGTTTTTCT 
C GGTTTTTCT 
CGGTTTTTCT 
C GGTTTTTCT 
* * * * * * * * * *
ACGTGGCAGT
ACGTGGCAGT
ACGTGGCAGT
ACGTGGCAGT
ACGTGGCAGT
ACGTGGCAGT
ACGTGGCAGT
ACGTGGCAGT
* * * * * * * * * *
GCCACGAGAC
GCCACGAGAC
GCCACGAGAC
GCCACGAGAC
GCCACGAGAC
GCCACGAGAC
GCCACGAGAC
GCCACGAGAC
* * * * * * * * * *
GCTCAAAGT
GCTCAAAGT
GCTCAAAGT
GCTCAAAGT
GCTCAAAGT
GCTCAAAGT
GCTCAAAGT
GCTCAAAGT
41 6
349
328
268
235
2 0 9
166
140
37
4 1 6
3 4 9
328
268
235
2 0 9
166
140
37
4 1 6
34 9
328
26 8
23 5
2 0 9
166
140
37
TATA b o x
CCTAATTTTT
CCTAATTTTT
CCTAATTTTT
CCTAATTTTT
CCTAATTTTT
CCTAATTTTT
CCTAATTTTT
CCTAATTTTT
TATTGTGTGC
TATTGTGTGC
TATTGTGTGC
TATTGTGTGC
TATTGTGTGC
TATTGTGTGC
TATTGTGTGC
TATTGTGTGC
TCAGCCCGTT 
TCAGCCCGTT 
TCAGCCCGTT 
TCAGCCCGTT 
TCAGCCCGTT 
TCAGCCCGTT 
TCAGCCCGTT 
TCAGCCCGTT 
******* **<£
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TGAGGG TATT
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
TAAA CACAGC
cap
H y p h e n a te d  sy m m e try
CAGAACATCA
CAGAACATCA
CAGAACATCA
CAGAACATCA
CAGAACATCA
CAGAACATCA
CAGAACATCA
CAGAACATCA
CAGAACATCA
AGAGGC<
AGAGGC<
AGAGGC<
AGAGGC<
AGAGGC(
AGAGGCt
AGAGGC<
AGAGGC<
AGAGGCC
CA3
c a :  
c a :  
c a :  
C AC 
CAC 
CAC 
CAC 
CAC
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
CTTGAGTGCG
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
AGCGAGTAGA
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
GTTTTCTCCT
CC
CC
CC
CC
CC
CC
CC
CC
CC
G L A S G O W  UL” ;
